{"d554f68f0143c2cfa0d52442dca0c3081e0a212c": [["INTRODUCTIONHepatitis B virus (HBV) infection is a major public health problem throughout the world, especially in East Asia and Africa.", [["INTRODUCTIONHepatitis B virus (HBV) infection", "DISEASE", 0, 45], ["INTRODUCTIONHepatitis B virus", "ORGANISM", 0, 29], ["HBV", "ORGANISM", 31, 34], ["B virus", "SPECIES", 22, 29], ["INTRODUCTIONHepatitis B virus", "SPECIES", 0, 29], ["HBV", "SPECIES", 31, 34], ["INTRODUCTIONHepatitis B virus (HBV) infection", "PROBLEM", 0, 45], ["virus", "OBSERVATION", 24, 29]]], ["An estimated two billion people, roughly 30% of the world's population, have been infected with HBV, and over 350 million patients have chronic hepatitis B (CHB) [Liaw and Chu, 2009] .", [["chronic hepatitis B", "DISEASE", 136, 155], ["CHB", "DISEASE", 157, 160], ["people", "ORGANISM", 25, 31], ["HBV", "ORGANISM", 96, 99], ["patients", "ORGANISM", 122, 130], ["chronic hepatitis B", "ORGANISM", 136, 155], ["people", "SPECIES", 25, 31], ["patients", "SPECIES", 122, 130], ["HBV", "SPECIES", 96, 99], ["HBV", "PROBLEM", 96, 99], ["chronic hepatitis B", "PROBLEM", 136, 155], ["two", "OBSERVATION_MODIFIER", 13, 16], ["billion", "OBSERVATION", 17, 24], ["infected", "OBSERVATION", 82, 90], ["HBV", "OBSERVATION", 96, 99], ["chronic", "OBSERVATION_MODIFIER", 136, 143], ["hepatitis", "OBSERVATION", 144, 153]]], ["Each year, about 786,000 deaths are caused by HBV infection or its associated liver diseases [Lozano et al., 2012] , including hepatic decompensation, cirrhosis, and hepatocellular carcinoma; HBV-infected individuals are at higher risk of all these HBV related diseases [Lee et al., 2013] .", [["liver", "ANATOMY", 78, 83], ["hepatic", "ANATOMY", 127, 134], ["hepatocellular carcinoma", "ANATOMY", 166, 190], ["deaths", "DISEASE", 25, 31], ["HBV infection", "DISEASE", 46, 59], ["liver diseases", "DISEASE", 78, 92], ["hepatic decompensation", "DISEASE", 127, 149], ["cirrhosis", "DISEASE", 151, 160], ["hepatocellular carcinoma", "DISEASE", 166, 190], ["HBV-infected", "DISEASE", 192, 204], ["HBV", "ORGANISM", 46, 49], ["liver", "ORGAN", 78, 83], ["hepatic", "ORGAN", 127, 134], ["hepatocellular carcinoma", "CANCER", 166, 190], ["HBV", "ORGANISM", 192, 195], ["individuals", "ORGANISM", 205, 216], ["HBV", "SPECIES", 46, 49], ["HBV", "SPECIES", 192, 195], ["HBV", "SPECIES", 249, 252], ["HBV infection", "PROBLEM", 46, 59], ["its associated liver diseases", "PROBLEM", 63, 92], ["hepatic decompensation", "PROBLEM", 127, 149], ["cirrhosis", "PROBLEM", 151, 160], ["hepatocellular carcinoma", "PROBLEM", 166, 190], ["HBV", "PROBLEM", 192, 195], ["infected individuals", "PROBLEM", 196, 216], ["all these HBV related diseases", "PROBLEM", 239, 269], ["infection", "OBSERVATION", 50, 59], ["liver", "ANATOMY", 78, 83], ["hepatic", "ANATOMY", 127, 134], ["decompensation", "OBSERVATION", 135, 149], ["cirrhosis", "OBSERVATION", 151, 160], ["hepatocellular", "ANATOMY", 166, 180], ["carcinoma", "OBSERVATION", 181, 190], ["infected", "OBSERVATION_MODIFIER", 196, 204], ["HBV", "OBSERVATION", 249, 252]]], ["Although efficient prophylactic vaccines have been developed for prevention of HBV infection, there is still no cure for existing infection.", [["HBV infection", "DISEASE", 79, 92], ["infection", "DISEASE", 130, 139], ["HBV", "ORGANISM", 79, 82], ["HBV", "SPECIES", 79, 82], ["efficient prophylactic vaccines", "TREATMENT", 9, 40], ["HBV infection", "PROBLEM", 79, 92], ["existing infection", "PROBLEM", 121, 139], ["HBV", "OBSERVATION_MODIFIER", 79, 82], ["infection", "OBSERVATION", 83, 92], ["infection", "OBSERVATION", 130, 139]]], ["The current clinical applied therapeutic agents for CHB are mainly immunomodulators and nucleoside/nucleotide analogues, which can be used either separately or in combination [Yuen and Lai, 2001; Papatheodoridis et al., 2008; Scaglione and Lok, 2012; Trepo et al., 2014] .", [["CHB", "DISEASE", 52, 55], ["nucleoside", "CHEMICAL", 88, 98], ["nucleotide", "CHEMICAL", 99, 109], ["nucleoside", "CHEMICAL", 88, 98], ["nucleotide", "CHEMICAL", 99, 109], ["nucleoside/nucleotide analogues", "SIMPLE_CHEMICAL", 88, 119], ["therapeutic agents", "TREATMENT", 29, 47], ["CHB", "PROBLEM", 52, 55], ["mainly immunomodulators", "TREATMENT", 60, 83], ["nucleoside/nucleotide analogues", "TREATMENT", 88, 119]]], ["Interferon alpha (IFN-a) is the best-known immunodulator, and controls HBV infection by stimulating the cellular antiviral cytokine expression to inhibit viral replication and by enhancing the host immune responses to eliminate the HBV-infected hepatocytes [Yuen and Lai, 2001] .", [["cellular", "ANATOMY", 104, 112], ["hepatocytes", "ANATOMY", 245, 256], ["Interferon alpha", "CHEMICAL", 0, 16], ["HBV infection", "DISEASE", 71, 84], ["Interferon alpha", "GENE_OR_GENE_PRODUCT", 0, 16], ["IFN-a", "GENE_OR_GENE_PRODUCT", 18, 23], ["immunodulator", "CANCER", 43, 56], ["HBV", "ORGANISM", 71, 74], ["cellular", "CELL", 104, 112], ["HBV", "ORGANISM", 232, 235], ["hepatocytes", "CELL", 245, 256], ["Interferon alpha", "PROTEIN", 0, 16], ["IFN", "PROTEIN", 18, 21], ["cytokine", "PROTEIN", 123, 131], ["infected hepatocytes", "CELL_TYPE", 236, 256], ["HBV", "SPECIES", 71, 74], ["HBV", "SPECIES", 232, 235], ["Interferon alpha (IFN", "TREATMENT", 0, 21], ["HBV infection", "PROBLEM", 71, 84], ["the cellular antiviral cytokine expression", "TREATMENT", 100, 142], ["viral replication", "TREATMENT", 154, 171], ["the HBV", "PROBLEM", 228, 235], ["infected hepatocytes", "PROBLEM", 236, 256], ["HBV infection", "OBSERVATION", 71, 84], ["hepatocytes", "ANATOMY", 245, 256]]], ["However, its poor response against CHB, high commercial cost, and various adverse effects (AEs) limit the wide clinical application of this drug.INTRODUCTIONMultiple nucleoside (lamivudine, entecavir, and telbivudine) and nucleotide analogues (adefovir and tenofovir) have been approved for clinical application [Liaw and Chu, 2009 ].", [["CHB", "DISEASE", 35, 38], ["nucleoside", "CHEMICAL", 166, 176], ["lamivudine", "CHEMICAL", 178, 188], ["entecavir", "CHEMICAL", 190, 199], ["telbivudine", "CHEMICAL", 205, 216], ["nucleotide", "CHEMICAL", 222, 232], ["adefovir", "CHEMICAL", 244, 252], ["tenofovir", "CHEMICAL", 257, 266], ["nucleoside", "CHEMICAL", 166, 176], ["lamivudine", "CHEMICAL", 178, 188], ["entecavir", "CHEMICAL", 190, 199], ["telbivudine", "CHEMICAL", 205, 216], ["nucleotide", "CHEMICAL", 222, 232], ["adefovir", "CHEMICAL", 244, 252], ["tenofovir", "CHEMICAL", 257, 266], ["nucleoside", "SIMPLE_CHEMICAL", 166, 176], ["lamivudine", "SIMPLE_CHEMICAL", 178, 188], ["entecavir", "SIMPLE_CHEMICAL", 190, 199], ["telbivudine", "SIMPLE_CHEMICAL", 205, 216], ["nucleotide analogues", "SIMPLE_CHEMICAL", 222, 242], ["adefovir", "SIMPLE_CHEMICAL", 244, 252], ["tenofovir", "SIMPLE_CHEMICAL", 257, 266], ["CHB", "PROBLEM", 35, 38], ["high commercial cost", "PROBLEM", 40, 60], ["various adverse effects (AEs)", "PROBLEM", 66, 95], ["this drug", "TREATMENT", 135, 144], ["INTRODUCTIONMultiple nucleoside", "TREATMENT", 145, 176], ["lamivudine", "TREATMENT", 178, 188], ["entecavir", "TREATMENT", 190, 199], ["telbivudine", "TREATMENT", 205, 216], ["nucleotide analogues", "TREATMENT", 222, 242], ["adefovir", "TREATMENT", 244, 252], ["tenofovir", "TREATMENT", 257, 266], ["high", "OBSERVATION_MODIFIER", 40, 44]]], ["These oral antiviral agents mainly target HBV polymerase and reverse transcriptase by rapidly and potently inhibiting their activities.", [["oral", "ANATOMY", 6, 10], ["oral", "ORGANISM_SUBDIVISION", 6, 10], ["HBV", "ORGANISM", 42, 45], ["HBV polymerase", "PROTEIN", 42, 56], ["reverse transcriptase", "PROTEIN", 61, 82], ["HBV", "SPECIES", 42, 45], ["These oral antiviral agents", "TREATMENT", 0, 27], ["target HBV polymerase", "TREATMENT", 35, 56]]], ["Although nucleoside/nucleotide analogues have fewer AEs, they fail to eradicate HBV covalently closed circular DNA (cccDNA) in the nuclei of infected hepatocytes, which results in viral relapse after stopping the medication [Yuen and Lai, 2001; Trepo et al., 2014] .", [["nuclei", "ANATOMY", 131, 137], ["hepatocytes", "ANATOMY", 150, 161], ["nucleoside", "CHEMICAL", 9, 19], ["nucleotide", "CHEMICAL", 20, 30], ["nucleoside", "CHEMICAL", 9, 19], ["nucleotide", "CHEMICAL", 20, 30], ["nucleoside/nucleotide analogues", "SIMPLE_CHEMICAL", 9, 40], ["DNA", "CELLULAR_COMPONENT", 111, 114], ["cccDNA", "CELLULAR_COMPONENT", 116, 122], ["nuclei", "CELLULAR_COMPONENT", 131, 137], ["hepatocytes", "CELL", 150, 161], ["HBV covalently closed circular DNA", "DNA", 80, 114], ["infected hepatocytes", "CELL_TYPE", 141, 161], ["HBV", "SPECIES", 80, 83], ["nucleoside/nucleotide analogues", "TREATMENT", 9, 40], ["fewer AEs", "PROBLEM", 46, 55], ["HBV covalently closed circular DNA (cccDNA", "PROBLEM", 80, 122], ["infected hepatocytes", "PROBLEM", 141, 161], ["viral relapse", "PROBLEM", 180, 193], ["the medication", "TREATMENT", 209, 223], ["nuclei", "ANATOMY_MODIFIER", 131, 137], ["infected", "OBSERVATION", 141, 149], ["hepatocytes", "ANATOMY", 150, 161], ["viral relapse", "OBSERVATION", 180, 193]]], ["In addition, the development of drug resistance during therapy also limits the effective application of nucleoside/nucleotide analogues.", [["nucleoside", "CHEMICAL", 104, 114], ["nucleotide", "CHEMICAL", 115, 125], ["nucleoside", "CHEMICAL", 104, 114], ["nucleotide", "CHEMICAL", 115, 125], ["nucleoside/nucleotide analogues", "SIMPLE_CHEMICAL", 104, 135], ["drug resistance", "PROBLEM", 32, 47], ["therapy", "TREATMENT", 55, 62], ["nucleoside/nucleotide analogues", "TREATMENT", 104, 135], ["drug resistance", "OBSERVATION", 32, 47]]], ["Some of the most recent drugs, such as entecavir and tenofovir, have been observed to induce only a very low level of drug resistance, but long-term application may still induce expansion of HBV strains with mutations resisting these drugs [Trepo et al., 2014] .", [["entecavir", "CHEMICAL", 39, 48], ["tenofovir", "CHEMICAL", 53, 62], ["entecavir", "CHEMICAL", 39, 48], ["tenofovir", "CHEMICAL", 53, 62], ["entecavir", "SIMPLE_CHEMICAL", 39, 48], ["tenofovir", "SIMPLE_CHEMICAL", 53, 62], ["HBV", "ORGANISM", 191, 194], ["HBV", "SPECIES", 191, 194], ["entecavir", "TREATMENT", 39, 48], ["tenofovir", "TREATMENT", 53, 62], ["long-term application", "TREATMENT", 139, 160], ["HBV strains", "PROBLEM", 191, 202], ["mutations", "PROBLEM", 208, 217], ["these drugs", "TREATMENT", 228, 239], ["drug resistance", "OBSERVATION", 118, 133], ["HBV", "OBSERVATION", 191, 194]]], ["Thus, developing novel effective therapeutic approaches and agents is a necessary step against HBV infection.INTRODUCTIONSelenium (Se) is an essential trace mineral for animals and humans.", [["HBV infection", "DISEASE", 95, 108], ["INTRODUCTIONSelenium", "CHEMICAL", 109, 129], ["Se", "CHEMICAL", 131, 133], ["INTRODUCTIONSelenium", "CHEMICAL", 109, 129], ["Se", "CHEMICAL", 131, 133], ["HBV", "ORGANISM", 95, 98], ["INTRODUCTIONSelenium", "SIMPLE_CHEMICAL", 109, 129], ["Se", "SIMPLE_CHEMICAL", 131, 133], ["humans", "ORGANISM", 181, 187], ["humans", "SPECIES", 181, 187], ["HBV", "SPECIES", 95, 98], ["humans", "SPECIES", 181, 187], ["agents", "TREATMENT", 60, 66], ["HBV infection", "PROBLEM", 95, 108], ["effective", "OBSERVATION_MODIFIER", 23, 32], ["infection", "OBSERVATION", 99, 108], ["trace mineral", "OBSERVATION", 151, 164]]], ["In addition to antioxidant activity, Se has also shown anti-inflammatory and anticancer properties [Rayman, 2000] .", [["anticancer", "ANATOMY", 77, 87], ["Se", "CHEMICAL", 37, 39], ["Se", "CHEMICAL", 37, 39], ["Se", "SIMPLE_CHEMICAL", 37, 39], ["anticancer", "CANCER", 77, 87], ["anti-inflammatory", "OBSERVATION_MODIFIER", 55, 72]]], ["Se functions in either its inorganic forms, such as sodium selenite (Na 2 SeO 3 ) and sodium selenate, or its organic forms, such as the amino acids selenocysteine (Sec) and selenomethionine (SeMet), and multiple selenomolecles as intermediary metabolites [Papp et al., 2007] .", [["Se", "CHEMICAL", 0, 2], ["sodium selenite", "CHEMICAL", 52, 67], ["Na 2 SeO 3", "CHEMICAL", 69, 79], ["sodium selenate", "CHEMICAL", 86, 101], ["amino acids", "CHEMICAL", 137, 148], ["selenocysteine", "CHEMICAL", 149, 163], ["selenomethionine", "CHEMICAL", 174, 190], ["SeMet", "CHEMICAL", 192, 197], ["Se", "CHEMICAL", 0, 2], ["sodium selenite", "CHEMICAL", 52, 67], ["Na 2 SeO 3", "CHEMICAL", 69, 79], ["sodium selenate", "CHEMICAL", 86, 101], ["amino acids", "CHEMICAL", 137, 148], ["selenocysteine", "CHEMICAL", 149, 163], ["Sec", "CHEMICAL", 165, 168], ["selenomethionine", "CHEMICAL", 174, 190], ["SeMet", "CHEMICAL", 192, 197], ["selenomolecles", "CHEMICAL", 213, 227], ["Se", "SIMPLE_CHEMICAL", 0, 2], ["sodium selenite", "SIMPLE_CHEMICAL", 52, 67], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 69, 79], ["sodium selenate", "SIMPLE_CHEMICAL", 86, 101], ["amino acids", "AMINO_ACID", 137, 148], ["selenocysteine", "AMINO_ACID", 149, 163], ["Sec", "SIMPLE_CHEMICAL", 165, 168], ["selenomethionine", "SIMPLE_CHEMICAL", 174, 190], ["SeMet", "SIMPLE_CHEMICAL", 192, 197], ["selenomolecles", "SIMPLE_CHEMICAL", 213, 227], ["sodium selenite", "TEST", 52, 67], ["Na", "TEST", 69, 71], ["sodium selenate", "TEST", 86, 101], ["its organic forms", "PROBLEM", 106, 123], ["the amino acids selenocysteine", "TREATMENT", 133, 163], ["selenomethionine (SeMet)", "TREATMENT", 174, 198]]], ["Upon absorption, the inorganic salts in their oxidized forms [selenite (Se 4\u00fe ) or selenate (Se 6\u00fe )] can be reduced to selenide (Se 2\u00c0 ) by using reducing equivalents from reduced glutathione and reduced nicotinamide adenine dinucleotide phosphate (NADPH) [Zeng and Combs, 2008] .", [["inorganic salts", "CHEMICAL", 21, 36], ["selenite", "CHEMICAL", 62, 70], ["Se 4\u00fe", "CHEMICAL", 72, 77], ["selenate", "CHEMICAL", 83, 91], ["Se 6\u00fe", "CHEMICAL", 93, 98], ["selenide", "CHEMICAL", 120, 128], ["Se 2\u00c0", "CHEMICAL", 130, 135], ["glutathione", "CHEMICAL", 181, 192], ["nicotinamide adenine dinucleotide phosphate", "CHEMICAL", 205, 248], ["NADPH", "CHEMICAL", 250, 255], ["selenite", "CHEMICAL", 62, 70], ["Se 4\u00fe )", "CHEMICAL", 72, 79], ["selenate", "CHEMICAL", 83, 91], ["Se 6\u00fe )", "CHEMICAL", 93, 100], ["selenide", "CHEMICAL", 120, 128], ["Se 2\u00c0 )", "CHEMICAL", 130, 137], ["reduced glutathione", "CHEMICAL", 173, 192], ["reduced nicotinamide adenine dinucleotide phosphate", "CHEMICAL", 197, 248], ["NADPH", "CHEMICAL", 250, 255], ["inorganic salts", "SIMPLE_CHEMICAL", 21, 36], ["selenite", "SIMPLE_CHEMICAL", 62, 70], ["Se 4\u00fe )", "SIMPLE_CHEMICAL", 72, 79], ["selenate", "SIMPLE_CHEMICAL", 83, 91], ["Se 6\u00fe )", "SIMPLE_CHEMICAL", 93, 100], ["selenide", "SIMPLE_CHEMICAL", 120, 128], ["Se 2\u00c0 )", "SIMPLE_CHEMICAL", 130, 137], ["glutathione", "SIMPLE_CHEMICAL", 181, 192], ["reduced nicotinamide adenine dinucleotide phosphate", "SIMPLE_CHEMICAL", 197, 248], ["NADPH", "SIMPLE_CHEMICAL", 250, 255], ["the inorganic salts in their oxidized forms", "TREATMENT", 17, 60], ["selenite (Se", "TREATMENT", 62, 74], ["reduced glutathione", "TREATMENT", 173, 192], ["reduced nicotinamide adenine dinucleotide phosphate (NADPH) [Zeng and Combs", "TREATMENT", 197, 272]]], ["As a storage mechanism, SeMet can replace normal methionine in protein synthesis, and then be released reversibly by the normal metabolic process as necessary [Schrauzer, 2000] .", [["SeMet", "CHEMICAL", 24, 29], ["methionine", "CHEMICAL", 49, 59], ["SeMet", "CHEMICAL", 24, 29], ["methionine", "CHEMICAL", 49, 59], ["SeMet", "SIMPLE_CHEMICAL", 24, 29], ["methionine", "SIMPLE_CHEMICAL", 49, 59], ["normal methionine in protein synthesis", "TREATMENT", 42, 80], ["metabolic process", "OBSERVATION", 128, 145]]], ["Sec is probably the most abundant biologically active form of selenium in vivo, and can be specially incorporated into selenoproteins as the 21st amino acid encoded by the UGA codon [Metanis and Hilvert, 2014] .", [["selenium", "CHEMICAL", 62, 70], ["amino acid", "CHEMICAL", 146, 156], ["Sec", "CHEMICAL", 0, 3], ["selenium", "CHEMICAL", 62, 70], ["amino acid", "CHEMICAL", 146, 156], ["Sec", "GENE_OR_GENE_PRODUCT", 0, 3], ["selenium", "SIMPLE_CHEMICAL", 62, 70], ["amino acid", "AMINO_ACID", 146, 156], ["selenoproteins", "PROTEIN", 119, 133], ["UGA codon", "DNA", 172, 181], ["the 21st amino acid", "TREATMENT", 137, 156], ["probably the", "UNCERTAINTY", 7, 19], ["most abundant", "OBSERVATION_MODIFIER", 20, 33], ["biologically", "OBSERVATION_MODIFIER", 34, 46], ["active", "OBSERVATION", 47, 53], ["selenium", "OBSERVATION", 62, 70]]], ["Importantly, Sec might play some important biological roles in vivo, as most of the 25 identified human selenoproteins have shown enzymatic redox function with catalytic or antioxidant activities conferred by Sec [Kryukov et al., 2003; Papp et al., 2007] .INTRODUCTIONBesides the biological functions described above, Se is also involved in the occurrence, virulence, and disease progression of some viral infections [Rayman, 2000; Moghadaszadeh and Beggs, 2006 ].", [["Se", "CHEMICAL", 318, 320], ["viral infections", "DISEASE", 400, 416], ["Sec", "CHEMICAL", 13, 16], ["Sec", "CHEMICAL", 209, 212], ["Se", "CHEMICAL", 318, 320], ["Sec", "GENE_OR_GENE_PRODUCT", 13, 16], ["human", "ORGANISM", 98, 103], ["Se", "SIMPLE_CHEMICAL", 318, 320], ["Sec", "PROTEIN", 13, 16], ["human selenoproteins", "PROTEIN", 98, 118], ["Se", "PROTEIN", 318, 320], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 98, 103], ["virulence", "PROBLEM", 357, 366], ["some viral infections", "PROBLEM", 395, 416]]], ["For some RNA viruses, including coxsackievirus B3 (CVB3/0) (cause of Keshan disease), human immunodeficiency virus (HIV), influenza A virus, SARS coronavirus, and Ebola virus, the absence of Se causes accumulation of mutations in their genome, leads to changes in the virulence-associated genetic structures [Beck et al., 2003; Harthill, 2011] .", [["Keshan disease", "DISEASE", 69, 83], ["human immunodeficiency virus (HIV), influenza A virus", "DISEASE", 86, 139], ["SARS coronavirus", "DISEASE", 141, 157], ["Ebola virus", "DISEASE", 163, 174], ["Se", "CHEMICAL", 191, 193], ["Se", "CHEMICAL", 191, 193], ["coxsackievirus B3", "ORGANISM", 32, 49], ["CVB3/0", "ORGANISM", 51, 57], ["Keshan", "ORGANISM", 69, 75], ["human immunodeficiency virus", "ORGANISM", 86, 114], ["HIV", "ORGANISM", 116, 119], ["influenza A virus", "ORGANISM", 122, 139], ["SARS coronavirus", "ORGANISM", 141, 157], ["Ebola virus", "ORGANISM", 163, 174], ["Se", "GENE_OR_GENE_PRODUCT", 191, 193], ["Se", "PROTEIN", 191, 193], ["human immunodeficiency virus (HIV", "SPECIES", 86, 119], ["influenza A virus", "SPECIES", 122, 139], ["SARS coronavirus", "SPECIES", 141, 157], ["Ebola virus", "SPECIES", 163, 174], ["coxsackievirus B3", "SPECIES", 32, 49], ["CVB3", "SPECIES", 51, 55], ["human immunodeficiency virus", "SPECIES", 86, 114], ["HIV", "SPECIES", 116, 119], ["influenza A virus", "SPECIES", 122, 139], ["SARS coronavirus", "SPECIES", 141, 157], ["Ebola virus", "SPECIES", 163, 174], ["some RNA viruses", "PROBLEM", 4, 20], ["coxsackievirus B3", "PROBLEM", 32, 49], ["CVB3", "TEST", 51, 55], ["Keshan disease", "PROBLEM", 69, 83], ["human immunodeficiency virus", "PROBLEM", 86, 114], ["HIV)", "PROBLEM", 116, 120], ["influenza A virus", "PROBLEM", 122, 139], ["SARS coronavirus", "PROBLEM", 141, 157], ["Ebola virus", "PROBLEM", 163, 174], ["mutations in their genome", "PROBLEM", 217, 242], ["RNA viruses", "OBSERVATION", 9, 20], ["Ebola virus", "OBSERVATION", 163, 174]]], ["Viral glutathione peroxidase (vGPx), a selenoprotein with antioxidant activity, has been found to be encoded by some RNA virus such as HIV and hepatitis C virus [Zhang et al., 1999] .", [["glutathione", "CHEMICAL", 6, 17], ["HIV and hepatitis C", "DISEASE", 135, 154], ["glutathione", "CHEMICAL", 6, 17], ["glutathione peroxidase", "GENE_OR_GENE_PRODUCT", 6, 28], ["vGPx", "GENE_OR_GENE_PRODUCT", 30, 34], ["selenoprotein", "GENE_OR_GENE_PRODUCT", 39, 52], ["HIV", "ORGANISM", 135, 138], ["hepatitis C virus", "ORGANISM", 143, 160], ["Viral glutathione peroxidase", "PROTEIN", 0, 28], ["vGPx", "PROTEIN", 30, 34], ["selenoprotein", "PROTEIN", 39, 52], ["HIV", "SPECIES", 135, 138], ["hepatitis C virus", "SPECIES", 143, 160], ["HIV", "SPECIES", 135, 138], ["hepatitis C virus", "SPECIES", 143, 160], ["Viral glutathione peroxidase (vGPx", "TREATMENT", 0, 34], ["a selenoprotein with antioxidant activity", "TREATMENT", 37, 78], ["some RNA virus", "PROBLEM", 112, 126], ["HIV", "PROBLEM", 135, 138], ["hepatitis C virus", "PROBLEM", 143, 160], ["glutathione peroxidase", "OBSERVATION", 6, 28], ["RNA virus", "OBSERVATION", 117, 126]]], ["In virus-infected cells, vGPx inhibits ROS-induced apoptosis, a host response against infection, and further promotes viral replication [Papp et al., 2007] .INTRODUCTIONTo date, only a few reports have described the possible relevance of Se to HBV infection [Yu et al., 1997; Khan et al., 2012] , but direct evidence is still lacking, and the underlying mechanism remains to be elucidated.", [["cells", "ANATOMY", 18, 23], ["vGPx", "CHEMICAL", 25, 29], ["ROS", "CHEMICAL", 39, 42], ["infection", "DISEASE", 86, 95], ["Se", "CHEMICAL", 238, 240], ["HBV infection", "DISEASE", 244, 257], ["vGPx", "CHEMICAL", 25, 29], ["Se", "CHEMICAL", 238, 240], ["cells", "CELL", 18, 23], ["vGPx", "SIMPLE_CHEMICAL", 25, 29], ["ROS", "SIMPLE_CHEMICAL", 39, 42], ["Se", "SIMPLE_CHEMICAL", 238, 240], ["HBV", "ORGANISM", 244, 247], ["virus-infected cells", "CELL_TYPE", 3, 23], ["vGPx", "PROTEIN", 25, 29], ["HBV", "SPECIES", 244, 247], ["virus", "PROBLEM", 3, 8], ["infected cells", "PROBLEM", 9, 23], ["vGPx", "PROBLEM", 25, 29], ["apoptosis", "PROBLEM", 51, 60], ["infection", "PROBLEM", 86, 95], ["HBV infection", "PROBLEM", 244, 257], ["virus", "OBSERVATION", 3, 8], ["infected cells", "OBSERVATION", 9, 23]]], ["In the present study, hepatoma cell HepG2.2.15 and HuH-7 transfected with two different HBV plasmids were utilized in order to investigate the effect of Na 2 SeO 3 on HBV.", [["hepatoma cell HepG2", "ANATOMY", 22, 41], ["plasmids", "ANATOMY", 92, 100], ["Na", "CHEMICAL", 153, 155], ["Na 2 SeO 3", "CHEMICAL", 153, 163], ["hepatoma cell HepG2", "CELL", 22, 41], ["HuH-7", "CELL", 51, 56], ["HBV", "ORGANISM", 88, 91], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 153, 163], ["HBV", "ORGANISM", 167, 170], ["hepatoma cell HepG2", "CELL_LINE", 22, 41], ["HBV plasmids", "DNA", 88, 100], ["HBV", "SPECIES", 88, 91], ["HBV", "SPECIES", 167, 170], ["the present study", "TEST", 3, 20], ["hepatoma cell HepG2", "PROBLEM", 22, 41], ["HuH", "TEST", 51, 54], ["two different HBV plasmids", "TREATMENT", 74, 100], ["Na", "TEST", 153, 155], ["HBV", "TREATMENT", 167, 170], ["hepatoma cell HepG2", "OBSERVATION", 22, 41]]], ["The data clearly clarify that application of Na 2 SeO 3 inhibits HBsAg/ HBeAg expression, HBV transcription, and genome replication in the examined models.", [["Na", "CHEMICAL", 45, 47], ["SeO 3", "CHEMICAL", 50, 55], ["HBsAg", "CHEMICAL", 65, 70], ["HBeAg", "CHEMICAL", 72, 77], ["Na 2 SeO 3", "CHEMICAL", 45, 55], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 45, 55], ["HBsAg", "GENE_OR_GENE_PRODUCT", 65, 70], ["HBeAg", "GENE_OR_GENE_PRODUCT", 72, 77], ["HBV", "ORGANISM", 90, 93], ["HBsAg", "PROTEIN", 65, 70], ["HBV", "SPECIES", 90, 93], ["Na", "TEST", 45, 47], ["HBsAg", "TEST", 65, 70], ["HBeAg expression", "TREATMENT", 72, 88], ["HBV transcription", "TREATMENT", 90, 107], ["genome replication", "TREATMENT", 113, 131]]], ["This is the first report with direct evidence confirming the suppressive effect of Se on HBV replication.Cells and PlasmidsThe human hepatoma cell lines HepG2.2.15 and HuH-7 were obtained from the China Center for Type Culture Collection (CCTCC), and maintained in Dulbecco's modified eagle's medium supplemented with 10% (v/v) fetal bovine serum, 100 mg/ml penicillin, and 100 mg/ml streptomycin (all from Gibco Life Technologies) at 37\u02daC in a 5% CO 2 incubator.", [["Cells", "ANATOMY", 105, 110], ["hepatoma cell lines HepG2.2.15", "ANATOMY", 133, 163], ["HuH-7", "ANATOMY", 168, 173], ["fetal bovine serum", "ANATOMY", 328, 346], ["Se", "CHEMICAL", 83, 85], ["penicillin", "CHEMICAL", 358, 368], ["streptomycin", "CHEMICAL", 384, 396], ["Se", "CHEMICAL", 83, 85], ["penicillin", "CHEMICAL", 358, 368], ["streptomycin", "CHEMICAL", 384, 396], ["CO 2", "CHEMICAL", 448, 452], ["Se", "SIMPLE_CHEMICAL", 83, 85], ["HBV", "ORGANISM", 89, 92], ["Cells", "CELL", 105, 110], ["Plasmids", "ORGANISM", 115, 123], ["human", "ORGANISM", 127, 132], ["hepatoma cell lines HepG2.2.15", "CELL", 133, 163], ["HuH-7", "CELL", 168, 173], ["bovine", "ORGANISM", 334, 340], ["serum", "ORGANISM_SUBSTANCE", 341, 346], ["penicillin", "SIMPLE_CHEMICAL", 358, 368], ["streptomycin", "SIMPLE_CHEMICAL", 384, 396], ["Plasmids", "DNA", 115, 123], ["human hepatoma cell lines", "CELL_LINE", 127, 152], ["HepG2.2.15", "CELL_LINE", 153, 163], ["HuH-7", "CELL_LINE", 168, 173], ["human", "SPECIES", 127, 132], ["bovine", "SPECIES", 334, 340], ["HBV", "SPECIES", 89, 92], ["human", "SPECIES", 127, 132], ["bovine", "SPECIES", 334, 340], ["HBV replication", "TREATMENT", 89, 104], ["Plasmids", "TREATMENT", 115, 123], ["The human hepatoma cell lines", "TEST", 123, 152], ["HuH", "TEST", 168, 171], ["Type Culture Collection", "TEST", 214, 237], ["v/v) fetal bovine serum", "TREATMENT", 323, 346], ["penicillin", "TREATMENT", 358, 368], ["streptomycin", "TREATMENT", 384, 396], ["hepatoma", "ANATOMY", 133, 141], ["cell lines", "OBSERVATION", 142, 152]]], ["HepG2.2.15 is derived from HepG2 cells by being stably transfected with a construct containing two head-to-tail dimers of the HBV genome (GenBank accession: U95551.1), so 200 mg/ml G418 was also added to maintain the cell line.Cells and PlasmidsPlasmid pCH-9/3091 (1.1\u00c2HBV) is an HBV construct containing 1.1 copies of the HBV genome (subtype ayw) driven by the human cytomegalovirus (HCMV) immediate early I protein (IE1) promoter [Nassal, 1992] (kind gift from Dr Michael Nassal), and p1.3HBV (1.3\u00c2HBV) is another HBV construct generated by inserting 1.3 copies of the HBV genome (subtype adw), starting from the enhancer-I-X promoter region, into pGEM-3Z [Doitsh and Shaul, 2003 ] (kind gift from Dr. Yosef Shaul).Transfection and TreatmentTo study viral replication, plasmid pCH-9/3091 and 1.3\u00c2HBV were transfected into 3 \u00c2 10 6 HuH-7 cells in 6 cm plates using Lipofectamine TM 2000 (Invitrogen, Waltham, MA) according to the manufacturer's instructions.", [["HepG2 cells", "ANATOMY", 27, 38], ["cell line", "ANATOMY", 217, 226], ["Cells", "ANATOMY", 227, 232], ["HuH-7 cells", "ANATOMY", 833, 844], ["HepG2.2.15", "CHEMICAL", 0, 10], ["G418", "CHEMICAL", 181, 185], ["pCH-9/3091", "CHEMICAL", 253, 263], ["G418", "CHEMICAL", 181, 185], ["HepG2.2.15", "GENE_OR_GENE_PRODUCT", 0, 10], ["HepG2 cells", "CELL", 27, 38], ["HBV", "ORGANISM", 126, 129], ["cell line", "CELL", 217, 226], ["Cells", "CELL", 227, 232], ["Plasmids", "ORGANISM", 237, 245], ["Plasmid pCH-9/3091", "ORGANISM", 245, 263], ["HBV", "ORGANISM", 280, 283], ["HBV", "ORGANISM", 323, 326], ["human cytomegalovirus", "ORGANISM", 362, 383], ["HCMV", "ORGANISM", 385, 389], ["immediate early I protein", "GENE_OR_GENE_PRODUCT", 391, 416], ["IE1", "GENE_OR_GENE_PRODUCT", 418, 421], ["p1.3HBV", "ORGANISM", 487, 494], ["HBV", "ORGANISM", 516, 519], ["HBV", "ORGANISM", 571, 574], ["pGEM-3Z", "GENE_OR_GENE_PRODUCT", 650, 657], ["HuH-7 cells", "CELL", 833, 844], ["HepG2.2.15", "CELL_LINE", 0, 10], ["HepG2 cells", "CELL_LINE", 27, 38], ["head-to-tail dimers", "PROTEIN", 99, 118], ["HBV genome", "DNA", 126, 136], ["cell line", "CELL_LINE", 217, 226], ["HBV construct", "DNA", 280, 293], ["HBV genome", "DNA", 323, 333], ["human cytomegalovirus (HCMV) immediate early I protein (IE1) promoter", "DNA", 362, 431], ["HBV construct", "DNA", 516, 529], ["HBV genome", "DNA", 571, 581], ["subtype adw", "DNA", 583, 594], ["enhancer-I-X promoter region", "DNA", 615, 643], ["pGEM", "DNA", 650, 654], ["plasmid pCH-9/3091 and 1.3\u00c2HBV", "DNA", 771, 801], ["HuH-7 cells", "CELL_LINE", 833, 844], ["human", "SPECIES", 362, 367], ["HBV", "SPECIES", 126, 129], ["pCH-9/3091", "SPECIES", 253, 263], ["1.1\u00c2HBV", "SPECIES", 265, 272], ["HBV", "SPECIES", 280, 283], ["HBV", "SPECIES", 323, 326], ["human cytomegalovirus", "SPECIES", 362, 383], ["HCMV", "SPECIES", 385, 389], ["HBV", "SPECIES", 491, 494], ["\u00c2HBV", "SPECIES", 499, 503], ["HBV", "SPECIES", 516, 519], ["HBV", "SPECIES", 571, 574], ["\u00c2HBV", "SPECIES", 797, 801], ["HepG2.2.15", "TREATMENT", 0, 10], ["HepG2 cells", "TEST", 27, 38], ["the cell line", "TREATMENT", 213, 226], ["Cells", "TEST", 227, 232], ["PlasmidsPlasmid pCH", "TEST", 237, 256], ["an HBV construct", "PROBLEM", 277, 293], ["the HBV genome", "PROBLEM", 319, 333], ["the human cytomegalovirus", "PROBLEM", 358, 383], ["HBV", "TEST", 491, 494], ["another HBV construct", "PROBLEM", 508, 529], ["the HBV genome", "PROBLEM", 567, 581], ["Transfection", "TREATMENT", 717, 729], ["Treatment", "TREATMENT", 734, 743], ["study viral replication", "TEST", 746, 769], ["plasmid pCH", "TEST", 771, 782], ["\u00c2HBV", "TEST", 797, 801], ["HuH", "TEST", 833, 836], ["Lipofectamine TM", "TREATMENT", 866, 882], ["Invitrogen", "TREATMENT", 889, 899], ["HBV genome", "OBSERVATION", 126, 136], ["cell line", "OBSERVATION", 217, 226], ["HBV genome", "OBSERVATION", 323, 333], ["HBV genome", "OBSERVATION", 571, 581], ["6 cm", "OBSERVATION_MODIFIER", 848, 852]]], ["After HepG2.2.15 was cultured for 24 hr or HuH-7 was transfected for 24 hr, then the medium was replaced by fresh medium with Na 2 SeO 3 or 30 nM entecavir (ETV) (both Sigma Aldrich, St. Louius, MO), which had been dissolved in 1\u00c2 sterile phosphate-buffered saline (PBS).", [["HepG2.2.15", "ANATOMY", 6, 16], ["Na", "CHEMICAL", 126, 128], ["entecavir", "CHEMICAL", 146, 155], ["ETV", "CHEMICAL", 157, 160], ["phosphate", "CHEMICAL", 239, 248], ["Na 2 SeO", "CHEMICAL", 126, 134], ["entecavir", "CHEMICAL", 146, 155], ["ETV", "CHEMICAL", 157, 160], ["phosphate", "CHEMICAL", 239, 248], ["HepG2.2.15", "CELL", 6, 16], ["HuH-7", "CELL", 43, 48], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 126, 136], ["entecavir", "SIMPLE_CHEMICAL", 146, 155], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 239, 264], ["HepG2.2.15", "CELL_LINE", 6, 16], ["HepG2", "TEST", 6, 11], ["HuH", "TEST", 43, 46], ["Na", "TEST", 126, 128], ["entecavir (ETV", "TREATMENT", 146, 160], ["1\u00c2 sterile phosphate", "TREATMENT", 228, 248], ["buffered saline (PBS", "TREATMENT", 249, 269]]], ["The treatment starting day was defined as Day 0, and samples were collected at the indicated time points.Cytotoxicity AssayHepG2.2.15 and HuH-7 cells (1\u00c210 4 cells/well) were cultured in 96-well plates, and Na 2 SeO 3 at the indicated concentrations was added to the culture 24 h later.", [["samples", "ANATOMY", 53, 60], ["HuH-7 cells", "ANATOMY", 138, 149], ["1\u00c210 4 cells", "ANATOMY", 151, 163], ["Na", "CHEMICAL", 207, 209], ["SeO 3", "CHEMICAL", 212, 217], ["Na 2 SeO 3", "CHEMICAL", 207, 217], ["HuH-7 cells", "CELL", 138, 149], ["1\u00c210 4 cells", "CELL", 151, 163], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 207, 217], ["AssayHepG2.2.15", "CELL_LINE", 118, 133], ["HuH-7 cells", "CELL_LINE", 138, 149], ["1\u00c210 4 cells", "CELL_LINE", 151, 163], ["The treatment", "TREATMENT", 0, 13], ["Cytotoxicity", "TEST", 105, 117], ["HuH", "TEST", 138, 141], ["cells", "TEST", 144, 149], ["cells", "TEST", 158, 163], ["Na", "TEST", 207, 209], ["the culture", "TEST", 263, 274]]], ["The cells were harvested at the indicated time points, and assayed by colorimetry (Cell Counting Kit-8; Dojindo Laboratories).Enzyme-Linked Immunosorbent Assay of HBV AntigensTo quantify HBsAg and HBeAg production, the supernatants of the cells with the indicated treatment were collected, and tested for the presence of HBsAg and HBeAg using a commercial enzymelinked immunosorbent assay (ELISA) kit (KEHUA Bio-engineering).", [["cells", "ANATOMY", 4, 9], ["Cell", "ANATOMY", 83, 87], ["supernatants", "ANATOMY", 219, 231], ["cells", "ANATOMY", 239, 244], ["HBsAg", "CHEMICAL", 187, 192], ["HBeAg", "CHEMICAL", 197, 202], ["HBsAg", "CHEMICAL", 321, 326], ["HBeAg", "CHEMICAL", 331, 336], ["cells", "CELL", 4, 9], ["HBV", "ORGANISM", 163, 166], ["HBsAg", "GENE_OR_GENE_PRODUCT", 187, 192], ["HBeAg", "GENE_OR_GENE_PRODUCT", 197, 202], ["cells", "CELL", 239, 244], ["HBsAg", "GENE_OR_GENE_PRODUCT", 321, 326], ["HBeAg", "GENE_OR_GENE_PRODUCT", 331, 336], ["HBV Antigens", "PROTEIN", 163, 175], ["HBsAg", "PROTEIN", 187, 192], ["HBsAg", "PROTEIN", 321, 326], ["HBV", "SPECIES", 163, 166], ["Kit", "TEST", 97, 100], ["Enzyme", "TEST", 126, 132], ["Immunosorbent Assay", "TEST", 140, 159], ["HBV Antigens", "TEST", 163, 175], ["HBsAg", "TEST", 187, 192], ["HBeAg production", "TEST", 197, 213], ["treatment", "TREATMENT", 264, 273], ["HBsAg", "TEST", 321, 326], ["HBeAg", "TEST", 331, 336]]], ["The results were normalized to the mock-treatment (PBS) control sample.Northern Blot Assay for Viral RNACells were washed twice with PBS and homogenized in TRIzol (Invitrogen).", [["Viral", "ORGANISM", 95, 100], ["treatment (PBS) control sample", "TREATMENT", 40, 70], ["Northern Blot Assay", "TEST", 71, 90], ["Viral RNACells", "PROBLEM", 95, 109], ["PBS", "TREATMENT", 133, 136], ["TRIzol (Invitrogen", "TREATMENT", 156, 174]]], ["Total RNA was isolated according to the manufacturer's protocol.", [["Total RNA", "TREATMENT", 0, 9], ["the manufacturer's protocol", "TREATMENT", 36, 63]]], ["Potential DNA contamination in the extraction was eliminated with recombinant RNase-free DNase I (TaKaRa).", [["DNA", "CELLULAR_COMPONENT", 10, 13], ["RNase-free DNase I", "GENE_OR_GENE_PRODUCT", 78, 96], ["TaKaRa", "GENE_OR_GENE_PRODUCT", 98, 104], ["RNase", "PROTEIN", 78, 83], ["DNase I", "PROTEIN", 89, 96], ["TaKaRa", "PROTEIN", 98, 104], ["Potential DNA contamination", "PROBLEM", 0, 27], ["the extraction", "TREATMENT", 31, 45], ["recombinant RNase-free DNase I (TaKaRa)", "TREATMENT", 66, 105], ["DNA", "OBSERVATION_MODIFIER", 10, 13], ["contamination", "OBSERVATION", 14, 27]]], ["Samples were incubated at 65\u02daC for 5 min for denaturation, and then 20 mg RNA was electrophoresed for 3 hr at 100 V in 1.2% (w/v) agarose gel in the presence of formaldehyde.", [["Samples", "ANATOMY", 0, 7], ["formaldehyde", "CHEMICAL", 161, 173], ["formaldehyde", "CHEMICAL", 161, 173], ["agarose", "SIMPLE_CHEMICAL", 130, 137], ["formaldehyde", "SIMPLE_CHEMICAL", 161, 173], ["Samples", "TEST", 0, 7], ["denaturation", "PROBLEM", 45, 57], ["w/v) agarose gel", "TREATMENT", 125, 141], ["formaldehyde", "OBSERVATION", 161, 173]]], ["As described previously [Tian et al., 2013] , the resolved RNA was then blotted onto a positively charged nylon membrane, and hybridized with a 32 P-labeled random-primed probe specific for the HBV genome.", [["nylon membrane", "ANATOMY", 106, 120], ["nylon membrane", "CELLULAR_COMPONENT", 106, 120], ["HBV", "ORGANISM", 194, 197], ["32 P-labeled random-primed probe", "DNA", 144, 176], ["HBV genome", "DNA", 194, 204], ["HBV", "SPECIES", 194, 197], ["a positively charged nylon membrane", "TREATMENT", 85, 120], ["the HBV genome", "PROBLEM", 190, 204], ["nylon membrane", "OBSERVATION", 106, 120], ["HBV genome", "OBSERVATION", 194, 204]]], ["The visualized image was obtained using Cyclone Plus Storage Phosphor System (PerkinElmer, Waltham, MA), and the cell level in the northern blot assay were normalized to 28S/18S RNA.Southern Blot Assay for Encapsidated HBV DNAIntracellular viral core DNA was isolated using the method described previously [Feng et al., 2013] .", [["cell", "ANATOMY", 113, 117], ["cell", "CELL", 113, 117], ["DNA", "CELLULAR_COMPONENT", 251, 254], ["28S/18S RNA", "RNA", 170, 181], ["Encapsidated HBV DNAIntracellular viral core DNA", "DNA", 206, 254], ["HBV", "SPECIES", 219, 222], ["The visualized image", "TEST", 0, 20], ["Cyclone Plus Storage Phosphor System", "TREATMENT", 40, 76], ["the cell level", "TEST", 109, 123], ["the northern blot assay", "TEST", 127, 150], ["Southern Blot Assay", "TEST", 182, 201], ["Encapsidated HBV DNAIntracellular viral core DNA", "TREATMENT", 206, 254]]], ["Briefly, cells were lysed in either 1 ml (HepG2.2.15, 10 7 cells per 10 cm plate,) or 0.6 ml (HuH-7, 3\u00c210 6 cells per 6 cm plate) lysis buffer (50 mM Tris-HCl pH 7.5, 140 mM NaCl, 0.5% NP-40).", [["cells", "ANATOMY", 9, 14], ["HepG2", "ANATOMY", 42, 47], ["cells", "ANATOMY", 59, 64], ["3\u00c210 6 cells", "ANATOMY", 101, 113], ["Tris-HCl", "CHEMICAL", 150, 158], ["NaCl", "CHEMICAL", 174, 178], ["Tris-HCl", "CHEMICAL", 150, 158], ["NaCl", "CHEMICAL", 174, 178], ["cells", "CELL", 9, 14], ["HepG2", "CELL", 42, 47], ["cells", "CELL", 59, 64], ["cells", "CELL", 108, 113], ["HepG2", "CELL_LINE", 42, 47], ["plate", "TEST", 75, 80], ["HuH", "TEST", 94, 97], ["lysis buffer", "TEST", 130, 142], ["Tris", "TEST", 150, 154], ["pH", "TEST", 159, 161], ["NaCl", "TEST", 174, 178], ["NP", "TEST", 185, 187]]], ["After removing the cell debris by centrifugation, the supernatants were treated with 60 U DNase I (TaKaRa) and 5 ml RNase A (TaKaRa), and then incubated at 37\u02daC for 2 hr in the presence of 8 mM MgCl 2 to completely digest the non-encapsidated DNA and RNA.", [["cell debris", "ANATOMY", 19, 30], ["supernatants", "ANATOMY", 54, 66], ["MgCl", "CHEMICAL", 194, 198], ["MgCl 2", "CHEMICAL", 194, 200], ["cell", "CELL", 19, 23], ["DNase I", "GENE_OR_GENE_PRODUCT", 90, 97], ["TaKaRa", "GENE_OR_GENE_PRODUCT", 99, 105], ["RNase A", "GENE_OR_GENE_PRODUCT", 116, 123], ["TaKaRa", "GENE_OR_GENE_PRODUCT", 125, 131], ["DNA", "CELLULAR_COMPONENT", 243, 246], ["DNase I", "PROTEIN", 90, 97], ["TaKaRa", "PROTEIN", 99, 105], ["RNase A", "PROTEIN", 116, 123], ["non-encapsidated DNA and RNA", "RNA", 226, 254], ["the cell debris", "TREATMENT", 15, 30], ["the supernatants", "TREATMENT", 50, 66], ["60 U DNase I (TaKaRa)", "TREATMENT", 85, 106], ["RNase A (TaKaRa)", "TREATMENT", 116, 132], ["8 mM MgCl", "TREATMENT", 189, 198], ["the non-encapsidated DNA", "PROBLEM", 222, 246], ["cell debris", "OBSERVATION", 19, 30], ["centrifugation", "OBSERVATION_MODIFIER", 34, 48], ["DNA", "OBSERVATION", 243, 246]]], ["Core particles were degraded with 200 mM proteinase K (TIANGEN), and encapsidated DNA was extracted with phenol chloroform and precipitated by ethanol.", [["K", "CHEMICAL", 52, 53], ["phenol chloroform", "CHEMICAL", 105, 122], ["ethanol", "CHEMICAL", 143, 150], ["phenol chloroform", "CHEMICAL", 105, 122], ["ethanol", "CHEMICAL", 143, 150], ["proteinase K", "GENE_OR_GENE_PRODUCT", 41, 53], ["TIANGEN", "SIMPLE_CHEMICAL", 55, 62], ["DNA", "CELLULAR_COMPONENT", 82, 85], ["phenol chloroform", "SIMPLE_CHEMICAL", 105, 122], ["ethanol", "SIMPLE_CHEMICAL", 143, 150], ["Core particles", "TEST", 0, 14], ["encapsidated DNA", "PROBLEM", 69, 85], ["phenol chloroform", "TREATMENT", 105, 122], ["particles", "OBSERVATION_MODIFIER", 5, 14]]], ["Following separation in a 1% agarose gel (w/v), the isolated encapsidated HBV DNA was blotted onto a positively charged nylon membrane (Millipore) and hybridized with the same probe used for the northern blot assay.", [["nylon membrane", "ANATOMY", 120, 134], ["nylon", "CHEMICAL", 120, 125], ["agarose", "SIMPLE_CHEMICAL", 29, 36], ["HBV", "ORGANISM", 74, 77], ["DNA", "CELLULAR_COMPONENT", 78, 81], ["membrane", "CELLULAR_COMPONENT", 126, 134], ["encapsidated HBV DNA", "DNA", 61, 81], ["HBV", "SPECIES", 74, 77], ["a 1% agarose gel", "TREATMENT", 24, 40], ["the isolated encapsidated HBV DNA", "PROBLEM", 48, 81], ["a positively charged nylon membrane", "TREATMENT", 99, 134], ["the same probe", "TREATMENT", 167, 181], ["the northern blot assay", "TEST", 191, 214], ["HBV", "OBSERVATION", 74, 77], ["nylon membrane", "OBSERVATION", 120, 134]]], ["Finally, the signals were visualized using Cyclone Plus Storage Phosphor System (Perkin Elmer).", [["Cyclone Plus Storage Phosphor System", "TREATMENT", 43, 79]]], ["The cell level in the Southern blot assay was normalized to the b-actin protein level.Quantitative Real-Time Polymerase ChainReaction (qPCR)Quantitative Real-Time Polymerase ChainThe quantitative real-time polymerase chain reaction was performed with the SYBR Premix Ex Taq II (TaKaRa) using a LightCycler 96 Real-Time PCR system (Roche, Penzberg, Germany).", [["cell", "ANATOMY", 4, 8], ["cell", "CELL", 4, 8], ["b-actin", "GENE_OR_GENE_PRODUCT", 64, 71], ["Taq II", "GENE_OR_GENE_PRODUCT", 270, 276], ["TaKaRa", "GENE_OR_GENE_PRODUCT", 278, 284], ["b-actin protein", "PROTEIN", 64, 79], ["SYBR Premix Ex Taq II", "PROTEIN", 255, 276], ["The cell level", "TEST", 0, 14], ["the Southern blot assay", "TEST", 18, 41], ["the b-actin protein level", "TEST", 60, 85], ["ChainReaction", "TEST", 120, 133], ["qPCR", "TEST", 135, 139], ["the SYBR Premix Ex Taq II (TaKaRa)", "TREATMENT", 251, 285], ["a LightCycler", "TEST", 292, 305], ["cell level", "OBSERVATION", 4, 14]]], ["The HBV genome sequence (GeneBank Accession no. DQ219811) was amplified with primer 5 0 -ACC AAT CGC CAG TCA GGA AG-3 0 and 5 0 -ACC AGC AGG GAA ATA CAG GC-3 0 ; and b-actin (GeneBank Accession no. NM_001101), serving as the internal reference, was amplified with primer 5 0 -CAT GTA CGT TGC TAT CCA GGC-3 0 and 5 0 -CTC CTT AAT GTC ACG CAC GAT-3 0 .", [["DQ219811", "CHEMICAL", 48, 56], ["NM_001101", "CHEMICAL", 198, 207], ["HBV", "ORGANISM", 4, 7], ["DQ219811", "SIMPLE_CHEMICAL", 48, 56], ["HBV genome sequence", "DNA", 4, 23], ["DQ219811", "DNA", 48, 56], ["primer 5 0 -ACC AAT", "DNA", 77, 96], ["CAG TCA GGA AG-3 0 and 5 0 -ACC AGC", "DNA", 101, 136], ["CAG GC-3 0", "DNA", 149, 159], ["b-actin", "DNA", 166, 173], ["primer 5 0 -CAT GTA CGT TGC TAT CCA GGC-3 0 and 5 0 -CTC CTT AAT GTC ACG CAC GAT-3 0", "DNA", 264, 348], ["HBV", "SPECIES", 4, 7], ["GeneBank Accession no.", "SPECIES", 25, 47], ["The HBV genome sequence", "TEST", 0, 23], ["primer", "TEST", 77, 83], ["CGC", "TEST", 97, 100], ["CAG", "TEST", 101, 104], ["TCA", "TEST", 105, 108], ["GGA", "TEST", 109, 112], ["AG", "TEST", 113, 115], ["ACC AGC", "TEST", 129, 136], ["AGG", "TEST", 137, 140], ["GAA", "TEST", 141, 144], ["CAG", "TEST", 149, 152], ["GC", "TEST", 153, 155], ["primer", "TEST", 264, 270], ["CGT", "TEST", 284, 287], ["GGC", "TEST", 300, 303], ["CTC CTT AAT GTC ACG CAC GAT", "TEST", 317, 344]]], ["The cycling program was run at 95\u02daC for 5 min, followed by 45 cycles at 95\u02daC for 10 sec, 60\u02daC for 10 sec, and 72\u02daC for 10 sec.Statistical AnalysisAll results for the toxicity assay and ELISA are shown as mean AE standard error from at least three independent experiments.", [["toxicity", "DISEASE", 166, 174], ["Statistical Analysis", "TEST", 126, 146], ["the toxicity assay", "TEST", 162, 180], ["ELISA", "TEST", 185, 190]]], ["Statistical differences were analyzed using unpaired two-tailed Student's t tests.", [["Student's t tests", "TEST", 64, 81]]], ["Results of Southern or northern blot assays are representative images selected from at least three independent experiments.Cytotoxicity of Na 2 SeO 3 to HepG2.2.15 and HuH-7 CellsTo eliminate the possibility that any observed influences of Na 2 SeO 3 on HBV replication were caused by cytotoxicity, the influence of Na 2 SeO 3 on HuH-7 and HepG2.2.15 proliferation was examined using CCK-8 assay.", [["HepG2", "ANATOMY", 153, 158], ["HuH-7", "ANATOMY", 330, 335], ["HepG2", "ANATOMY", 340, 345], ["Na", "CHEMICAL", 139, 141], ["Na", "CHEMICAL", 240, 242], ["SeO 3", "CHEMICAL", 245, 250], ["Na", "CHEMICAL", 316, 318], ["Na 2 SeO 3", "CHEMICAL", 139, 149], ["Na 2 SeO 3", "CHEMICAL", 240, 250], ["Na 2 SeO 3", "CHEMICAL", 316, 326], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 139, 149], ["HepG2", "CELL", 153, 158], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 240, 250], ["HBV", "ORGANISM", 254, 257], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 316, 326], ["HuH-7", "CELL", 330, 335], ["HepG2", "CELL", 340, 345], ["CCK-8", "GENE_OR_GENE_PRODUCT", 384, 389], ["HepG2", "CELL_LINE", 153, 158], ["HuH-7", "CELL_LINE", 330, 335], ["HepG2", "CELL_LINE", 340, 345], ["HBV", "SPECIES", 254, 257], ["northern blot assays", "TEST", 23, 43], ["representative images", "TEST", 48, 69], ["HuH", "TEST", 168, 171], ["Na", "TEST", 240, 242], ["HBV replication", "TREATMENT", 254, 269], ["cytotoxicity", "PROBLEM", 285, 297], ["Na", "TEST", 316, 318], ["HuH", "TEST", 330, 333], ["CCK", "TEST", 384, 387], ["HepG2", "ANATOMY", 340, 345]]], ["No significant toxicity of Na 2-SeO 3 on HuH-7 cells was observed at concentrations 2.5 mM, whereas Na 2 SeO 3 treatment beyond this concentration displayed inhibition of HuH-7 growth in a dose-dependent manner (Fig. 1A) .", [["HuH-7 cells", "ANATOMY", 41, 52], ["toxicity", "DISEASE", 15, 23], ["Na 2-SeO", "CHEMICAL", 27, 35], ["Na", "CHEMICAL", 100, 102], ["SeO 3", "CHEMICAL", 105, 110], ["Na 2-SeO 3", "CHEMICAL", 27, 37], ["Na 2 SeO 3", "CHEMICAL", 100, 110], ["Na 2-SeO 3", "SIMPLE_CHEMICAL", 27, 37], ["HuH-7 cells", "CELL", 41, 52], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 100, 110], ["HuH-7", "GENE_OR_GENE_PRODUCT", 171, 176], ["HuH-7 cells", "CELL_LINE", 41, 52], ["significant toxicity", "PROBLEM", 3, 23], ["Na", "TEST", 27, 29], ["HuH", "TEST", 41, 44], ["Na", "TEST", 100, 102], ["this concentration", "TEST", 128, 146], ["HuH", "TEST", 171, 174], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["toxicity", "OBSERVATION", 15, 23]]], ["HepG2.2.15 cells showed greater tolerance against Na 2 SeO 3 treatment.", [["HepG2.2.15 cells", "ANATOMY", 0, 16], ["Na", "CHEMICAL", 50, 52], ["SeO 3", "CHEMICAL", 55, 60], ["Na 2 SeO 3", "CHEMICAL", 50, 60], ["HepG2.2.15 cells", "CELL", 0, 16], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 50, 60], ["HepG2.2.15 cells", "CELL_LINE", 0, 16], ["HepG2.2.15 cells", "TEST", 0, 16], ["Na 2 SeO 3 treatment", "TREATMENT", 50, 70], ["greater", "OBSERVATION_MODIFIER", 24, 31]]], ["Treatment with 10 mM Na 2 SeO 3 for three days and 5 mM Na 2 SeO 3 for five days did not change the growth of HepG2.2.15 compared with the mocktreated control.", [["HepG2", "ANATOMY", 110, 115], ["Na", "CHEMICAL", 21, 23], ["SeO 3", "CHEMICAL", 26, 31], ["Na", "CHEMICAL", 56, 58], ["SeO 3", "CHEMICAL", 61, 66], ["Na 2 SeO 3", "CHEMICAL", 21, 31], ["Na 2 SeO 3", "CHEMICAL", 56, 66], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 21, 31], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 56, 66], ["HepG2", "CELL", 110, 115], ["HepG2", "CELL_LINE", 110, 115], ["10 mM Na", "TREATMENT", 15, 23], ["the mocktreated control", "TREATMENT", 135, 158]]], ["Beyond this concentration, the cell numbers of HepG2.2.15 decreased gradually, indicating cytotoxicity of Na 2 SeO 3 (Fig. 1B) .", [["cell", "ANATOMY", 31, 35], ["HepG2", "ANATOMY", 47, 52], ["Na", "CHEMICAL", 106, 108], ["Na 2 SeO 3", "CHEMICAL", 106, 116], ["cell", "CELL", 31, 35], ["HepG2", "CELL", 47, 52], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 106, 116], ["HepG2", "CELL_LINE", 47, 52], ["cytotoxicity", "TEST", 90, 102], ["Na", "TEST", 106, 108], ["HepG2", "ANATOMY", 47, 52], ["decreased", "OBSERVATION_MODIFIER", 58, 67], ["cytotoxicity", "OBSERVATION_MODIFIER", 90, 102]]], ["For both cell types, no significant differences were observed during the Na 2 SeO 3 treatment period at or below the safe concentration of 2.5 mM for HuH-7 and 5 mM for HepG2.2.15.", [["cell", "ANATOMY", 9, 13], ["HepG2.2", "ANATOMY", 169, 176], ["Na", "CHEMICAL", 73, 75], ["SeO", "CHEMICAL", 78, 81], ["Na 2 SeO 3", "CHEMICAL", 73, 83], ["cell", "CELL", 9, 13], ["HepG2.2", "CELL", 169, 176], ["significant differences", "PROBLEM", 24, 47], ["HuH", "TEST", 150, 153], ["HepG2", "TEST", 169, 174], ["cell types", "OBSERVATION", 9, 19], ["no", "UNCERTAINTY", 21, 23], ["significant", "OBSERVATION_MODIFIER", 24, 35]]], ["However, the numbers of viable cells were obviously decreased during the treatment period beyond the safe concentration ( Fig. 1A and B) .", [["cells", "ANATOMY", 31, 36], ["cells", "CELL", 31, 36], ["viable cells", "PROBLEM", 24, 36], ["viable cells", "OBSERVATION", 24, 36], ["decreased", "OBSERVATION_MODIFIER", 52, 61]]], ["For HuH-7, the decline in cell growth at one, three, and five days was relatively consistent (Fig. 1A) , but HepG2.2.15 treated for five days showed a more dramatic decrease in cell growth compared with Days one and three (Fig. 1B) .Cytotoxicity of Na 2 SeO 3 to HepG2.2.15 and HuH-7 CellsHence, 2.5 mM, which showed no significant cytotoxicity for either cell type, was set as the maximum concentration of Na 2 SeO 3 treatment for subsequent experiments.Inhibition of HBsAg and HBeAg Production by Na 2 SeO 3To study the effect of Na 2 SeO 3 on HBV viral protein production, HepG2.2.15 cells or HBV plasmid-transfected HuH-7 cells were treated with Na 2 SeO 3 .", [["cell", "ANATOMY", 26, 30], ["HepG2.2.15", "ANATOMY", 109, 119], ["cell", "ANATOMY", 177, 181], ["HepG2", "ANATOMY", 263, 268], ["cell", "ANATOMY", 356, 360], ["HepG2", "ANATOMY", 576, 581], ["2.15 cells", "ANATOMY", 582, 592], ["plasmid", "ANATOMY", 600, 607], ["HuH-7 cells", "ANATOMY", 620, 631], ["Na", "CHEMICAL", 249, 251], ["Na", "CHEMICAL", 407, 409], ["HBsAg", "CHEMICAL", 469, 474], ["HBeAg", "CHEMICAL", 479, 484], ["Na", "CHEMICAL", 499, 501], ["Na", "CHEMICAL", 532, 534], ["Na", "CHEMICAL", 650, 652], ["Na 2 SeO 3", "CHEMICAL", 249, 259], ["Na 2 SeO 3", "CHEMICAL", 407, 417], ["Na 2 SeO 3To", "CHEMICAL", 499, 511], ["Na 2 SeO 3", "CHEMICAL", 532, 542], ["Na 2 SeO 3", "CHEMICAL", 650, 660], ["HuH-7", "CELL", 4, 9], ["cell", "CELL", 26, 30], ["HepG2.2.15", "CELL", 109, 119], ["cell", "CELL", 177, 181], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 249, 259], ["HepG2", "CELL", 263, 268], ["HuH-7 CellsHence", "CELL", 278, 294], ["cell", "CELL", 356, 360], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 407, 417], ["HBsAg", "GENE_OR_GENE_PRODUCT", 469, 474], ["HBeAg", "GENE_OR_GENE_PRODUCT", 479, 484], ["Na 2 SeO 3To", "SIMPLE_CHEMICAL", 499, 511], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 532, 542], ["HBV", "ORGANISM", 546, 549], ["HepG2", "CELL", 576, 581], ["2.15 cells", "CELL", 582, 592], ["HBV", "ORGANISM", 596, 599], ["HuH-7 cells", "CELL", 620, 631], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 650, 660], ["HuH", "PROTEIN", 4, 7], ["HepG2.2.15", "CELL_LINE", 109, 119], ["HepG2", "CELL_LINE", 263, 268], ["HBsAg", "PROTEIN", 469, 474], ["HBV viral protein", "PROTEIN", 546, 563], ["HepG2", "CELL_LINE", 576, 581], ["HBV plasmid", "DNA", 596, 607], ["HuH-7 cells", "CELL_LINE", 620, 631], ["HBV", "SPECIES", 546, 549], ["HBV", "SPECIES", 596, 599], ["HuH", "TEST", 4, 7], ["the decline in cell growth", "PROBLEM", 11, 37], ["HepG2", "TEST", 109, 114], ["a more dramatic decrease in cell growth", "PROBLEM", 149, 188], ["HuH", "TEST", 278, 281], ["significant cytotoxicity", "PROBLEM", 320, 344], ["Na 2 SeO 3 treatment", "TREATMENT", 407, 427], ["HBsAg", "TEST", 469, 474], ["HBeAg Production", "TEST", 479, 495], ["Na", "TEST", 499, 501], ["Na", "TEST", 532, 534], ["HBV viral protein production", "PROBLEM", 546, 574], ["cells", "TEST", 587, 592], ["HBV plasmid", "TEST", 596, 607], ["HuH", "TEST", 620, 623], ["cell growth", "OBSERVATION", 26, 37], ["dramatic", "OBSERVATION_MODIFIER", 156, 164], ["decrease", "OBSERVATION_MODIFIER", 165, 173], ["cell", "OBSERVATION", 177, 181], ["growth", "OBSERVATION_MODIFIER", 182, 188], ["no", "UNCERTAINTY", 317, 319], ["significant", "OBSERVATION_MODIFIER", 320, 331], ["cytotoxicity", "OBSERVATION", 332, 344], ["cell type", "OBSERVATION", 356, 365], ["HBsAg", "OBSERVATION", 469, 474]]], ["Four concentrations, 0.5, 1.5, 2.0, and 2.5 mM, of Na 2 SeO 3 were investigated for cytotoxicity (Fig. 1) .", [["Na", "CHEMICAL", 51, 53], ["Na 2 SeO 3", "CHEMICAL", 51, 61], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 51, 61], ["Na 2 SeO", "TREATMENT", 51, 59], ["cytotoxicity", "PROBLEM", 84, 96]]], ["PBS and 30 nM ETV were used as controls.", [["ETV", "CHEMICAL", 14, 17], ["ETV", "CHEMICAL", 14, 17], ["PBS", "TEST", 0, 3], ["30 nM ETV", "TREATMENT", 8, 17], ["30 nM", "OBSERVATION_MODIFIER", 8, 13], ["ETV", "OBSERVATION", 14, 17]]], ["At three days posttreatment (HuH-7) or post-culture (HepG2.2.15), supernatants of the cultures were collected, and HBsAg and HBeAg expression were measured by ELISA.", [["supernatants", "ANATOMY", 66, 78], ["cultures", "ANATOMY", 86, 94], ["HBsAg", "CHEMICAL", 115, 120], ["HBeAg", "CHEMICAL", 125, 130], ["HBsAg", "GENE_OR_GENE_PRODUCT", 115, 120], ["HBeAg", "GENE_OR_GENE_PRODUCT", 125, 130], ["HBsAg", "PROTEIN", 115, 120], ["HBeAg", "PROTEIN", 125, 130], ["HuH", "TEST", 29, 32], ["the cultures", "TEST", 82, 94], ["HBsAg", "TEST", 115, 120], ["HBeAg expression", "TEST", 125, 141], ["ELISA", "TEST", 159, 164]]], ["For HepG2.2.15, 0.5 mM Na 2 SeO 3 was enough to cause a significant reduction in HBsAg and HBeAg expression compared with the mock-treated control, and Na 2 SeO 3 at the examined concentrations inhibited HBV antigen production in HepG2.2.15 in a dosedependent manner ( Fig. 2A and B) .Inhibition of HBsAg and HBeAg Production by Na 2 SeO 3In HuH-7 cells transfected with 1.1\u00c2 HBV plasmid, 0.5 mM Na 2 SeO 3 failed to decrease HBsAg and HBeAg levels.", [["HepG2", "ANATOMY", 230, 235], ["HuH-7 cells", "ANATOMY", 342, 353], ["Na", "CHEMICAL", 23, 25], ["SeO 3", "CHEMICAL", 28, 33], ["HBsAg", "CHEMICAL", 81, 86], ["HBeAg", "CHEMICAL", 91, 96], ["Na", "CHEMICAL", 152, 154], ["HBsAg", "CHEMICAL", 299, 304], ["HBeAg", "CHEMICAL", 309, 314], ["Na", "CHEMICAL", 329, 331], ["Na", "CHEMICAL", 396, 398], ["SeO 3", "CHEMICAL", 401, 406], ["HBsAg", "CHEMICAL", 426, 431], ["HBeAg", "CHEMICAL", 436, 441], ["Na 2 SeO 3", "CHEMICAL", 23, 33], ["Na 2 SeO 3", "CHEMICAL", 152, 162], ["Na 2 SeO 3", "CHEMICAL", 396, 406], ["HepG2.2.15", "SIMPLE_CHEMICAL", 4, 14], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 23, 33], ["HBsAg", "GENE_OR_GENE_PRODUCT", 81, 86], ["HBeAg", "GENE_OR_GENE_PRODUCT", 91, 96], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 152, 162], ["HBV", "ORGANISM", 204, 207], ["HepG2", "CELL", 230, 235], ["HBsAg", "GENE_OR_GENE_PRODUCT", 299, 304], ["HBeAg", "GENE_OR_GENE_PRODUCT", 309, 314], ["HuH-7 cells", "CELL", 342, 353], ["HBV", "ORGANISM", 376, 379], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 396, 406], ["HBsAg", "GENE_OR_GENE_PRODUCT", 426, 431], ["HBeAg", "GENE_OR_GENE_PRODUCT", 436, 441], ["HBsAg", "PROTEIN", 81, 86], ["HepG2", "CELL_LINE", 230, 235], ["HBsAg", "PROTEIN", 299, 304], ["HuH-7 cells", "CELL_LINE", 342, 353], ["1.1\u00c2 HBV plasmid", "DNA", 371, 387], ["HBsAg", "PROTEIN", 426, 431], ["HBV", "SPECIES", 204, 207], ["HBV", "SPECIES", 376, 379], ["HepG2.2.15", "TREATMENT", 4, 14], ["a significant reduction in HBsAg", "PROBLEM", 54, 86], ["HBeAg expression", "PROBLEM", 91, 107], ["the mock", "TEST", 122, 130], ["Na", "TEST", 152, 154], ["HBV antigen production in HepG2", "PROBLEM", 204, 235], ["HBsAg", "TEST", 299, 304], ["HBeAg Production", "TEST", 309, 325], ["Na", "TEST", 329, 331], ["HuH", "TEST", 342, 345], ["HBV plasmid", "TEST", 376, 387], ["mM Na", "TEST", 393, 398], ["HBsAg", "TEST", 426, 431], ["HBeAg levels", "TEST", 436, 448], ["significant", "OBSERVATION_MODIFIER", 56, 67], ["reduction", "OBSERVATION_MODIFIER", 68, 77], ["HBsAg", "OBSERVATION", 81, 86], ["HBeAg expression", "OBSERVATION", 91, 107], ["HBV", "OBSERVATION", 204, 207], ["HepG2", "ANATOMY", 230, 235], ["HBsAg", "OBSERVATION", 299, 304]]], ["A dose-dependent suppression was observed, starting from 1.5 mM Na 2 SeO 3 ( Fig. 2C and D) .", [["Na", "CHEMICAL", 64, 66], ["Na 2 SeO 3", "CHEMICAL", 64, 74], ["dependent suppression", "PROBLEM", 7, 28], ["dependent", "OBSERVATION_MODIFIER", 7, 16], ["suppression", "OBSERVATION", 17, 28]]], ["Viral antigen in 1.3\u00c2 HBV plasmid-transfected HuH-7 cells showed even stronger resistance to Na 2 SeO 3 .", [["HuH-7 cells", "ANATOMY", 46, 57], ["Na", "CHEMICAL", 93, 95], ["Na 2 SeO 3", "CHEMICAL", 93, 103], ["HBV", "ORGANISM", 22, 25], ["HuH-7 cells", "CELL", 46, 57], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 93, 103], ["Viral antigen", "PROTEIN", 0, 13], ["HBV plasmid", "DNA", 22, 33], ["HuH-7 cells", "CELL_LINE", 46, 57], ["HBV", "SPECIES", 22, 25], ["Viral antigen", "TEST", 0, 13], ["HBV plasmid", "TEST", 22, 33], ["HuH", "TEST", 46, 49], ["Na", "TEST", 93, 95]]], ["HBsAg and HBeAg levels started to decline with 2 mM Na 2-SeO 3 , and the decline was further enhanced by 2.5 mM Na 2 SeO 3 treatment ( Fig. 2E and F) .Inhibition of HBsAg and HBeAg Production by Na 2 SeO 3Next, a fixed concentration (2.5 mM) of Na 2 SeO 3 was used to assess viral antigens expression over a time course.", [["HBsAg", "CHEMICAL", 0, 5], ["HBeAg", "CHEMICAL", 10, 15], ["Na 2-SeO", "CHEMICAL", 52, 60], ["Na", "CHEMICAL", 112, 114], ["SeO 3", "CHEMICAL", 117, 122], ["HBsAg", "CHEMICAL", 165, 170], ["HBeAg", "CHEMICAL", 175, 180], ["Na 2 SeO 3Next", "CHEMICAL", 195, 209], ["Na", "CHEMICAL", 245, 247], ["Na 2-SeO 3", "CHEMICAL", 52, 62], ["Na 2 SeO 3", "CHEMICAL", 112, 122], ["Na 2 SeO", "CHEMICAL", 195, 203], ["Na 2 SeO 3", "CHEMICAL", 245, 255], ["HBsAg", "GENE_OR_GENE_PRODUCT", 0, 5], ["HBeAg", "GENE_OR_GENE_PRODUCT", 10, 15], ["Na 2-SeO 3", "SIMPLE_CHEMICAL", 52, 62], ["HBsAg", "GENE_OR_GENE_PRODUCT", 165, 170], ["HBeAg", "GENE_OR_GENE_PRODUCT", 175, 180], ["Na 2 SeO 3Next", "SIMPLE_CHEMICAL", 195, 209], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 245, 255], ["HBsAg", "PROTEIN", 0, 5], ["HBsAg", "PROTEIN", 165, 170], ["viral antigens", "PROTEIN", 275, 289], ["HBsAg", "TEST", 0, 5], ["HBeAg levels", "TEST", 10, 22], ["Na", "TEST", 52, 54], ["HBsAg", "TEST", 165, 170], ["HBeAg Production", "TEST", 175, 191], ["Na", "TEST", 195, 197], ["a fixed concentration", "TEST", 211, 232], ["Na", "TEST", 245, 247], ["viral antigens expression", "PROBLEM", 275, 300], ["HBsAg", "OBSERVATION", 165, 170]]], ["For HepG2.2.15 cells, 2.5 mM Na 2 SeO 3 showed significant inhibition of HBV antigen expression from Day 2, and these repressive effects increased with time ( Fig. 3A and B) .", [["HepG2.2.15 cells", "ANATOMY", 4, 20], ["Na", "CHEMICAL", 29, 31], ["SeO 3", "CHEMICAL", 34, 39], ["Na 2 SeO 3", "CHEMICAL", 29, 39], ["HepG2.2.15 cells", "CELL", 4, 20], ["HBV", "ORGANISM", 73, 76], ["HepG2.2.15 cells", "CELL_LINE", 4, 20], ["HBV antigen", "PROTEIN", 73, 84], ["HBV", "SPECIES", 73, 76], ["HepG2", "TEST", 4, 9], ["cells", "TEST", 15, 20], ["mM Na", "TEST", 26, 31], ["HBV antigen expression", "PROBLEM", 73, 95], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["inhibition", "OBSERVATION_MODIFIER", 59, 69], ["HBV", "OBSERVATION", 73, 76], ["repressive", "OBSERVATION_MODIFIER", 118, 128], ["effects", "OBSERVATION_MODIFIER", 129, 136], ["increased", "OBSERVATION_MODIFIER", 137, 146]]], ["On the final assessment day (Day 4), 2.5 mM Na 2 SeO 3 treatment had caused a reduction of 62.81 AE 2.59% and 54.69 AE 7.88% in production of HBsAg and HBeAg, respectively.", [["Na", "CHEMICAL", 44, 46], ["SeO 3", "CHEMICAL", 49, 54], ["HBsAg", "CHEMICAL", 142, 147], ["HBeAg", "CHEMICAL", 152, 157], ["Na 2 SeO 3", "CHEMICAL", 44, 54], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 44, 54], ["HBsAg", "GENE_OR_GENE_PRODUCT", 142, 147], ["HBeAg", "GENE_OR_GENE_PRODUCT", 152, 157], ["HBsAg", "PROTEIN", 142, 147], ["a reduction", "TEST", 76, 87], ["AE", "TEST", 97, 99], ["AE", "TEST", 116, 118], ["HBsAg", "TEST", 142, 147], ["HBeAg", "TEST", 152, 157]]], ["A similar time-dependent suppression enhancement was also observed in HBV plasmidtransfected HuH-7 cells, with the maximum decrease in viral antigen levels also occurring on Day 4.", [["HuH-7 cells", "ANATOMY", 93, 104], ["HBV", "ORGANISM", 70, 73], ["HuH-7 cells", "CELL", 93, 104], ["HBV plasmidtransfected HuH-7 cells", "CELL_LINE", 70, 104], ["HBV", "SPECIES", 70, 73], ["A similar time-dependent suppression enhancement", "PROBLEM", 0, 48], ["HBV plasmidtransfected HuH", "TEST", 70, 96], ["the maximum decrease in viral antigen levels", "PROBLEM", 111, 155], ["dependent suppression", "OBSERVATION_MODIFIER", 15, 36], ["maximum", "OBSERVATION_MODIFIER", 115, 122], ["decrease", "OBSERVATION_MODIFIER", 123, 131], ["viral antigen levels", "OBSERVATION", 135, 155]]], ["Compared with the mock-treated control, 2.5 mM Na 2 SeO 3 treatment in HuH-7 cells transfected with 1.1 or 1.3\u00c2 HBV plasmid produced a drop in HBsAg level to 41.16 AE 10.55% and 42.14 AE 10.15% ( Fig. 3C and E) , respectively, and a drop in HBeAg level to 29.73 AE 8.33% and 32.32 AE 9.03%, respectively ( Fig. 3D and F).", [["HuH-7 cells", "ANATOMY", 71, 82], ["Na", "CHEMICAL", 47, 49], ["SeO 3", "CHEMICAL", 52, 57], ["HBsAg", "CHEMICAL", 143, 148], ["HBeAg", "CHEMICAL", 241, 246], ["Na 2 SeO 3", "CHEMICAL", 47, 57], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 47, 57], ["HuH-7 cells", "CELL", 71, 82], ["HBV", "ORGANISM", 112, 115], ["HBsAg", "GENE_OR_GENE_PRODUCT", 143, 148], ["HBeAg", "GENE_OR_GENE_PRODUCT", 241, 246], ["HuH-7 cells", "CELL_LINE", 71, 82], ["1.1 or 1.3\u00c2 HBV plasmid", "DNA", 100, 123], ["HBsAg", "PROTEIN", 143, 148], ["HBV", "SPECIES", 112, 115], ["the mock", "TEST", 14, 22], ["Na", "TEST", 47, 49], ["HuH", "TEST", 71, 74], ["HBV plasmid", "TEST", 112, 123], ["a drop", "PROBLEM", 133, 139], ["HBsAg level", "TEST", 143, 154], ["AE", "TEST", 164, 166], ["AE", "TEST", 184, 186], ["Fig.", "TEST", 196, 200], ["a drop in HBeAg level", "PROBLEM", 231, 252], ["AE", "TEST", 262, 264], ["AE", "TEST", 281, 283], ["drop", "OBSERVATION_MODIFIER", 135, 139], ["drop", "OBSERVATION_MODIFIER", 233, 237], ["HBeAg", "OBSERVATION", 241, 246]]], ["There was no obvious decrease in 1.3\u00c2 HBV plasmid-transfected HuH-7 cells on Day 1, but at this time point, HBeAg was already significantly suppressed in 1.1\u00c2 HBV plasmid-transfected HuH-7 cells (Fig. 3D) .Inhibition of HBsAg and HBeAg Production by Na 2 SeO 3Notably, ETV treatment did not affect viral antigen production in any of the models (Figs.", [["HuH-7 cells", "ANATOMY", 62, 73], ["HuH-7 cells", "ANATOMY", 183, 194], ["HBeAg", "CHEMICAL", 108, 113], ["HBsAg", "CHEMICAL", 220, 225], ["HBeAg", "CHEMICAL", 230, 235], ["Na", "CHEMICAL", 250, 252], ["ETV", "CHEMICAL", 269, 272], ["Na 2 SeO", "CHEMICAL", 250, 258], ["ETV", "CHEMICAL", 269, 272], ["HBV", "ORGANISM", 38, 41], ["HuH-7 cells", "CELL", 62, 73], ["Day 1", "CELL", 77, 82], ["HBeAg", "GENE_OR_GENE_PRODUCT", 108, 113], ["HBV", "ORGANISM", 159, 162], ["HuH-7 cells", "CELL", 183, 194], ["HBsAg", "GENE_OR_GENE_PRODUCT", 220, 225], ["HBeAg", "GENE_OR_GENE_PRODUCT", 230, 235], ["Na 2 SeO", "SIMPLE_CHEMICAL", 250, 258], ["ETV", "SIMPLE_CHEMICAL", 269, 272], ["viral antigen", "GENE_OR_GENE_PRODUCT", 298, 311], ["HBV plasmid", "DNA", 38, 49], ["HuH-7 cells", "CELL_LINE", 62, 73], ["HBV plasmid", "DNA", 159, 170], ["HuH-7 cells", "CELL_LINE", 183, 194], ["HBsAg", "PROTEIN", 220, 225], ["HBV", "SPECIES", 38, 41], ["HBV", "SPECIES", 159, 162], ["obvious decrease", "PROBLEM", 13, 29], ["HBV plasmid", "TEST", 38, 49], ["HBeAg", "TEST", 108, 113], ["HBV plasmid", "TEST", 159, 170], ["HuH", "TEST", 183, 186], ["HBsAg", "TEST", 220, 225], ["HBeAg Production", "TEST", 230, 246], ["ETV treatment", "TREATMENT", 269, 282], ["viral antigen production", "PROBLEM", 298, 322], ["no obvious", "UNCERTAINTY", 10, 20], ["decrease", "OBSERVATION_MODIFIER", 21, 29], ["HBsAg", "OBSERVATION", 220, 225]]], ["2 and 3) .Suppression of HBV Transcription by Na 2 SeO 3Because HBsAg and HBeAg are products of preS/S mRNAs and precore mRNA, levels of various HBV mRNAs were further analyzed in HepG2.2.15 and 1.1/1.3\u00c2 HBV plasmid-transfected HuH-7 cells in the presence of Na 2 SeO 3 .", [["HepG2.2.15", "ANATOMY", 180, 190], ["HuH-7 cells", "ANATOMY", 228, 239], ["Na", "CHEMICAL", 46, 48], ["HBsAg", "CHEMICAL", 64, 69], ["HBeAg", "CHEMICAL", 74, 79], ["Na", "CHEMICAL", 259, 261], ["Na 2 SeO 3", "CHEMICAL", 259, 269], ["HBV", "ORGANISM", 25, 28], ["Na 2 SeO", "GENE_OR_GENE_PRODUCT", 46, 54], ["HBsAg", "GENE_OR_GENE_PRODUCT", 64, 69], ["HBeAg", "GENE_OR_GENE_PRODUCT", 74, 79], ["preS/S", "GENE_OR_GENE_PRODUCT", 96, 102], ["HBV", "ORGANISM", 145, 148], ["HepG2.2.15", "CELL", 180, 190], ["HBV", "ORGANISM", 204, 207], ["HuH-7 cells", "CELL", 228, 239], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 259, 269], ["HBsAg", "PROTEIN", 64, 69], ["preS/S mRNAs", "RNA", 96, 108], ["precore mRNA", "RNA", 113, 125], ["HBV mRNAs", "RNA", 145, 154], ["HBV plasmid", "DNA", 204, 215], ["HuH-7 cells", "CELL_LINE", 228, 239], ["HBV", "SPECIES", 25, 28], ["HBV", "SPECIES", 145, 148], ["HBV", "SPECIES", 204, 207], ["HBV Transcription", "TREATMENT", 25, 42], ["Na", "TEST", 46, 48], ["HBsAg", "TEST", 64, 69], ["HBeAg", "TEST", 74, 79], ["preS/S mRNAs", "PROBLEM", 96, 108], ["precore mRNA", "TEST", 113, 125], ["levels", "TEST", 127, 133], ["various HBV mRNAs", "TEST", 137, 154], ["HepG2", "TEST", 180, 185], ["HBV plasmid", "TEST", 204, 215], ["HuH", "TEST", 228, 231], ["Na", "TEST", 259, 261], ["HBV", "OBSERVATION", 25, 28]]], ["Four concentrations, 0.5, 1.5, 2.0, and 2.5 mM, of Na 2 SeO 3 were used, and the concentration of 2.5 mM was further analyzed at different time points.", [["Na", "CHEMICAL", 51, 53], ["Na 2 SeO 3", "CHEMICAL", 51, 61], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 51, 61], ["Na 2 SeO", "TREATMENT", 51, 59]]], ["The HBV RNAs in all the examined models were decreased by Na 2 SeO 3 treatment, but with slight differences.Suppression of HBV Transcription by Na 2 SeO 3In HepG2.2.15 cells, 0.5 mM Na 2 SeO 3 had no obvious effect on viral transcription, but 1.5 mM dramatically decreased HBV RNA level, which was further decreased with 2.0 mM Na 2 SeO 3 treatment (Fig. 4A) .", [["HepG2", "ANATOMY", 157, 162], ["2.15 cells", "ANATOMY", 163, 173], ["Na", "CHEMICAL", 58, 60], ["Na", "CHEMICAL", 144, 146], ["Na", "CHEMICAL", 182, 184], ["SeO 3", "CHEMICAL", 187, 192], ["Na", "CHEMICAL", 328, 330], ["SeO 3", "CHEMICAL", 333, 338], ["Na 2 SeO 3", "CHEMICAL", 58, 68], ["Na 2 SeO 3", "CHEMICAL", 182, 192], ["Na 2 SeO 3", "CHEMICAL", 328, 338], ["HBV", "ORGANISM", 4, 7], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 58, 68], ["HBV", "ORGANISM", 123, 126], ["2.15 cells", "CELL", 163, 173], ["HBV", "ORGANISM", 273, 276], ["HBV RNAs", "RNA", 4, 12], ["HepG2", "CELL_LINE", 157, 162], ["HBV RNA", "RNA", 273, 280], ["HBV", "SPECIES", 4, 7], ["HBV", "SPECIES", 123, 126], ["HBV", "SPECIES", 273, 276], ["The HBV RNAs", "TEST", 0, 12], ["HBV Transcription", "TREATMENT", 123, 140], ["cells", "TEST", 168, 173], ["mM Na", "TEST", 179, 184], ["obvious effect on viral transcription", "PROBLEM", 200, 237], ["1.5 mM dramatically decreased HBV RNA level", "PROBLEM", 243, 286], ["2.0 mM Na", "TREATMENT", 321, 330], ["HBV RNAs", "OBSERVATION", 4, 12], ["decreased", "OBSERVATION_MODIFIER", 45, 54], ["slight", "OBSERVATION_MODIFIER", 89, 95], ["HBV", "OBSERVATION", 123, 126], ["no obvious", "UNCERTAINTY", 197, 207], ["effect", "OBSERVATION_MODIFIER", 208, 214], ["viral transcription", "OBSERVATION", 218, 237], ["1.5 mM", "OBSERVATION_MODIFIER", 243, 249], ["dramatically", "OBSERVATION_MODIFIER", 250, 262], ["decreased", "OBSERVATION_MODIFIER", 263, 272], ["HBV RNA", "OBSERVATION", 273, 280], ["decreased", "OBSERVATION_MODIFIER", 306, 315]]], ["When the concentration was fixed at Dose-dependent suppression of HBsAg/HBeAg expression by Na 2 SeO 3 .", [["HBsAg", "CHEMICAL", 66, 71], ["HBeAg", "CHEMICAL", 72, 77], ["Na", "CHEMICAL", 92, 94], ["Na 2 SeO 3", "CHEMICAL", 92, 102], ["HBsAg", "GENE_OR_GENE_PRODUCT", 66, 71], ["HBeAg", "GENE_OR_GENE_PRODUCT", 72, 77], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 92, 102], ["HBsAg", "PROTEIN", 66, 71], ["HBeAg", "PROTEIN", 72, 77], ["HBsAg", "TEST", 66, 71]]], ["HepG2.2.15 and 1.1 \u00c2 or 1.3\u00c2 HBV-transfected HuH-7 cells were treated with Na 2 SeO 3 at the indicated concentrations or with 30 nM ETV.", [["HuH-7 cells", "ANATOMY", 45, 56], ["Na", "CHEMICAL", 75, 77], ["Na 2 SeO 3", "CHEMICAL", 75, 85], ["ETV", "CHEMICAL", 132, 135], ["HepG2.2.15", "SIMPLE_CHEMICAL", 0, 10], ["HBV", "ORGANISM", 29, 32], ["HuH-7 cells", "CELL", 45, 56], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 75, 85], ["HepG2.2.15", "CELL_LINE", 0, 10], ["HuH-7 cells", "CELL_LINE", 45, 56], ["HBV", "SPECIES", 29, 32], ["HepG2.2.15", "TEST", 0, 10], ["HBV", "TEST", 29, 32], ["HuH", "TEST", 45, 48], ["Na 2 SeO", "TREATMENT", 75, 83], ["30 nM ETV", "TREATMENT", 126, 135]]], ["On Day 3, culture supernatants were collected and assayed for HBsAg and HBeAg concentration by ELISA.", [["supernatants", "ANATOMY", 18, 30], ["HBsAg", "CHEMICAL", 62, 67], ["HBeAg", "CHEMICAL", 72, 77], ["HBsAg", "GENE_OR_GENE_PRODUCT", 62, 67], ["HBeAg", "GENE_OR_GENE_PRODUCT", 72, 77], ["HBsAg", "PROTEIN", 62, 67], ["culture supernatants", "TEST", 10, 30], ["HBsAg", "TEST", 62, 67], ["HBeAg concentration", "TEST", 72, 91]]], ["All data were normalized to the mock-treated control.", [["All data", "TEST", 0, 8], ["the mock", "TEST", 28, 36]]], ["\u00c3 P < 0.05; \u00c3\u00c3 P < 0.01.", [["P", "TEST", 2, 3]]], ["Time-dependent suppression of HBsAg/HBeAg expression by Na 2 SeO 3 .", [["HBsAg", "CHEMICAL", 30, 35], ["HBeAg", "CHEMICAL", 36, 41], ["Na", "CHEMICAL", 56, 58], ["Na 2 SeO 3", "CHEMICAL", 56, 66], ["HBsAg", "GENE_OR_GENE_PRODUCT", 30, 35], ["HBeAg", "GENE_OR_GENE_PRODUCT", 36, 41], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 56, 66], ["HBsAg", "PROTEIN", 30, 35], ["HBeAg", "PROTEIN", 36, 41], ["HBsAg", "TEST", 30, 35]]], ["HepG2.2.15 and 1.1\u00c2or 1.3\u00c2 HBV-transfected HuH-7 cells were treated with 2.5 mM Na 2 SeO 3 or 30 nM ETV.", [["HuH-7 cells", "ANATOMY", 43, 54], ["Na", "CHEMICAL", 80, 82], ["SeO", "CHEMICAL", 85, 88], ["Na 2 SeO", "CHEMICAL", 80, 88], ["ETV", "CHEMICAL", 100, 103], ["HepG2.2.15", "SIMPLE_CHEMICAL", 0, 10], ["HBV", "ORGANISM", 27, 30], ["HuH-7 cells", "CELL", 43, 54], ["HepG2.2.15", "CELL_LINE", 0, 10], ["HuH-7 cells", "CELL_LINE", 43, 54], ["HBV", "SPECIES", 27, 30], ["HepG2.2.15", "TEST", 0, 10], ["HBV", "TEST", 27, 30], ["HuH", "TEST", 43, 46]]], ["Supernatants of the Na 2 SeO 3 -treated cultures were collected daily for four days, and ETVtreated supernatant was harvested on Day 4.", [["Supernatants", "ANATOMY", 0, 12], ["cultures", "ANATOMY", 40, 48], ["supernatant", "ANATOMY", 100, 111], ["Na", "CHEMICAL", 20, 22], ["SeO 3", "CHEMICAL", 25, 30], ["Na 2 SeO 3", "CHEMICAL", 20, 30], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 20, 30], ["Na 2 SeO 3 -treated cultures", "CELL_LINE", 20, 48], ["the Na", "TEST", 16, 22], ["cultures", "TEST", 40, 48], ["ETVtreated supernatant", "TREATMENT", 89, 111]]], ["HBsAg and HBeAg concentrations were measured by ELISA.", [["HBsAg", "CHEMICAL", 0, 5], ["HBeAg", "CHEMICAL", 10, 15], ["HBsAg", "GENE_OR_GENE_PRODUCT", 0, 5], ["HBeAg", "GENE_OR_GENE_PRODUCT", 10, 15], ["HBsAg", "PROTEIN", 0, 5], ["HBsAg", "TEST", 0, 5], ["HBeAg concentrations", "TEST", 10, 30], ["ELISA", "TEST", 48, 53], ["HBeAg", "OBSERVATION", 10, 15]]], ["All data were normalized to the mock-treated control.", [["All data", "TEST", 0, 8], ["the mock", "TEST", 28, 36]]], ["\u00c3 P < 0.05; \u00c3\u00c3 P < 0.01.", [["P", "TEST", 2, 3]]], ["2.5 mM, progressive repression by Na 2 SeO 3 of HBV RNA level in HepG2.2.15 cells occurred in line with the length of treatment, starting from Day 1 (Fig. 4A) .", [["HepG2", "ANATOMY", 65, 70], ["2.15 cells", "ANATOMY", 71, 81], ["Na", "CHEMICAL", 34, 36], ["Na 2 SeO 3", "CHEMICAL", 34, 44], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 34, 44], ["HBV", "ORGANISM", 48, 51], ["HepG2", "CELL", 65, 70], ["2.15 cells", "CELL", 71, 81], ["HBV RNA", "RNA", 48, 55], ["HepG2", "CELL_LINE", 65, 70], ["HBV", "SPECIES", 48, 51], ["progressive repression", "PROBLEM", 8, 30], ["Na", "TEST", 34, 36], ["HBV RNA level", "TEST", 48, 61], ["treatment", "TREATMENT", 118, 127], ["progressive", "OBSERVATION_MODIFIER", 8, 19], ["repression", "OBSERVATION", 20, 30], ["Na 2 SeO", "OBSERVATION_MODIFIER", 34, 42], ["HepG2", "ANATOMY", 65, 70], ["line", "OBSERVATION_MODIFIER", 94, 98]]], ["Moreover, the viral transcription level in HepG2.2.15 was quantified using qPCR, and the host gene b-actin was chosen as the internal reference.", [["HepG2.2.15", "GENE_OR_GENE_PRODUCT", 43, 53], ["b-actin", "GENE_OR_GENE_PRODUCT", 99, 106], ["HepG2.2.15", "CELL_LINE", 43, 53], ["host gene b-actin", "DNA", 89, 106], ["the viral transcription level", "TEST", 10, 39], ["HepG2.2.15", "TREATMENT", 43, 53], ["qPCR", "TEST", 75, 79], ["the host gene b-actin", "TREATMENT", 85, 106]]], ["The result of qPCR (Fig. S1 ) was consistent with northern blot assay (Fig. 4A ).", [["qPCR", "TEST", 14, 18], ["northern blot assay", "TEST", 50, 69], ["consistent with", "UNCERTAINTY", 34, 49]]], ["Viral mRNA was inhibited by Na 2 SeO 3 treatment in dose-dependent and time-dependent manners, which was reduced to 49.28 AE 3.82% in the presence of 2.5 mM Na 2 SeO 3 for four days.", [["Na 2 SeO 3", "CHEMICAL", 28, 38], ["Na", "CHEMICAL", 157, 159], ["Na 2 SeO 3", "CHEMICAL", 28, 38], ["Na 2 SeO 3", "CHEMICAL", 157, 167], ["Viral", "ORGANISM", 0, 5], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 28, 38], ["Viral mRNA", "RNA", 0, 10], ["Viral mRNA", "TEST", 0, 10], ["Na", "TEST", 28, 30]]], ["In HuH-7 cells transfected with 1.1\u00c2HBV plasmids, there was a dose-dependent suppression of viral mRNA by Na 2 SeO 3 (Fig. 4B ).", [["HuH-7 cells", "ANATOMY", 3, 14], ["plasmids", "ANATOMY", 40, 48], ["Na", "CHEMICAL", 106, 108], ["Na 2 SeO 3", "CHEMICAL", 106, 116], ["HuH-7 cells", "CELL", 3, 14], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 106, 116], ["HuH-7 cells", "CELL_LINE", 3, 14], ["1.1\u00c2HBV plasmids", "DNA", 32, 48], ["viral mRNA", "RNA", 92, 102], ["Na 2 SeO 3", "PROTEIN", 106, 116], ["HuH", "TEST", 3, 6], ["\u00c2HBV plasmids", "TREATMENT", 35, 48], ["viral mRNA", "TEST", 92, 102], ["Na", "TEST", 106, 108], ["viral mRNA", "OBSERVATION", 92, 102]]], ["In addition, perceptible repression of HBV transcription was observed from Day 2 of 2.5 mM Na 2 SeO 3 treatment, which also occurred in a time-dependent manner (Fig. 4B) .", [["Na", "CHEMICAL", 91, 93], ["SeO 3", "CHEMICAL", 96, 101], ["Na 2 SeO 3", "CHEMICAL", 91, 101], ["HBV", "ORGANISM", 39, 42], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 91, 101], ["HBV", "SPECIES", 39, 42], ["HBV transcription", "PROBLEM", 39, 56], ["2.5 mM Na 2 SeO 3 treatment", "TREATMENT", 84, 111], ["HBV", "OBSERVATION", 39, 42]]], ["Na 2 SeO 3 -induced suppression of HBV transcripts also occurred in HuH-7 cells transfected with 1.3\u00c2HBV plasmids.", [["HuH-7 cells", "ANATOMY", 68, 79], ["plasmids", "ANATOMY", 105, 113], ["Na", "CHEMICAL", 0, 2], ["SeO 3", "CHEMICAL", 5, 10], ["Na 2 SeO 3", "CHEMICAL", 0, 10], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 0, 10], ["HBV", "ORGANISM", 35, 38], ["HuH-7 cells", "CELL", 68, 79], ["HBV transcripts", "RNA", 35, 50], ["HuH-7 cells", "CELL_LINE", 68, 79], ["1.3\u00c2HBV plasmids", "DNA", 97, 113], ["HBV", "SPECIES", 35, 38], ["HuH-7", "SPECIES", 68, 73], ["Na", "TEST", 0, 2], ["HBV transcripts", "PROBLEM", 35, 50], ["HuH", "TEST", 68, 71], ["\u00c2HBV plasmids", "TREATMENT", 100, 113], ["HBV transcripts", "OBSERVATION", 35, 50]]], ["As shown in Figure 4C , suppression was evident with as little as 0.5 mM Na 2 SeO 3 , and progressed in a dose-dependent manner.", [["Na", "CHEMICAL", 73, 75], ["Na 2 SeO 3", "CHEMICAL", 73, 83]]], ["Na 2-SeO 3 treatment at 2.5 mM caused a dramatic suppression of HBV RNAs from Day 1; however, the timedependent suppression effect was not as clear as in the other two models.", [["Na 2-SeO 3", "CHEMICAL", 0, 10], ["Na 2-SeO 3", "CHEMICAL", 0, 10], ["Na 2-SeO 3", "SIMPLE_CHEMICAL", 0, 10], ["HBV", "ORGANISM", 64, 67], ["HBV RNAs", "RNA", 64, 72], ["HBV", "SPECIES", 64, 67], ["Na", "TEST", 0, 2], ["SeO 3 treatment", "TREATMENT", 5, 20], ["a dramatic suppression of HBV RNAs", "PROBLEM", 38, 72], ["the timedependent suppression effect", "PROBLEM", 94, 130], ["dramatic", "OBSERVATION_MODIFIER", 40, 48], ["HBV RNAs", "OBSERVATION", 64, 72]]], ["This was probably because the RNA amount had already dropped to a very low level, and therefore the effects at the subsequent examined time points were less obvious (Fig. 4C) .", [["the RNA amount", "PROBLEM", 26, 40], ["very low level", "OBSERVATION_MODIFIER", 66, 80]]], ["In all models, 30 nM ETV treatment produced no effect on HBV transcription levels, because it specifically inhibits protein-priming activity [Jones et al., 2013] .Suppression of HBV Transcription by Na 2 SeO 3Intracellular viral core protein was also determined using western blot assay in all three models, with the host protein b-actin as the internal reference.", [["ETV", "CHEMICAL", 21, 24], ["Na", "CHEMICAL", 199, 201], ["ETV", "CHEMICAL", 21, 24], ["Na 2 SeO", "CHEMICAL", 199, 207], ["HBV", "ORGANISM", 57, 60], ["HBV", "ORGANISM", 178, 181], ["Na 2 SeO 3Intracellular", "GENE_OR_GENE_PRODUCT", 199, 222], ["b-actin", "GENE_OR_GENE_PRODUCT", 330, 337], ["Na 2 SeO 3Intracellular viral core protein", "PROTEIN", 199, 241], ["b-actin", "PROTEIN", 330, 337], ["HBV", "SPECIES", 57, 60], ["HBV", "SPECIES", 178, 181], ["30 nM ETV treatment", "TREATMENT", 15, 34], ["HBV transcription levels", "TEST", 57, 81], ["HBV Transcription", "TREATMENT", 178, 195], ["3Intracellular viral core protein", "TEST", 208, 241], ["blot assay", "TEST", 276, 286], ["the host protein b-actin", "TREATMENT", 313, 337], ["no", "UNCERTAINTY", 44, 46], ["HBV", "OBSERVATION", 178, 181]]], ["Core protein level was decreased gradually following Na 2-SeO 3 treatment in a dose-dependent manner, whereas b-actin level remained unchanged (Fig. S2) .", [["Na 2-SeO 3", "CHEMICAL", 53, 63], ["Na 2-SeO 3", "CHEMICAL", 53, 63], ["Na 2-SeO 3", "SIMPLE_CHEMICAL", 53, 63], ["b-actin", "SIMPLE_CHEMICAL", 110, 117], ["b-actin", "PROTEIN", 110, 117], ["S2", "PROTEIN", 149, 151], ["Core protein level", "TEST", 0, 18], ["Na", "TEST", 53, 55], ["b-actin level", "TEST", 110, 123], ["decreased", "OBSERVATION_MODIFIER", 23, 32], ["unchanged", "OBSERVATION_MODIFIER", 133, 142]]], ["But 30 nM ETV treatment could not affect core expression in all models (Fig. S2) .", [["ETV", "CHEMICAL", 10, 13], ["ETV", "CHEMICAL", 10, 13], ["S2", "PROTEIN", 77, 79], ["nM ETV treatment", "TREATMENT", 7, 23]]], ["The result indicated that Na 2 SeO 3 influence specifically HBV transcription and expression.Suppression of HBV DNA Replication by Na 2 SeO 3The fact that Na 2 SeO 3 repressed HBV protein synthesis and transcription in a dose-dependent and time-dependent manner prompted us to investigate whether it also influenced HBV DNA levels.", [["Na", "CHEMICAL", 26, 28], ["Na", "CHEMICAL", 131, 133], ["Na", "CHEMICAL", 155, 157], ["Na 2 SeO 3", "CHEMICAL", 26, 36], ["Na 2 SeO 3", "CHEMICAL", 131, 141], ["Na 2 SeO 3", "CHEMICAL", 155, 165], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 26, 36], ["HBV", "ORGANISM", 60, 63], ["HBV", "ORGANISM", 108, 111], ["DNA", "CELLULAR_COMPONENT", 112, 115], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 131, 141], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 155, 165], ["HBV", "ORGANISM", 176, 179], ["HBV", "ORGANISM", 316, 319], ["DNA", "CELLULAR_COMPONENT", 320, 323], ["Na 2 SeO 3", "PROTEIN", 155, 165], ["HBV protein", "PROTEIN", 176, 187], ["HBV", "SPECIES", 60, 63], ["HBV", "SPECIES", 108, 111], ["HBV", "SPECIES", 176, 179], ["HBV", "SPECIES", 316, 319], ["Na", "TEST", 26, 28], ["HBV transcription", "TREATMENT", 60, 77], ["HBV DNA Replication", "TREATMENT", 108, 127], ["Na", "TEST", 155, 157], ["HBV protein synthesis", "TREATMENT", 176, 197], ["transcription", "TREATMENT", 202, 215], ["HBV DNA levels", "PROBLEM", 316, 330], ["HBV", "OBSERVATION", 108, 111], ["HBV", "OBSERVATION", 316, 319]]], ["To address this issue, the encapsidated HBV DNA was extracted from the cells treated with Na 2 SeO 3 or ETV, and analyzed by Southern blot assay.", [["cells", "ANATOMY", 71, 76], ["Na", "CHEMICAL", 90, 92], ["Na 2 SeO 3", "CHEMICAL", 90, 100], ["ETV", "CHEMICAL", 104, 107], ["HBV", "ORGANISM", 40, 43], ["DNA", "CELLULAR_COMPONENT", 44, 47], ["cells", "CELL", 71, 76], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 90, 100], ["encapsidated HBV DNA", "DNA", 27, 47], ["HBV", "SPECIES", 40, 43], ["the encapsidated HBV DNA", "PROBLEM", 23, 47], ["Na 2 SeO", "TREATMENT", 90, 98], ["ETV", "TREATMENT", 104, 107], ["HBV", "OBSERVATION", 40, 43]]], ["In all models, the viral nucleic acids were barely detectable after 30 nM ETV treatment for three days (Fig. 5A , C, and E) or four days (Fig. 5B, D, and F) .", [["nucleic acids", "CHEMICAL", 25, 38], ["ETV", "CHEMICAL", 74, 77], ["ETV", "CHEMICAL", 74, 77], ["the viral nucleic acids", "TEST", 15, 38], ["30 nM ETV treatment", "TREATMENT", 68, 87], ["nucleic acids", "OBSERVATION", 25, 38]]], ["Considering that ETV hardly changed the level of viral proteins or RNAs, the dramatic inhibition of HBV DNA was consistent with its specific suppression of HBV replication.", [["ETV", "CHEMICAL", 17, 20], ["HBV", "ORGANISM", 100, 103], ["DNA", "CELLULAR_COMPONENT", 104, 107], ["HBV", "ORGANISM", 156, 159], ["viral proteins", "PROTEIN", 49, 63], ["RNAs", "RNA", 67, 71], ["HBV DNA", "DNA", 100, 107], ["HBV", "SPECIES", 100, 103], ["HBV", "SPECIES", 156, 159], ["ETV", "TREATMENT", 17, 20], ["viral proteins", "PROBLEM", 49, 63], ["RNAs", "TREATMENT", 67, 71], ["HBV DNA", "PROBLEM", 100, 107], ["HBV replication", "TREATMENT", 156, 171], ["ETV", "OBSERVATION", 17, 20], ["consistent with", "UNCERTAINTY", 112, 127], ["HBV", "OBSERVATION", 156, 159]]], ["A previous study also reported that 30 nM ETV was sufficient to reduce HBV DNA level by 90% [Bader and Korba, 2010] , which is in agreement with this result.Suppression of HBV DNA Replication by Na 2 SeO 3In general, Na 2 SeO 3 treatment displayed a clear dose-dependent and time-dependent suppression of HBV DNA level in all models (Fig. 5) , although some slight differences still existed between the different models.", [["ETV", "CHEMICAL", 42, 45], ["Na", "CHEMICAL", 195, 197], ["Na 2 SeO 3", "CHEMICAL", 217, 227], ["ETV", "CHEMICAL", 42, 45], ["Na 2 SeO 3In", "CHEMICAL", 195, 207], ["Na 2 SeO 3", "CHEMICAL", 217, 227], ["HBV", "ORGANISM", 71, 74], ["DNA", "CELLULAR_COMPONENT", 75, 78], ["HBV", "ORGANISM", 172, 175], ["DNA", "CELLULAR_COMPONENT", 176, 179], ["Na 2 SeO 3In", "SIMPLE_CHEMICAL", 195, 207], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 217, 227], ["HBV", "ORGANISM", 305, 308], ["DNA", "CELLULAR_COMPONENT", 309, 312], ["HBV", "SPECIES", 71, 74], ["HBV", "SPECIES", 172, 175], ["HBV", "SPECIES", 305, 308], ["A previous study", "TEST", 0, 16], ["30 nM ETV", "TREATMENT", 36, 45], ["HBV DNA level", "TEST", 71, 84], ["HBV DNA level", "TEST", 305, 318], ["some slight differences", "PROBLEM", 353, 376], ["HBV", "OBSERVATION", 172, 175], ["HBV DNA", "OBSERVATION", 305, 312], ["slight", "OBSERVATION_MODIFIER", 358, 364], ["differences", "OBSERVATION", 365, 376]]], ["Treatment with Na 2 SeO 3 resulted in a very obvious repression of HBV DNA in HepG2.2.15 cells.", [["HepG2", "ANATOMY", 78, 83], ["2.15 cells", "ANATOMY", 84, 94], ["Na 2 SeO 3", "CHEMICAL", 15, 25], ["Na 2 SeO 3", "CHEMICAL", 15, 25], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 15, 25], ["HBV", "ORGANISM", 67, 70], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["HepG2", "CELL", 78, 83], ["2.15 cells", "CELL", 84, 94], ["HBV DNA", "DNA", 67, 74], ["HepG2", "CELL_LINE", 78, 83], ["2.15 cells", "CELL_LINE", 84, 94], ["HBV", "SPECIES", 67, 70], ["HBV DNA in HepG2", "PROBLEM", 67, 83], ["HBV DNA", "OBSERVATION", 67, 74], ["HepG2", "ANATOMY", 78, 83]]], ["HepG2.2.15 and 1.1 or 1.3\u00c2HBV-transfected HuH-7 were treated with Na 2 SeO 3 .", [["HepG2.2.15", "CHEMICAL", 0, 10], ["Na", "CHEMICAL", 66, 68], ["Na 2 SeO 3", "CHEMICAL", 66, 76], ["HepG2.2.15", "SIMPLE_CHEMICAL", 0, 10], ["HuH-7", "CELL", 42, 47], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 66, 76], ["HuH-7", "CELL_LINE", 42, 47], ["HepG2.2.15", "TEST", 0, 10], ["\u00c2HBV", "TEST", 25, 29], ["HuH", "TEST", 42, 45]]], ["Partial samples were treated with various concentrations of Na 2 SeO 3 and harvested on Day 3, and some samples were treated with a fixed concentration of 2.5 mM Na 2 SeO 3 , but harvested at different time points.", [["samples", "ANATOMY", 8, 15], ["samples", "ANATOMY", 104, 111], ["Na", "CHEMICAL", 60, 62], ["Na", "CHEMICAL", 162, 164], ["Na 2 SeO 3", "CHEMICAL", 60, 70], ["Na 2 SeO 3", "CHEMICAL", 162, 172], ["Partial samples", "TEST", 0, 15], ["a fixed concentration", "TREATMENT", 130, 151], ["harvested", "OBSERVATION", 179, 188]]], ["Mock-treated control and 30 nM ETV-treated cells were collected on Day 4.", [["cells", "ANATOMY", 43, 48], ["ETV", "CHEMICAL", 31, 34], ["ETV", "CHEMICAL", 31, 34], ["cells", "CELL", 43, 48], ["ETV-treated cells", "CELL_LINE", 31, 48], ["Mock-treated control", "TREATMENT", 0, 20], ["30 nM ETV-treated cells", "TREATMENT", 25, 48]]], ["HBV RNA levels were determined by northern blot assay.", [["HBV", "ORGANISM", 0, 3], ["HBV RNA", "RNA", 0, 7], ["HBV", "SPECIES", 0, 3], ["HBV RNA levels", "TEST", 0, 14], ["blot assay", "TEST", 43, 53]]], ["Suppression of HBV genome replication by Na 2 SeO 3 .", [["Na", "CHEMICAL", 41, 43], ["Na 2 SeO 3", "CHEMICAL", 41, 51], ["HBV", "ORGANISM", 15, 18], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 41, 51], ["HBV genome", "DNA", 15, 25], ["HBV", "SPECIES", 15, 18], ["HBV genome replication", "TREATMENT", 15, 37], ["HBV genome", "OBSERVATION", 15, 25]]], ["HepG2.2.15 and 1.1 or 1.3\u00c2HBVtransfected HuH-7 were treated with Na 2 SeO 3 .", [["HepG2.2.15", "CHEMICAL", 0, 10], ["Na", "CHEMICAL", 65, 67], ["Na 2 SeO 3", "CHEMICAL", 65, 75], ["HepG2.2.15", "SIMPLE_CHEMICAL", 0, 10], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 65, 75], ["HepG2.2.15", "TEST", 0, 10], ["\u00c2HBVtransfected HuH", "TEST", 25, 44]]], ["Partial samples were treated with various concentrations of Na 2 SeO 3 and harvested on Day 3, and some samples were treated with a fixed concentration of 2.5 mM Na 2 SeO 3 but harvested at different time points.", [["samples", "ANATOMY", 8, 15], ["samples", "ANATOMY", 104, 111], ["Na", "CHEMICAL", 60, 62], ["Na", "CHEMICAL", 162, 164], ["Na 2 SeO 3", "CHEMICAL", 60, 70], ["Na 2 SeO 3", "CHEMICAL", 162, 172], ["Partial samples", "TEST", 0, 15], ["various concentrations of Na", "TREATMENT", 34, 62], ["a fixed concentration", "TREATMENT", 130, 151]]], ["Mock-treated control and 30 nM ETV-treated cells were collected on Day 4.", [["cells", "ANATOMY", 43, 48], ["ETV", "CHEMICAL", 31, 34], ["ETV", "CHEMICAL", 31, 34], ["cells", "CELL", 43, 48], ["ETV-treated cells", "CELL_LINE", 31, 48], ["Mock-treated control", "TREATMENT", 0, 20], ["30 nM ETV-treated cells", "TREATMENT", 25, 48]]], ["HBV DNA levels were determined by Southern blot assay.Suppression of HBV DNA Replication by Na 2 SeO 3Clear DNA decline occurred with 0.5 mM Na 2 SeO 3 treatment on Day 4, as well as with 2.5 mM Na 2 SeO 3 on Day 1.", [["Na", "CHEMICAL", 92, 94], ["Na", "CHEMICAL", 141, 143], ["SeO 3", "CHEMICAL", 146, 151], ["Na", "CHEMICAL", 195, 197], ["Na 2 SeO", "CHEMICAL", 92, 100], ["Na 2 SeO 3", "CHEMICAL", 141, 151], ["Na 2 SeO 3", "CHEMICAL", 195, 205], ["HBV", "ORGANISM", 0, 3], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["HBV", "ORGANISM", 69, 72], ["DNA", "CELLULAR_COMPONENT", 73, 76], ["DNA", "CELLULAR_COMPONENT", 108, 111], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 141, 151], ["HBV DNA", "DNA", 69, 76], ["HBV", "SPECIES", 0, 3], ["HBV", "SPECIES", 69, 72], ["HBV DNA levels", "TEST", 0, 14], ["blot assay", "TEST", 43, 53], ["HBV DNA Replication", "TREATMENT", 69, 88], ["DNA decline", "PROBLEM", 108, 119], ["0.5 mM Na", "TREATMENT", 134, 143], ["HBV", "OBSERVATION", 69, 72]]], ["The HBV DNA levels then reduced progressively in line with increasing concentration and exposure time ( Fig. 5A and B) .", [["HBV", "ORGANISM", 4, 7], ["DNA", "CELLULAR_COMPONENT", 8, 11], ["HBV", "SPECIES", 4, 7], ["The HBV DNA levels", "TEST", 0, 18], ["increasing concentration", "TREATMENT", 59, 83], ["HBV", "OBSERVATION", 4, 7], ["reduced", "OBSERVATION_MODIFIER", 24, 31], ["progressively", "OBSERVATION_MODIFIER", 32, 45]]], ["In HuH-7 transfected with 1.1\u00c2HBV plasmid, Na 2 SeO 3 treatment resulted in a dose-dependent inhibition of HBV DNAs, starting at 1.5 mM.", [["HuH-7", "ANATOMY", 3, 8], ["plasmid", "ANATOMY", 34, 41], ["Na", "CHEMICAL", 43, 45], ["SeO 3", "CHEMICAL", 48, 53], ["Na 2 SeO 3", "CHEMICAL", 43, 53], ["HuH-7", "CELL", 3, 8], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 43, 53], ["HBV", "ORGANISM", 107, 110], ["HuH-7", "CELL_LINE", 3, 8], ["1.1\u00c2HBV plasmid", "DNA", 26, 41], ["HBV DNAs", "DNA", 107, 115], ["\u00c2HBV", "SPECIES", 29, 33], ["HBV", "SPECIES", 107, 110], ["HuH", "TEST", 3, 6], ["\u00c2HBV plasmid", "TREATMENT", 29, 41], ["Na", "TEST", 43, 45], ["HBV DNAs", "PROBLEM", 107, 115], ["HBV DNAs", "OBSERVATION", 107, 115]]], ["Time-dependent reduction of HBV DNAs was also observed, but this was less obvious than that in HepG2.2.15 or 1.3\u00c2HBV plasmid-transfected HuH-7.", [["HepG2", "ANATOMY", 95, 100], ["HBV", "ORGANISM", 28, 31], ["HepG2", "CELL", 95, 100], ["HuH-7", "CELL", 137, 142], ["HBV DNAs", "DNA", 28, 36], ["HepG2", "CELL_LINE", 95, 100], ["\u00c2HBV plasmid", "DNA", 112, 124], ["HuH-7", "CELL_LINE", 137, 142], ["HBV", "SPECIES", 28, 31], ["HBV DNAs", "PROBLEM", 28, 36], ["\u00c2HBV plasmid", "TEST", 112, 124], ["HuH", "TEST", 137, 140], ["HBV DNAs", "OBSERVATION", 28, 36], ["HepG2", "ANATOMY", 95, 100]]], ["This was possibly due to the profound decrease in viral DNA level observed as early as Day 1 (Fig. 5D) .", [["DNA", "CELLULAR_COMPONENT", 56, 59], ["the profound decrease in viral DNA level", "PROBLEM", 25, 65], ["possibly due to", "UNCERTAINTY", 9, 24], ["profound", "OBSERVATION_MODIFIER", 29, 37], ["decrease", "OBSERVATION", 38, 46], ["viral DNA", "OBSERVATION", 50, 59]]], ["In 1.3\u00c2HBV plasmid-transfected HuH-7 cells, the decrease induced by Na 2 SeO 3 was weaker than in the other two tested models.", [["HuH-7 cells", "ANATOMY", 31, 42], ["Na", "CHEMICAL", 68, 70], ["Na 2 SeO 3", "CHEMICAL", 68, 78], ["HuH-7 cells", "CELL", 31, 42], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 68, 78], ["HuH-7 cells", "CELL_LINE", 31, 42], ["\u00c2HBV", "SPECIES", 6, 10], ["\u00c2HBV plasmid", "TEST", 6, 18], ["HuH", "TEST", 31, 34], ["Na", "TEST", 68, 70], ["decrease", "OBSERVATION_MODIFIER", 48, 56]]], ["The reduction in HBV DNA was visible with 2.0 mM Na 2 SeO 3 treatment on Day 3 (Fig. 5E ) or with 2.5 mM on Day 2 (Fig. 5F ).Suppression of HBV DNA Replication by Na 2 SeO 3To further investigate its anti-HBV activity, Na 2-SeO 3 was compared with clinically applied nucleos(t) ide analogs, including lamivudine (3TC), entecavir (ETV), and adefovir (Ade).", [["Na", "CHEMICAL", 49, 51], ["SeO 3", "CHEMICAL", 54, 59], ["Na", "CHEMICAL", 163, 165], ["Na 2-SeO", "CHEMICAL", 219, 227], ["nucleos(t) ide", "CHEMICAL", 267, 281], ["lamivudine", "CHEMICAL", 301, 311], ["3TC", "CHEMICAL", 313, 316], ["entecavir", "CHEMICAL", 319, 328], ["ETV", "CHEMICAL", 330, 333], ["adefovir", "CHEMICAL", 340, 348], ["Ade", "CHEMICAL", 350, 353], ["Na 2 SeO 3", "CHEMICAL", 49, 59], ["Na 2 SeO 3To", "CHEMICAL", 163, 175], ["Na 2-SeO 3", "CHEMICAL", 219, 229], ["nucleos(t) ide", "CHEMICAL", 267, 281], ["lamivudine", "CHEMICAL", 301, 311], ["3TC", "CHEMICAL", 313, 316], ["entecavir", "CHEMICAL", 319, 328], ["ETV", "CHEMICAL", 330, 333], ["adefovir", "CHEMICAL", 340, 348], ["Ade", "CHEMICAL", 350, 353], ["HBV", "ORGANISM", 17, 20], ["DNA", "CELLULAR_COMPONENT", 21, 24], ["HBV", "ORGANISM", 140, 143], ["DNA", "CELLULAR_COMPONENT", 144, 147], ["Na 2 SeO 3To", "SIMPLE_CHEMICAL", 163, 175], ["anti-HBV", "CANCER", 200, 208], ["Na 2-SeO 3", "SIMPLE_CHEMICAL", 219, 229], ["nucleos(t) ide analogs", "SIMPLE_CHEMICAL", 267, 289], ["lamivudine", "SIMPLE_CHEMICAL", 301, 311], ["3TC", "SIMPLE_CHEMICAL", 313, 316], ["entecavir", "SIMPLE_CHEMICAL", 319, 328], ["ETV", "SIMPLE_CHEMICAL", 330, 333], ["adefovir", "SIMPLE_CHEMICAL", 340, 348], ["Ade", "SIMPLE_CHEMICAL", 350, 353], ["HBV DNA", "DNA", 17, 24], ["HBV", "SPECIES", 17, 20], ["HBV", "SPECIES", 140, 143], ["The reduction", "TREATMENT", 0, 13], ["HBV DNA", "PROBLEM", 17, 24], ["2.0 mM Na", "TREATMENT", 42, 51], ["HBV DNA Replication", "TREATMENT", 140, 159], ["its anti-HBV activity", "TEST", 196, 217], ["Na", "TEST", 219, 221], ["nucleos(t) ide analogs", "TREATMENT", 267, 289], ["lamivudine (3TC)", "TREATMENT", 301, 317], ["entecavir (ETV)", "TREATMENT", 319, 334], ["adefovir", "TREATMENT", 340, 348], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["HBV DNA", "OBSERVATION", 17, 24], ["HBV", "OBSERVATION", 140, 143]]], ["After three or six days' treatment with single or combine drugs, encapsidated HBV DNA levels were quantified using qPCR in HepG2.2.15.", [["HepG2.2", "ANATOMY", 123, 130], ["HBV", "ORGANISM", 78, 81], ["DNA", "CELLULAR_COMPONENT", 82, 85], ["HepG2.2", "CELL", 123, 130], ["HepG2.2", "CELL_LINE", 123, 130], ["HBV", "SPECIES", 78, 81], ["treatment", "TREATMENT", 25, 34], ["single or combine drugs", "TREATMENT", 40, 63], ["encapsidated HBV DNA levels", "TEST", 65, 92], ["qPCR", "TEST", 115, 119], ["HepG2", "TEST", 123, 128]]], ["The result showed three days treatment with 2.5 mM Na 2 SeO 3 , 70 nM lamivudine, 9 nM entecavir, and 1.2 mM adefovir reduced viral DNA levels to 48.97 AE 2.30%, 42.16 AE 2.70%, 17.62 AE 1.22%, and 13.15 AE 0.95%, respectively (Fig. 6) .", [["Na", "CHEMICAL", 51, 53], ["SeO 3", "CHEMICAL", 56, 61], ["lamivudine", "CHEMICAL", 70, 80], ["entecavir", "CHEMICAL", 87, 96], ["adefovir", "CHEMICAL", 109, 117], ["Na 2 SeO 3", "CHEMICAL", 51, 61], ["lamivudine", "CHEMICAL", 70, 80], ["entecavir", "CHEMICAL", 87, 96], ["adefovir", "CHEMICAL", 109, 117], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 51, 61], ["lamivudine", "SIMPLE_CHEMICAL", 70, 80], ["entecavir", "SIMPLE_CHEMICAL", 87, 96], ["adefovir", "SIMPLE_CHEMICAL", 109, 117], ["DNA", "CELLULAR_COMPONENT", 132, 135], ["2.5 mM Na", "TREATMENT", 44, 53], ["lamivudine", "TREATMENT", 70, 80], ["9 nM entecavir", "TREATMENT", 82, 96], ["1.2 mM adefovir", "TREATMENT", 102, 117], ["viral DNA levels", "TEST", 126, 142], ["AE", "TEST", 152, 154], ["AE", "TEST", 168, 170], ["AE", "TEST", 184, 186], ["AE", "TEST", 204, 206]]], ["On Day 6, the inhibitory effect on DNA levels were further enhanced in Na 2 SeO 3 and lamivudine treated cells, with HBV DNA levels decreasing to 24.53 AE 11.09% and 24.56 AE 0.07%, respectively (Fig. 6) .", [["cells", "ANATOMY", 105, 110], ["Na 2 SeO 3", "CHEMICAL", 71, 81], ["lamivudine", "CHEMICAL", 86, 96], ["Na 2 SeO 3", "CHEMICAL", 71, 81], ["lamivudine", "CHEMICAL", 86, 96], ["DNA", "CELLULAR_COMPONENT", 35, 38], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 71, 81], ["lamivudine", "SIMPLE_CHEMICAL", 86, 96], ["cells", "CELL", 105, 110], ["HBV", "ORGANISM", 117, 120], ["DNA", "CELLULAR_COMPONENT", 121, 124], ["lamivudine treated cells", "CELL_LINE", 86, 110], ["HBV", "SPECIES", 117, 120], ["DNA levels", "TEST", 35, 45], ["Na", "TEST", 71, 73], ["lamivudine treated cells", "TREATMENT", 86, 110], ["HBV DNA levels", "TEST", 117, 131], ["AE", "TEST", 152, 154], ["AE", "TEST", 172, 174]]], ["Moreover, combined drug treatment dramatically enhanced the inhibitory effect on HBV DNA replication.", [["HBV", "ORGANISM", 81, 84], ["DNA", "CELLULAR_COMPONENT", 85, 88], ["HBV", "SPECIES", 81, 84], ["combined drug treatment", "TREATMENT", 10, 33], ["HBV DNA replication", "TREATMENT", 81, 100]]], ["On Day 6, Na 2 SeO 3 plus lamivudine, entecavir, or adefovir reduced the encapsidated HBV DNA levels to 5.49 AE 0.11%, 0.44 AE 0.04%, and 1.92 AE 0.07%, respectively (Fig. 6) .DISCUSSIONHepatitis B virus, a prototype member of Hepadnaviridae family, replicates by a unique protein-primed reverse transcription mechanism [Nassal, 2008] .", [["Na", "CHEMICAL", 10, 12], ["SeO 3", "CHEMICAL", 15, 20], ["lamivudine", "CHEMICAL", 26, 36], ["entecavir", "CHEMICAL", 38, 47], ["adefovir", "CHEMICAL", 52, 60], ["Na 2 SeO 3", "CHEMICAL", 10, 20], ["lamivudine", "CHEMICAL", 26, 36], ["entecavir", "CHEMICAL", 38, 47], ["adefovir", "CHEMICAL", 52, 60], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 10, 20], ["lamivudine", "SIMPLE_CHEMICAL", 26, 36], ["entecavir", "SIMPLE_CHEMICAL", 38, 47], ["adefovir", "SIMPLE_CHEMICAL", 52, 60], ["HBV", "ORGANISM", 86, 89], ["DNA", "CELLULAR_COMPONENT", 90, 93], [".DISCUSSIONHepatitis B virus", "ORGANISM", 175, 203], ["Hepadnaviridae", "GENE_OR_GENE_PRODUCT", 227, 241], ["Hepadnaviridae family", "PROTEIN", 227, 248], ["HBV", "SPECIES", 86, 89], ["B virus", "SPECIES", 196, 203], ["Na", "TEST", 10, 12], ["lamivudine", "TREATMENT", 26, 36], ["entecavir", "TREATMENT", 38, 47], ["adefovir", "TREATMENT", 52, 60], ["the encapsidated HBV DNA levels", "TEST", 69, 100], ["AE", "TEST", 109, 111], ["AE", "TEST", 124, 126], ["AE", "TEST", 143, 145]]], ["Infectious virions contain the genome as a 3.2 kb relaxed circular DNA (RC DNA), which is transformed into a plasmid-like cccDNA in the host cell nucleus [Beck and Nassal, 2007] .", [["virions", "ANATOMY", 11, 18], ["cell nucleus", "ANATOMY", 141, 153], ["DNA", "CELLULAR_COMPONENT", 67, 70], ["DNA", "CELLULAR_COMPONENT", 75, 78], ["cccDNA", "CELLULAR_COMPONENT", 122, 128], ["cell nucleus", "CELLULAR_COMPONENT", 141, 153], ["3.2 kb relaxed circular DNA", "DNA", 43, 70], ["RC DNA", "DNA", 72, 78], ["plasmid", "DNA", 109, 116], ["Infectious virions", "PROBLEM", 0, 18], ["a 3.2 kb relaxed circular DNA (RC DNA", "PROBLEM", 41, 78], ["circular", "OBSERVATION_MODIFIER", 58, 66], ["DNA", "OBSERVATION_MODIFIER", 67, 70], ["RC DNA", "OBSERVATION_MODIFIER", 72, 78], ["cccDNA", "OBSERVATION", 122, 128], ["host cell", "OBSERVATION", 136, 145], ["nucleus", "ANATOMY_MODIFIER", 146, 153]]], ["The two subsets of viral RNAs, namely, the subgenomic RNAs (preS/S mRNAs and HBx mRNA), and the greater-thangenome-length pregenomic RNA (pgRNA) and precore mRNA, are transcribed by cellular RNA polymerase II using cccDNA as the template [Beck and Nassal, 2007] .", [["cellular", "ANATOMY", 182, 190], ["preS/S mRNAs", "GENE_OR_GENE_PRODUCT", 60, 72], ["HBx", "GENE_OR_GENE_PRODUCT", 77, 80], ["pgRNA", "GENE_OR_GENE_PRODUCT", 138, 143], ["cellular RNA polymerase II", "GENE_OR_GENE_PRODUCT", 182, 208], ["cccDNA", "CELLULAR_COMPONENT", 215, 221], ["viral RNAs", "RNA", 19, 29], ["subgenomic RNAs", "RNA", 43, 58], ["preS/S mRNAs", "RNA", 60, 72], ["HBx mRNA", "RNA", 77, 85], ["thangenome-length pregenomic RNA", "RNA", 104, 136], ["pgRNA", "RNA", 138, 143], ["precore mRNA", "RNA", 149, 161], ["cellular RNA polymerase II", "PROTEIN", 182, 208], ["viral RNAs", "PROBLEM", 19, 29], ["the subgenomic RNAs", "PROBLEM", 39, 58], ["preS/S mRNAs", "TEST", 60, 72], ["HBx mRNA", "TEST", 77, 85], ["precore mRNA", "PROBLEM", 149, 161], ["two", "OBSERVATION_MODIFIER", 4, 7], ["subsets", "OBSERVATION_MODIFIER", 8, 15], ["viral RNAs", "OBSERVATION", 19, 29], ["subgenomic RNAs", "OBSERVATION", 43, 58]]], ["Although Se has been reported to influence multiple virus infections [Rayman, 2000; Beck et al., 2003; Beck, 2007; Harthill, 2011] , only limited information is available about whether it has any effect on HBV infection.", [["Se", "CHEMICAL", 9, 11], ["infections", "DISEASE", 58, 68], ["HBV infection", "DISEASE", 206, 219], ["Se", "CHEMICAL", 9, 11], ["Se", "SIMPLE_CHEMICAL", 9, 11], ["HBV", "ORGANISM", 206, 209], ["Se", "PROTEIN", 9, 11], ["HBV", "SPECIES", 206, 209], ["multiple virus infections", "PROBLEM", 43, 68], ["HBV infection", "PROBLEM", 206, 219], ["infection", "OBSERVATION", 210, 219]]], ["One study has shown significantly lower concentrations of Se in serum from patients with HBV infection compared with healthy individuals [Khan et al., 2012] .", [["serum", "ANATOMY", 64, 69], ["Se", "CHEMICAL", 58, 60], ["HBV infection", "DISEASE", 89, 102], ["Se", "CHEMICAL", 58, 60], ["Se", "SIMPLE_CHEMICAL", 58, 60], ["serum", "ORGANISM_SUBSTANCE", 64, 69], ["patients", "ORGANISM", 75, 83], ["HBV", "ORGANISM", 89, 92], ["patients", "SPECIES", 75, 83], ["HBV", "SPECIES", 89, 92], ["One study", "TEST", 0, 9], ["significantly lower concentrations", "PROBLEM", 20, 54], ["Se in serum", "PROBLEM", 58, 69], ["HBV infection", "PROBLEM", 89, 102], ["significantly", "OBSERVATION_MODIFIER", 20, 33], ["lower", "OBSERVATION_MODIFIER", 34, 39], ["concentrations", "OBSERVATION_MODIFIER", 40, 54], ["infection", "OBSERVATION", 93, 102]]], ["Moreover, according to an eight-year follow-up investigation of 130,471 individuals in Qidong, China, Se supplementation via table salt significantly reduced the incidence of primary liver cancer [Yu et al., 1997] .", [["primary liver cancer", "ANATOMY", 175, 195], ["Se", "CHEMICAL", 102, 104], ["salt", "CHEMICAL", 131, 135], ["primary liver cancer", "DISEASE", 175, 195], ["Se", "CHEMICAL", 102, 104], ["Se", "SIMPLE_CHEMICAL", 102, 104], ["liver cancer", "CANCER", 183, 195], ["Se supplementation via table salt", "TREATMENT", 102, 135], ["primary liver cancer", "PROBLEM", 175, 195], ["liver", "ANATOMY", 183, 188], ["cancer", "OBSERVATION", 189, 195]]], ["However, none of the available studies showed solid evidence of the relationship between Se and HBV replication.", [["Se", "CHEMICAL", 89, 91], ["Se", "CHEMICAL", 89, 91], ["Se", "SIMPLE_CHEMICAL", 89, 91], ["HBV", "ORGANISM", 96, 99], ["HBV", "SPECIES", 96, 99], ["the available studies", "TEST", 17, 38], ["HBV replication", "TREATMENT", 96, 111], ["HBV", "OBSERVATION", 96, 99]]], ["The present study is the first to demonstrate direct inhibitory effects of Na 2 SeO 3 on HBV at the cellular level, using different HBV cell models.DISCUSSIONBoth HBeAg and HBsAg are secreted to serum from HBV-infected hepatocytes, but appear at different phases of infection, and have different clinical implications [Papatheodoridis et al., 2008; Trepo et al., 2014] .", [["cellular", "ANATOMY", 100, 108], ["cell", "ANATOMY", 136, 140], ["serum", "ANATOMY", 195, 200], ["hepatocytes", "ANATOMY", 219, 230], ["Na", "CHEMICAL", 75, 77], ["HBeAg", "CHEMICAL", 163, 168], ["HBsAg", "CHEMICAL", 173, 178], ["infection", "DISEASE", 266, 275], ["Na 2 SeO 3", "CHEMICAL", 75, 85], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 75, 85], ["HBV", "ORGANISM", 89, 92], ["cellular", "CELL", 100, 108], ["cell", "CELL", 136, 140], ["HBeAg", "GENE_OR_GENE_PRODUCT", 163, 168], ["HBsAg", "GENE_OR_GENE_PRODUCT", 173, 178], ["serum", "ORGANISM_SUBSTANCE", 195, 200], ["HBV", "ORGANISM", 206, 209], ["hepatocytes", "CELL", 219, 230], ["HBeAg", "PROTEIN", 163, 168], ["HBsAg", "PROTEIN", 173, 178], ["HBV-infected hepatocytes", "CELL_TYPE", 206, 230], ["HBV", "SPECIES", 89, 92], ["HBV", "SPECIES", 132, 135], ["HBV", "SPECIES", 206, 209], ["The present study", "TEST", 0, 17], ["Na", "TEST", 75, 77], ["HBV", "PROBLEM", 89, 92], ["different HBV cell models", "TEST", 122, 147], ["HBeAg", "TEST", 163, 168], ["HBsAg", "TEST", 173, 178], ["serum", "TEST", 195, 200], ["HBV", "PROBLEM", 206, 209], ["infected hepatocytes", "PROBLEM", 210, 230], ["infection", "PROBLEM", 266, 275], ["HBV cell models", "OBSERVATION", 132, 147], ["infected", "OBSERVATION", 210, 218], ["hepatocytes", "ANATOMY", 219, 230], ["different phases", "OBSERVATION_MODIFIER", 246, 262], ["infection", "OBSERVATION", 266, 275]]], ["HBsAg is a hallmark of infection, although HBeAg is usually associated with high levels of viral replication.", [["HBsAg", "CHEMICAL", 0, 5], ["infection", "DISEASE", 23, 32], ["HBeAg", "CHEMICAL", 43, 48], ["HBsAg", "GENE_OR_GENE_PRODUCT", 0, 5], ["HBeAg", "GENE_OR_GENE_PRODUCT", 43, 48], ["HBsAg", "PROTEIN", 0, 5], ["HBsAg", "TEST", 0, 5], ["infection", "PROBLEM", 23, 32], ["HBeAg", "PROBLEM", 43, 48], ["viral replication", "TREATMENT", 91, 108], ["hallmark", "OBSERVATION_MODIFIER", 11, 19], ["infection", "OBSERVATION", 23, 32], ["HBeAg", "OBSERVATION", 43, 48], ["viral replication", "OBSERVATION", 91, 108]]], ["Although nucleoside/nucleotide analogues can inhibit HBV replication and result in obvious reductions in HBV DNA and HBeAg levels in serum, they have little impact on HBsAg secretion [Scaglione and Lok, 2012] .", [["serum", "ANATOMY", 133, 138], ["nucleoside", "CHEMICAL", 9, 19], ["nucleotide", "CHEMICAL", 20, 30], ["HBeAg", "CHEMICAL", 117, 122], ["HBsAg", "CHEMICAL", 167, 172], ["nucleoside", "CHEMICAL", 9, 19], ["nucleotide", "CHEMICAL", 20, 30], ["nucleoside/nucleotide analogues", "SIMPLE_CHEMICAL", 9, 40], ["HBV", "ORGANISM", 53, 56], ["HBV", "ORGANISM", 105, 108], ["DNA", "CELLULAR_COMPONENT", 109, 112], ["HBeAg", "GENE_OR_GENE_PRODUCT", 117, 122], ["serum", "ORGANISM_SUBSTANCE", 133, 138], ["HBsAg", "GENE_OR_GENE_PRODUCT", 167, 172], ["HBsAg", "PROTEIN", 167, 172], ["HBV", "SPECIES", 53, 56], ["HBV", "SPECIES", 105, 108], ["nucleoside/nucleotide analogues", "TREATMENT", 9, 40], ["HBV replication", "PROBLEM", 53, 68], ["obvious reductions", "PROBLEM", 83, 101], ["HBV DNA", "TEST", 105, 112], ["HBeAg levels in serum", "TEST", 117, 138], ["HBsAg secretion", "PROBLEM", 167, 182]]], ["The present study revealed evident declines in HBsAg/ HBeAg levels with Na 2 SeO 3 treatment in all three tested models (Figs.", [["HBsAg", "CHEMICAL", 47, 52], ["HBeAg", "CHEMICAL", 54, 59], ["Na 2 SeO 3", "CHEMICAL", 72, 82], ["Na 2 SeO 3", "CHEMICAL", 72, 82], ["HBsAg", "GENE_OR_GENE_PRODUCT", 47, 52], ["HBeAg", "GENE_OR_GENE_PRODUCT", 54, 59], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 72, 82], ["HBsAg", "PROTEIN", 47, 52], ["The present study", "TEST", 0, 17], ["evident declines", "PROBLEM", 27, 43], ["HBsAg", "TEST", 47, 52], ["HBeAg levels", "TEST", 54, 66], ["Na", "TEST", 72, 74], ["SeO 3 treatment", "TREATMENT", 77, 92], ["declines", "OBSERVATION_MODIFIER", 35, 43]]], ["However, it must be noted that the HCMV-promoter driven 1.1\u00c2HBV construct should not allow for the synthesis of HBeAg because of the lack of intact precore region at the 5' end [Nassal, 1992] .", [["HBeAg", "CHEMICAL", 112, 117], ["HCMV", "ORGANISM", 35, 39], ["HBeAg", "GENE_OR_GENE_PRODUCT", 112, 117], ["HCMV-promoter driven 1.1\u00c2HBV construct", "DNA", 35, 73], ["precore region", "DNA", 148, 162], ["5' end", "DNA", 170, 176], ["HCMV", "SPECIES", 35, 39], ["the HCMV-promoter driven 1.1\u00c2HBV construct", "TREATMENT", 31, 73], ["the synthesis of HBeAg", "TREATMENT", 95, 117]]], ["And HBeAg detected in HuH-7 transfected with 1.1\u00c2HBV plasmid might be core proteins due to antibody cross reactivity.", [["HuH-7", "ANATOMY", 22, 27], ["plasmid", "ANATOMY", 53, 60], ["HBeAg", "CHEMICAL", 4, 9], ["HBeAg", "GENE_OR_GENE_PRODUCT", 4, 9], ["HuH-7", "CELL", 22, 27], ["1.1\u00c2HBV plasmid", "DNA", 45, 60], ["HuH-7", "SPECIES", 22, 27], ["\u00c2HBV", "SPECIES", 48, 52], ["HBeAg", "TEST", 4, 9], ["HuH", "TEST", 22, 25], ["\u00c2HBV plasmid", "TREATMENT", 48, 60], ["core proteins", "TEST", 70, 83], ["antibody cross reactivity", "PROBLEM", 91, 116], ["HBeAg", "OBSERVATION", 4, 9]]], ["So, intracellular core protein level was also determined in these models, and the result showed Na 2 SeO 3 treatment obviously reduced core expression in host cell, but not the internal reference protein (Fig. S2) .", [["intracellular", "ANATOMY", 4, 17], ["cell", "ANATOMY", 159, 163], ["Na", "CHEMICAL", 96, 98], ["SeO 3", "CHEMICAL", 101, 106], ["Na 2 SeO 3", "CHEMICAL", 96, 106], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 17], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 96, 106], ["host cell", "CELL", 154, 163], ["host cell", "CELL_TYPE", 154, 163], ["internal reference protein", "PROTEIN", 177, 203], ["S2", "PROTEIN", 210, 212], ["intracellular core protein level", "TEST", 4, 36], ["Na", "TEST", 96, 98], ["reduced core expression in host cell", "PROBLEM", 127, 163], ["host cell", "OBSERVATION", 154, 163]]], ["These results prompted us to further investigate the reason of the viral antigen decreases at the HBV transcription level.DISCUSSIONMany published research articles have revealed that Se regulates various physiological activities of cells, such as gene transcription, signaling transduction, and cell apoptosis [McKenzie et al., 2002; Fig. 6 .", [["cells", "ANATOMY", 233, 238], ["cell", "ANATOMY", 296, 300], ["Se", "CHEMICAL", 184, 186], ["Se", "CHEMICAL", 184, 186], ["Se", "SIMPLE_CHEMICAL", 184, 186], ["cells", "CELL", 233, 238], ["cell", "CELL", 296, 300], ["viral antigen", "PROTEIN", 67, 80], ["Se", "PROTEIN", 184, 186], ["HBV", "SPECIES", 98, 101], ["the viral antigen decreases", "PROBLEM", 63, 90], ["Se regulates various physiological activities of cells", "PROBLEM", 184, 238], ["gene transcription", "TREATMENT", 248, 266], ["signaling transduction", "TREATMENT", 268, 290], ["cell apoptosis", "PROBLEM", 296, 310]]], ["Combined treatment of Na 2 SeO 3 with clinically applied nucleos(t) ide drugs.", [["Na", "CHEMICAL", 22, 24], ["nucleos(t) ide", "CHEMICAL", 57, 71], ["Na 2 SeO 3", "CHEMICAL", 22, 32], ["nucleos(t) ide", "CHEMICAL", 57, 71], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 22, 32], ["nucleos(t) ide drugs", "SIMPLE_CHEMICAL", 57, 77], ["nucleos(t) ide drugs", "TREATMENT", 57, 77]]], ["HepG2.2.15 were treated with 2.5 mM Na 2 SeO 3 (Se) alone or in combination with lamivudine (3TC, 70 nM), entecavir (ETV, 9 nM) or adefovir (Ade, 1.2 mM) for three days and six days.", [["HepG2.2.15", "CHEMICAL", 0, 10], ["Na", "CHEMICAL", 36, 38], ["SeO 3", "CHEMICAL", 41, 46], ["Se", "CHEMICAL", 48, 50], ["lamivudine", "CHEMICAL", 81, 91], ["3TC", "CHEMICAL", 93, 96], ["entecavir", "CHEMICAL", 106, 115], ["ETV", "CHEMICAL", 117, 120], ["adefovir", "CHEMICAL", 131, 139], ["Ade", "CHEMICAL", 141, 144], ["Na 2 SeO 3", "CHEMICAL", 36, 46], ["Se", "CHEMICAL", 48, 50], ["lamivudine", "CHEMICAL", 81, 91], ["3TC", "CHEMICAL", 93, 96], ["entecavir", "CHEMICAL", 106, 115], ["ETV", "CHEMICAL", 117, 120], ["adefovir", "CHEMICAL", 131, 139], ["Ade", "CHEMICAL", 141, 144], ["HepG2.2.15", "SIMPLE_CHEMICAL", 0, 10], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 36, 46], ["Se", "SIMPLE_CHEMICAL", 48, 50], ["lamivudine", "SIMPLE_CHEMICAL", 81, 91], ["3TC", "SIMPLE_CHEMICAL", 93, 96], ["entecavir", "SIMPLE_CHEMICAL", 106, 115], ["adefovir", "SIMPLE_CHEMICAL", 131, 139], ["Ade", "SIMPLE_CHEMICAL", 141, 144], ["HepG2.2.15", "TREATMENT", 0, 10], ["2.5 mM Na 2 SeO", "TREATMENT", 29, 44], ["lamivudine", "TREATMENT", 81, 91], ["3TC", "TREATMENT", 93, 96], ["entecavir (ETV", "TREATMENT", 106, 120], ["adefovir", "TREATMENT", 131, 139]]], ["Intracellular DNA of samples were extracted and viral DNA was determined using qPCR.", [["Intracellular", "ANATOMY", 0, 13], ["samples", "ANATOMY", 21, 28], ["Intracellular", "CELLULAR_COMPONENT", 0, 13], ["DNA", "CELLULAR_COMPONENT", 14, 17], ["DNA", "CELLULAR_COMPONENT", 54, 57], ["viral DNA", "DNA", 48, 57], ["Intracellular DNA of samples", "TEST", 0, 28], ["viral DNA", "PROBLEM", 48, 57], ["qPCR", "TEST", 79, 83], ["DNA", "OBSERVATION", 14, 17]]], ["All data were normalized to the mock-treated control.", [["All data", "TEST", 0, 8], ["the mock", "TEST", 28, 36]]], ["Na 2 SeO 3 was shown by northern blot assay and qPCR to inhibit HBV transcription in a dose-dependent and timedependent manner (Figs.", [["Na", "CHEMICAL", 0, 2], ["Na 2 SeO 3", "CHEMICAL", 0, 10], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 0, 10], ["HBV", "ORGANISM", 64, 67], ["Na 2 SeO 3", "PROTEIN", 0, 10], ["HBV", "SPECIES", 64, 67], ["Na", "TEST", 0, 2], ["blot assay", "TEST", 33, 43], ["qPCR", "TEST", 48, 52], ["HBV transcription", "TREATMENT", 64, 81]]], ["4 and S1).", [["S1", "PROTEIN", 6, 8]]], ["As HBV mRNAs synthesis is primarily dependent on RNA polymerase II and the transcriptional regulation system of the host cells [Levrero et al., 2009; Quasdorff and Protzer, 2010] , it is likely that the following cellular factors were possibly involved in the observed suppression.DISCUSSIONThe first potential candidate is p53.", [["cells", "ANATOMY", 121, 126], ["cellular", "ANATOMY", 213, 221], ["HBV", "ORGANISM", 3, 6], ["RNA polymerase II", "GENE_OR_GENE_PRODUCT", 49, 66], ["host cells", "CELL", 116, 126], ["cellular", "CELL", 213, 221], ["p53", "GENE_OR_GENE_PRODUCT", 324, 327], ["HBV mRNAs", "RNA", 3, 12], ["RNA polymerase II", "PROTEIN", 49, 66], ["host cells", "CELL_TYPE", 116, 126], ["cellular factors", "PROTEIN", 213, 229], ["p53", "PROTEIN", 324, 327], ["HBV", "SPECIES", 3, 6], ["HBV mRNAs synthesis", "TEST", 3, 22], ["p53", "PROBLEM", 324, 327], ["host cells", "OBSERVATION", 116, 126]]], ["Na 2 SeO 3 treatment may activate p53 by promoting its expression and phosphorylating multiple sites [Smith et al., 2004] .", [["Na", "CHEMICAL", 0, 2], ["SeO 3", "CHEMICAL", 5, 10], ["Na 2 SeO 3", "CHEMICAL", 0, 10], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 0, 10], ["p53", "GENE_OR_GENE_PRODUCT", 34, 37], ["p53", "PROTEIN", 34, 37], ["Na", "TEST", 0, 2]]], ["Both p53 and its homologue p73 have been reported to repress the activities of HBV promoters and enhancers [Lee et al., 1998; Buhlmann et al., 2008] .", [["p53", "GENE_OR_GENE_PRODUCT", 5, 8], ["p73", "GENE_OR_GENE_PRODUCT", 27, 30], ["HBV", "ORGANISM", 79, 82], ["p53", "PROTEIN", 5, 8], ["p73", "PROTEIN", 27, 30], ["HBV promoters", "DNA", 79, 92], ["enhancers", "DNA", 97, 106], ["HBV", "SPECIES", 79, 82], ["HBV promoters", "TREATMENT", 79, 92]]], ["Hence, p53 is a possible intermediary between Na 2 SeO 3 and HBV transcription.DISCUSSIONThe second possible factor is specificity protein 1 (Sp1), which binds to guanine-cytosine-rich DNA elements and regulates a wide variety of genes in mammalian cells [Chu, 2012] .", [["cells", "ANATOMY", 249, 254], ["Na", "CHEMICAL", 46, 48], ["guanine-cytosine", "CHEMICAL", 163, 179], ["Na 2 SeO 3", "CHEMICAL", 46, 56], ["guanine", "CHEMICAL", 163, 170], ["cytosine", "CHEMICAL", 171, 179], ["p53", "GENE_OR_GENE_PRODUCT", 7, 10], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 46, 56], ["HBV", "ORGANISM", 61, 64], ["specificity protein 1", "GENE_OR_GENE_PRODUCT", 119, 140], ["Sp1", "GENE_OR_GENE_PRODUCT", 142, 145], ["cytosine", "SIMPLE_CHEMICAL", 171, 179], ["DNA", "CELLULAR_COMPONENT", 185, 188], ["mammalian cells", "CELL", 239, 254], ["p53", "PROTEIN", 7, 10], ["specificity protein 1", "PROTEIN", 119, 140], ["Sp1", "PROTEIN", 142, 145], ["guanine-cytosine-rich DNA elements", "DNA", 163, 197], ["mammalian cells", "CELL_TYPE", 239, 254], ["HBV", "SPECIES", 61, 64], ["Na", "TEST", 46, 48], ["HBV transcription", "TREATMENT", 61, 78], ["specificity protein 1 (Sp1)", "PROBLEM", 119, 146], ["cytosine-rich DNA elements", "TREATMENT", 171, 197]]], ["At least three binding sites have been identified in the HBV genome, Sp1 activates the transcription of HBV genes by binding to these sites [Quasdorff and Protzer, 2010] .", [["HBV", "ORGANISM", 57, 60], ["Sp1", "GENE_OR_GENE_PRODUCT", 69, 72], ["HBV", "ORGANISM", 104, 107], ["HBV genome", "DNA", 57, 67], ["Sp1", "PROTEIN", 69, 72], ["HBV genes", "DNA", 104, 113], ["HBV", "SPECIES", 57, 60], ["HBV", "SPECIES", 104, 107], ["three binding sites", "PROBLEM", 9, 28], ["HBV genes", "PROBLEM", 104, 113], ["binding sites", "OBSERVATION", 15, 28], ["HBV genome", "OBSERVATION", 57, 67]]], ["Se has been demonstrated to decrease Sp1 expression and activity [Husbeck et al., 2006] , and prevent activation of Sp1-regulated HBV genes.", [["Se", "CHEMICAL", 0, 2], ["Se", "CHEMICAL", 0, 2], ["Se", "SIMPLE_CHEMICAL", 0, 2], ["Sp1", "GENE_OR_GENE_PRODUCT", 37, 40], ["Sp1", "GENE_OR_GENE_PRODUCT", 116, 119], ["HBV", "ORGANISM", 130, 133], ["Sp1", "PROTEIN", 37, 40], ["Sp1", "PROTEIN", 116, 119], ["HBV genes", "DNA", 130, 139], ["HBV", "SPECIES", 130, 133], ["Sp1", "PROBLEM", 116, 119], ["decrease", "OBSERVATION_MODIFIER", 28, 36], ["Sp1 expression", "OBSERVATION", 37, 51], ["HBV genes", "OBSERVATION", 130, 139]]], ["Therefore, Se is likely to affect HBV transcription through a complicated regulatory network.DISCUSSIONFinally, a trans-acting factor, HBx, encoded by the HBV genome, is a multifunctional viral protein and is broadly involved in transcription, signal transduction, cell cycle progress, apoptosis, genetic stability, and oncogenesis through protein-protein interaction [Bouchard and Schneider, 2004; Tang et al., 2006; Ng and Lee, 2011; Motavaf et al., 2013] .", [["cell", "ANATOMY", 265, 269], ["Se", "CHEMICAL", 11, 13], ["Se", "CHEMICAL", 11, 13], ["Se", "SIMPLE_CHEMICAL", 11, 13], ["HBV", "ORGANISM", 34, 37], ["HBx", "GENE_OR_GENE_PRODUCT", 135, 138], ["HBV", "ORGANISM", 155, 158], ["cell", "CELL", 265, 269], ["trans-acting factor", "PROTEIN", 114, 133], ["HBx", "PROTEIN", 135, 138], ["HBV genome", "DNA", 155, 165], ["multifunctional viral protein", "PROTEIN", 172, 201], ["HBV", "SPECIES", 34, 37], ["HBV", "SPECIES", 155, 158], ["HBV transcription", "PROBLEM", 34, 51], ["HBx", "PROBLEM", 135, 138], ["a multifunctional viral protein", "PROBLEM", 170, 201], ["signal transduction", "TEST", 244, 263], ["apoptosis", "PROBLEM", 286, 295], ["likely to", "UNCERTAINTY", 17, 26], ["HBV genome", "OBSERVATION", 155, 165], ["Schneider", "ANATOMY", 382, 391]]], ["Tang et al. reported that both HBV transcription and replication can be affected simultaneously by HBx, but the transcriptional activation of HBx may be critical for its augmenting effect on HBV replication [Tang et al., 2006] .", [["HBV", "ORGANISM", 31, 34], ["HBx", "GENE_OR_GENE_PRODUCT", 99, 102], ["HBx", "GENE_OR_GENE_PRODUCT", 142, 145], ["HBV", "ORGANISM", 191, 194], ["HBx", "PROTEIN", 99, 102], ["HBx", "PROTEIN", 142, 145], ["HBV", "SPECIES", 31, 34], ["HBV", "SPECIES", 191, 194], ["both HBV transcription", "TREATMENT", 26, 48], ["replication", "TREATMENT", 53, 64], ["HBx", "TREATMENT", 142, 145], ["HBV replication", "TREATMENT", 191, 206], ["HBV", "OBSERVATION", 31, 34]]], ["HBx also induces cytosolic calcium elevation and viral DNA replication, but not viral transcription, by interacting with Bcl-2 family members [Geng et al., 2012] or by activating cytosolic calcium-dependent proline-rich tyrosine kinase-2 (Pyk2) [Bouchard et al., 2001] .", [["cytosolic", "ANATOMY", 17, 26], ["cytosolic", "ANATOMY", 179, 188], ["calcium", "CHEMICAL", 27, 34], ["calcium", "CHEMICAL", 189, 196], ["proline", "CHEMICAL", 207, 214], ["tyrosine", "CHEMICAL", 220, 228], ["calcium", "CHEMICAL", 27, 34], ["calcium", "CHEMICAL", 189, 196], ["proline", "CHEMICAL", 207, 214], ["tyrosine", "CHEMICAL", 220, 228], ["HBx", "GENE_OR_GENE_PRODUCT", 0, 3], ["cytosolic", "ORGANISM_SUBSTANCE", 17, 26], ["calcium", "SIMPLE_CHEMICAL", 27, 34], ["DNA", "CELLULAR_COMPONENT", 55, 58], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 121, 126], ["calcium-dependent proline-rich tyrosine kinase-2", "GENE_OR_GENE_PRODUCT", 189, 237], ["Pyk2", "GENE_OR_GENE_PRODUCT", 239, 243], ["HBx", "PROTEIN", 0, 3], ["Bcl-2 family members", "PROTEIN", 121, 141], ["cytosolic calcium-dependent proline-rich tyrosine kinase-2", "PROTEIN", 179, 237], ["Pyk2", "PROTEIN", 239, 243], ["HBx", "TREATMENT", 0, 3], ["cytosolic calcium elevation", "TREATMENT", 17, 44], ["viral DNA replication", "TREATMENT", 49, 70], ["cytosolic calcium", "TEST", 179, 196], ["dependent proline-rich tyrosine kinase", "TREATMENT", 197, 235], ["cytosolic calcium elevation", "OBSERVATION", 17, 44], ["viral DNA", "OBSERVATION", 49, 58]]], ["Although Se has not been proved to have direct effects on HBx, it has been demonstrated to affect HBx-related host factors, including p53 and nuclear factor-kB, and to result in a significant decrease in cellular calcium release [Uguz and Naziroglu, 2012] .", [["cellular", "ANATOMY", 204, 212], ["Se", "CHEMICAL", 9, 11], ["calcium", "CHEMICAL", 213, 220], ["Se", "CHEMICAL", 9, 11], ["calcium", "CHEMICAL", 213, 220], ["Se", "SIMPLE_CHEMICAL", 9, 11], ["HBx", "GENE_OR_GENE_PRODUCT", 58, 61], ["HBx", "GENE_OR_GENE_PRODUCT", 98, 101], ["p53", "GENE_OR_GENE_PRODUCT", 134, 137], ["nuclear factor-kB", "GENE_OR_GENE_PRODUCT", 142, 159], ["cellular", "CELL", 204, 212], ["calcium", "SIMPLE_CHEMICAL", 213, 220], ["Se", "PROTEIN", 9, 11], ["HBx", "PROTEIN", 58, 61], ["HBx", "PROTEIN", 98, 101], ["host factors", "PROTEIN", 110, 122], ["p53", "PROTEIN", 134, 137], ["nuclear factor-kB", "PROTEIN", 142, 159], ["HBx", "TREATMENT", 58, 61], ["HBx", "TEST", 98, 101], ["p53", "TEST", 134, 137], ["nuclear factor-kB", "TEST", 142, 159], ["a significant decrease in cellular calcium release", "PROBLEM", 178, 228], ["significant", "OBSERVATION_MODIFIER", 180, 191], ["decrease", "OBSERVATION_MODIFIER", 192, 200]]], ["Thus, HBx is another suspected viral factor that possibly mediates selenite-induced inhibition of HBV transcription and replication.DISCUSSIONThe Southern blot assay shown in Figure 5 showed an evident decline in HBV DNA level with Na 2 SeO 3 treatment in all three tested models.", [["selenite", "CHEMICAL", 67, 75], ["Na", "CHEMICAL", 232, 234], ["SeO 3", "CHEMICAL", 237, 242], ["selenite", "CHEMICAL", 67, 75], ["Na 2 SeO 3", "CHEMICAL", 232, 242], ["HBx", "GENE_OR_GENE_PRODUCT", 6, 9], ["selenite", "SIMPLE_CHEMICAL", 67, 75], ["HBV", "ORGANISM", 98, 101], ["HBV", "ORGANISM", 213, 216], ["DNA", "CELLULAR_COMPONENT", 217, 220], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 232, 242], ["HBx", "PROTEIN", 6, 9], ["HBV", "SPECIES", 98, 101], ["HBV", "SPECIES", 213, 216], ["HBx", "PROBLEM", 6, 9], ["viral factor", "PROBLEM", 31, 43], ["HBV transcription", "TREATMENT", 98, 115], ["Southern blot assay", "TEST", 146, 165], ["an evident decline", "PROBLEM", 191, 209], ["HBV DNA level", "PROBLEM", 213, 226], ["Na 2 SeO 3 treatment", "TREATMENT", 232, 252], ["HBx", "OBSERVATION", 6, 9], ["HBV", "OBSERVATION", 98, 101], ["HBV", "OBSERVATION", 213, 216]]], ["However, there were dissimilarities in selenite-induced suppression in the three models, possibly due to the differences in their cell lines and HBV-expressing systems.", [["cell lines", "ANATOMY", 130, 140], ["selenite", "CHEMICAL", 39, 47], ["selenite", "CHEMICAL", 39, 47], ["selenite", "SIMPLE_CHEMICAL", 39, 47], ["cell lines", "CELL", 130, 140], ["HBV", "ORGANISM", 145, 148], ["cell lines", "CELL_LINE", 130, 140], ["HBV", "SPECIES", 145, 148], ["selenite-induced suppression in the three models", "PROBLEM", 39, 87], ["their cell lines", "TREATMENT", 124, 140], ["selenite", "OBSERVATION_MODIFIER", 39, 47], ["-induced", "OBSERVATION_MODIFIER", 47, 55], ["suppression", "OBSERVATION", 56, 67], ["possibly due to", "UNCERTAINTY", 89, 104], ["cell lines", "OBSERVATION", 130, 140]]], ["The progressive reduction in HBV DNA displayed a similar trend to the decrease in HBV mRNAs, which indicated that one potential mechanism of Na 2 SeO 3 in suppressing HBV replication is by inhibition of viral transcription.", [["Na", "CHEMICAL", 141, 143], ["SeO", "CHEMICAL", 146, 149], ["Na 2 SeO 3", "CHEMICAL", 141, 151], ["HBV", "ORGANISM", 29, 32], ["DNA", "CELLULAR_COMPONENT", 33, 36], ["HBV", "ORGANISM", 82, 85], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 141, 151], ["HBV", "ORGANISM", 167, 170], ["HBV DNA", "DNA", 29, 36], ["HBV mRNAs", "RNA", 82, 91], ["Na 2 SeO 3", "PROTEIN", 141, 151], ["HBV", "SPECIES", 29, 32], ["HBV", "SPECIES", 82, 85], ["HBV", "SPECIES", 167, 170], ["The progressive reduction", "PROBLEM", 0, 25], ["HBV DNA", "PROBLEM", 29, 36], ["the decrease in HBV mRNAs", "PROBLEM", 66, 91], ["Na", "TEST", 141, 143], ["suppressing HBV replication", "TREATMENT", 155, 182], ["viral transcription", "TREATMENT", 203, 222], ["progressive", "OBSERVATION_MODIFIER", 4, 15], ["reduction", "OBSERVATION_MODIFIER", 16, 25], ["HBV DNA", "OBSERVATION", 29, 36], ["decrease", "OBSERVATION_MODIFIER", 70, 78], ["HBV mRNAs", "OBSERVATION", 82, 91], ["viral transcription", "OBSERVATION", 203, 222]]], ["In addition to suppressing viral transcription, Se may also inhibit HBV replication by cytosolic calcium release, which is related to HBx in host cells [Bouchard et al., 2001; Geng et al., 2012] .", [["cytosolic", "ANATOMY", 87, 96], ["cells", "ANATOMY", 146, 151], ["Se", "CHEMICAL", 48, 50], ["calcium", "CHEMICAL", 97, 104], ["Se", "CHEMICAL", 48, 50], ["calcium", "CHEMICAL", 97, 104], ["Se", "SIMPLE_CHEMICAL", 48, 50], ["HBV", "ORGANISM", 68, 71], ["cytosolic", "ORGANISM_SUBSTANCE", 87, 96], ["calcium", "SIMPLE_CHEMICAL", 97, 104], ["HBx", "GENE_OR_GENE_PRODUCT", 134, 137], ["host cells", "CELL", 141, 151], ["HBx", "PROTEIN", 134, 137], ["host cells", "CELL_TYPE", 141, 151], ["HBV", "SPECIES", 68, 71], ["suppressing viral transcription", "TREATMENT", 15, 46], ["HBV replication", "TREATMENT", 68, 83], ["cytosolic calcium release", "TEST", 87, 112], ["HBx", "OBSERVATION", 134, 137]]], ["The hypothesis that selenite inhibits HBV transcription and replication via host and viral factors still needs to be verified, and the potential involved factor (s) need to be identified by further experiments.DISCUSSIONIn addition, the anti-HBV efficacy of Na 2 SeO 3 was quantitatively compared with nucleos(t) ide analogues using qPCR, alone or in combination (Fig. 6) .", [["selenite", "CHEMICAL", 20, 28], ["Na", "CHEMICAL", 258, 260], ["nucleos(t) ide", "CHEMICAL", 302, 316], ["selenite", "CHEMICAL", 20, 28], ["Na 2 SeO 3", "CHEMICAL", 258, 268], ["nucleos(t) ide", "CHEMICAL", 302, 316], ["selenite", "SIMPLE_CHEMICAL", 20, 28], ["HBV", "ORGANISM", 38, 41], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 258, 268], ["nucleos(t) ide analogues", "SIMPLE_CHEMICAL", 302, 326], ["viral factors", "PROTEIN", 85, 98], ["HBV", "SPECIES", 38, 41], ["The hypothesis", "PROBLEM", 0, 14], ["HBV transcription", "TREATMENT", 38, 55], ["replication via host", "TREATMENT", 60, 80], ["viral factors", "PROBLEM", 85, 98], ["nucleos(t) ide analogues", "TREATMENT", 302, 326], ["qPCR", "TEST", 333, 337]]], ["On Day 6, Na 2 SeO 3 , in spite of a higher treating concertation, exhibited similar efficacy to the other drugs.", [["Na", "CHEMICAL", 10, 12], ["Na 2 SeO 3", "CHEMICAL", 10, 20], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 10, 20], ["Na", "TEST", 10, 12]]], ["The less potent of Na 2 SeO 3 on inhibiting HBV replication compared to the other tested drugs is probably due to its indirect effect on viral polymerase.", [["Na", "CHEMICAL", 19, 21], ["SeO 3", "CHEMICAL", 24, 29], ["Na 2 SeO 3", "CHEMICAL", 19, 29], ["Na 2 SeO 3", "SIMPLE_CHEMICAL", 19, 29], ["HBV", "ORGANISM", 44, 47], ["viral polymerase", "PROTEIN", 137, 153], ["HBV", "SPECIES", 44, 47], ["inhibiting HBV replication", "TREATMENT", 33, 59], ["the other tested drugs", "TREATMENT", 72, 94], ["viral polymerase", "PROBLEM", 137, 153], ["less", "OBSERVATION_MODIFIER", 4, 8], ["potent", "OBSERVATION_MODIFIER", 9, 15], ["probably due to", "UNCERTAINTY", 98, 113], ["viral polymerase", "OBSERVATION", 137, 153]]], ["However, as Na 2 SeO 3 and the nucleos(t) ide drugs affected different factors in the replication cycle of HBV, their combination showed more efficacy than either treatment alone did (Fig. 6) .DISCUSSIONIn conclusion, these data to date, for the first time, directly prove that Na 2 SeO 3 inhibits HBsAg/HBeAg expression, HBV transcription, as well as viral genome replication.", [["Na", "CHEMICAL", 12, 14], ["nucleos(t) ide", "CHEMICAL", 31, 45], ["Na", "CHEMICAL", 278, 280], ["SeO 3", "CHEMICAL", 283, 288], ["HBsAg", "CHEMICAL", 298, 303], ["HBeAg", "CHEMICAL", 304, 309], ["Na 2 SeO 3", "CHEMICAL", 12, 22], ["nucleos(t) ide", "CHEMICAL", 31, 45], ["Na 2 SeO 3", "CHEMICAL", 278, 288], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 12, 22], ["nucleos(t) ide", "SIMPLE_CHEMICAL", 31, 45], ["HBV", "ORGANISM", 107, 110], ["Na 2 SeO 3", "GENE_OR_GENE_PRODUCT", 278, 288], ["HBsAg", "GENE_OR_GENE_PRODUCT", 298, 303], ["HBeAg", "GENE_OR_GENE_PRODUCT", 304, 309], ["HBV", "ORGANISM", 322, 325], ["HBsAg", "PROTEIN", 298, 303], ["HBV", "SPECIES", 107, 110], ["HBV", "SPECIES", 322, 325], ["Na", "TEST", 12, 14], ["the nucleos(t) ide drugs", "TREATMENT", 27, 51], ["affected different factors", "PROBLEM", 52, 78], ["HBV", "TREATMENT", 107, 110], ["Na", "TEST", 278, 280], ["HBsAg", "TEST", 298, 303], ["HBeAg expression", "PROBLEM", 304, 320], ["HBV transcription", "TREATMENT", 322, 339], ["viral genome replication", "TREATMENT", 352, 376]]], ["This HBV suppressing effect has made Se a potential therapeutic medication to control HBV infection.AUTHOR CONTRIBUTIONSZC and XZ performed the experiments.", [["Se", "CHEMICAL", 37, 39], ["HBV infection", "DISEASE", 86, 99], ["Se", "CHEMICAL", 37, 39], ["HBV", "ORGANISM", 5, 8], ["Se", "SIMPLE_CHEMICAL", 37, 39], ["HBV", "ORGANISM", 86, 89], ["HBV", "SPECIES", 5, 8], ["HBV", "SPECIES", 86, 89], ["This HBV suppressing effect", "TREATMENT", 0, 27], ["a potential therapeutic medication", "TREATMENT", 40, 74], ["HBV infection", "PROBLEM", 86, 99], ["infection", "OBSERVATION", 90, 99]]], ["ZC, FZ, and KH designed the research.", [["ZC", "CHEMICAL", 0, 2], ["FZ", "CHEMICAL", 4, 6], ["ZC", "SIMPLE_CHEMICAL", 0, 2], ["FZ", "SIMPLE_CHEMICAL", 4, 6]]], ["GS, GW, WS, YH, and XT provided experimental support.", [["experimental support", "TREATMENT", 32, 52]]], ["ZC and FZ drafted the manuscript.", [["ZC", "CHEMICAL", 0, 2], ["FZ", "CHEMICAL", 7, 9], ["ZC", "SIMPLE_CHEMICAL", 0, 2], ["FZ", "SIMPLE_CHEMICAL", 7, 9]]]], "89bf0bc0389f4be5fcac65dcab288aa62de6853b": [["INTRODUCTIONFrom the end of 2019, a new coronavirus namely COVID-19, was confirmed in human bodies as a new category of diseases that cause dangerous respiratory problems, heart infection, and even death.INTRODUCTIONTo more effectively control COVID-19 spread and treat patients to reduce mortality rate, medical images can play an important role [1] .", [["respiratory", "ANATOMY", 150, 161], ["heart", "ANATOMY", 172, 177], ["coronavirus", "DISEASE", 40, 51], ["COVID-19", "CHEMICAL", 59, 67], ["respiratory problems", "DISEASE", 150, 170], ["heart infection", "DISEASE", 172, 187], ["death", "DISEASE", 198, 203], ["coronavirus", "ORGANISM", 40, 51], ["COVID-19", "CELL", 59, 67], ["human", "ORGANISM", 86, 91], ["heart", "ORGAN", 172, 177], ["patients", "ORGANISM", 270, 278], ["human", "SPECIES", 86, 91], ["patients", "SPECIES", 270, 278], ["human", "SPECIES", 86, 91], ["a new coronavirus namely COVID", "TEST", 34, 64], ["diseases", "PROBLEM", 120, 128], ["dangerous respiratory problems", "PROBLEM", 140, 170], ["heart infection", "PROBLEM", 172, 187], ["even death", "PROBLEM", 193, 203], ["COVID", "TEST", 244, 249], ["mortality rate", "TEST", 289, 303], ["medical images", "TEST", 305, 319], ["new", "OBSERVATION_MODIFIER", 104, 107], ["diseases", "OBSERVATION", 120, 128], ["heart", "ANATOMY", 172, 177], ["infection", "OBSERVATION", 178, 187]]], ["In current clinical practice, chest X-ray radiography and computed tomography (CT) are two imaging modalities to detect COVID-19, assess its severity, and monitor its prognosis (or response to treatment).", [["chest X-ray radiography", "TEST", 30, 53], ["computed tomography (CT", "TEST", 58, 81], ["two imaging modalities", "TEST", 87, 109], ["COVID", "TEST", 120, 125], ["treatment", "TREATMENT", 193, 202], ["chest", "ANATOMY", 30, 35]]], ["Although CT can achieve higher detection sensitivity, chest X-ray radiography is more commonly used in clinical practice due to the advantages, including J o u r n a l P r e -p r o o f low cost, low radiation dose, easy-to-operate and wide accessibility in the general or community hospitals [2] .", [["CT", "TEST", 9, 11], ["chest X-ray radiography", "TEST", 54, 77], ["low cost", "PROBLEM", 185, 193], ["low radiation dose", "TREATMENT", 195, 213], ["chest", "ANATOMY", 54, 59]]], ["However, pneumonia can be caused by many different types of viruses and bacterial.INTRODUCTIONThus, it may be time-consuming and challenging for general radiologists in the community hospitals to read a high volume of chest X-ray images to detect subtle COVID-19 infected pneumonia and distinguish it from other community-acquired non-COVID-19 infected pneumonia.", [["pneumonia", "DISEASE", 9, 18], ["pneumonia", "DISEASE", 272, 281], ["pneumonia", "DISEASE", 353, 362], ["pneumonia", "PROBLEM", 9, 18], ["viruses", "PROBLEM", 60, 67], ["bacterial", "PROBLEM", 72, 81], ["chest X-ray images", "TEST", 218, 236], ["subtle COVID-19 infected pneumonia", "PROBLEM", 247, 281], ["acquired non-COVID-19 infected pneumonia", "PROBLEM", 322, 362], ["pneumonia", "OBSERVATION", 9, 18], ["viruses", "OBSERVATION", 60, 67], ["bacterial", "OBSERVATION_MODIFIER", 72, 81], ["chest", "ANATOMY", 218, 223], ["infected", "OBSERVATION_MODIFIER", 263, 271], ["pneumonia", "OBSERVATION", 272, 281], ["infected", "OBSERVATION_MODIFIER", 344, 352], ["pneumonia", "OBSERVATION", 353, 362]]], ["It is because there are many similarities between pneumonia infected by COVID-19 and other types of viruses or bacteria.INTRODUCTIONThus, this is a clinical challenge faced by the radiologists in this pandemic [3] .INTRODUCTIONTo address this challenge, developing computer-aided detection or diagnosis (CAD) schemes based on medical image processing and machine learning has been attracting broad research interest, which aims to automatically analyze disease characteristics and provide radiologists valuable decisionmaking supporting tools for more accurate or efficient detection and diagnosis of COVID-19 infected pneumonia.", [["pneumonia", "DISEASE", 50, 59], ["COVID-19", "CHEMICAL", 72, 80], ["CAD", "DISEASE", 304, 307], ["pneumonia", "DISEASE", 619, 628], ["COVID-19", "ORGANISM", 72, 80], ["COVID-19", "SPECIES", 601, 609], ["pneumonia", "PROBLEM", 50, 59], ["COVID", "TEST", 72, 77], ["viruses", "PROBLEM", 100, 107], ["bacteria", "PROBLEM", 111, 119], ["CAD) schemes", "PROBLEM", 304, 316], ["medical image processing", "TEST", 326, 350], ["COVID-19 infected pneumonia", "PROBLEM", 601, 628], ["pneumonia", "OBSERVATION", 50, 59], ["viruses", "OBSERVATION", 100, 107], ["bacteria", "OBSERVATION", 111, 119], ["infected", "OBSERVATION_MODIFIER", 610, 618], ["pneumonia", "OBSERVATION", 619, 628]]], ["To this aim, studies may involve following steps of preprocessing images, segmenting regions of interest (ROIs) related to the targeted diseases, computing and identifying effective image features, and building multiple-feature fusion-based machine learning models to detect and classify cases.", [["studies", "TEST", 13, 20], ["preprocessing images", "TEST", 52, 72], ["the targeted diseases", "PROBLEM", 123, 144], ["targeted", "OBSERVATION_MODIFIER", 127, 135], ["diseases", "OBSERVATION", 136, 144]]], ["For example, one study [4] computed 961 image features from the segmented ROIs depicting chest X-ray images.", [["one study", "TEST", 13, 22], ["the segmented ROIs depicting chest X-ray images", "TEST", 60, 107], ["chest", "ANATOMY", 89, 94]]], ["After applying a feature selection algorithm, a KNN classification model was built and yielded an accuracy of 96.1% to classify between COVID-19 and non-COVID-19 cases.INTRODUCTIONHowever, due to the difficulty in identifying and segmenting subtle pneumonia-related disease patterns or ROIs on chest X-ray images, recent studies have demonstrated that developing CAD schemes based on deep learning algorithms without segmentation of suspicious ROIs and computing handcrafted image features is more efficient and reliable than the use of the classical machine learning methods.", [["pneumonia", "DISEASE", 248, 257], ["CAD", "DISEASE", 363, 366], ["a KNN classification model", "TEST", 46, 72], ["an accuracy", "TEST", 95, 106], ["COVID", "TEST", 136, 141], ["non-COVID", "TEST", 149, 158], ["segmenting subtle pneumonia", "PROBLEM", 230, 257], ["disease patterns", "PROBLEM", 266, 282], ["ROIs on chest X-ray images", "TEST", 286, 312], ["recent studies", "TEST", 314, 328], ["developing CAD schemes", "PROBLEM", 352, 374], ["deep learning algorithms", "TEST", 384, 408], ["suspicious ROIs", "PROBLEM", 433, 448], ["computing handcrafted image features", "TEST", 453, 489], ["the classical machine learning methods", "TREATMENT", 537, 575], ["subtle", "OBSERVATION_MODIFIER", 241, 247], ["pneumonia", "OBSERVATION", 248, 257], ["chest", "ANATOMY", 294, 299], ["CAD", "OBSERVATION", 363, 366], ["suspicious", "OBSERVATION_MODIFIER", 433, 443]]], ["As a result, many deep learning models have been reported recently in the literature to detect and classify COVID-19 cases [2, [5] [6] [7] [8] [9] [10] [11] [12] [13] .", [["[2, [5] [6] [7] [8] [9] [10] [11]", "CHEMICAL", 123, 156], ["[5] [6] [7] [8] [9] [10] [11] [12] [13]", "SIMPLE_CHEMICAL", 127, 166], ["many deep learning models", "PROBLEM", 13, 38], ["COVID", "TEST", 108, 113]]], ["Although some deep learning convolution neural network (CNN) models are applied to CT images [5, 6] , more studies applied CNN models to detect and classify COVID-19 cases using chest X-ray images.", [["neural network", "MULTI-TISSUE_STRUCTURE", 40, 54], ["COVID", "DNA", 157, 162], ["some deep learning convolution neural network (CNN) models", "PROBLEM", 9, 67], ["CT images", "TEST", 83, 92], ["CNN models", "TEST", 123, 133], ["COVID", "TEST", 157, 162], ["chest X-ray images", "TEST", 178, 196], ["deep", "ANATOMY_MODIFIER", 14, 18], ["chest", "ANATOMY", 178, 183]]], ["They include different existing CNN models (i.e., Resnet50 [2, 7] , MobileNetV2 [8] , CoroNet [9] , Xception+ResNet50V2 [10] ) and several new special CNN models (i.e., DarkCovidNet [11] , COVID-Net [12] and COVIDX-Net [13] ).", [["CoroNet", "TEST", 86, 93], ["Xception", "TEST", 100, 108], ["new special CNN models", "TEST", 139, 161], ["COVID", "TEST", 189, 194], ["COVIDX", "TEST", 208, 214]]], ["These studies used different image datasets with a varying number of COVID-19 cases (i.e., from 25 to 224) among the total number of cases from 50 to 11,302.", [["These studies", "TEST", 0, 13], ["COVID", "TEST", 69, 74]]], ["The reported sensitivity to detect COVID-19 cases ranged from 79.0% to 98.6%.INTRODUCTIONDespite the promising results reported in previous studies, many issues have not been well investigated regarding how to train deep learning models optimally.", [["COVID", "TEST", 35, 40], ["cases", "TEST", 44, 49], ["previous studies", "TEST", 131, 147]]], ["For instance, whether applying image preprocessing algorithms can help to improve the performance and robustness of the deep learning models.", [["deep", "ANATOMY_MODIFIER", 120, 124]]], ["To better address some of the challenges or technical issues, we in this study develop J o u r n a l P r e -p r o o f and test a new deep learning based CAD scheme of chest X-ray radiography images.", [["P r e", "DNA", 101, 106], ["this study", "TEST", 68, 78], ["test", "TEST", 122, 126], ["chest X-ray radiography images", "TEST", 167, 197], ["chest", "ANATOMY", 167, 172]]], ["The scheme can detect and classify images into 3 classes namely, COVID-19 infected pneumonia, the other community-acquired non-COVID-19 infected pneumonia, and normal (non-pneumonia) cases.", [["infected pneumonia", "DISEASE", 74, 92], ["infected pneumonia", "DISEASE", 136, 154], ["non-pneumonia", "DISEASE", 168, 181], ["COVID", "TEST", 65, 70], ["infected pneumonia", "PROBLEM", 74, 92], ["acquired non-COVID-19 infected pneumonia", "PROBLEM", 114, 154], ["infected", "OBSERVATION_MODIFIER", 74, 82], ["pneumonia", "OBSERVATION", 83, 92], ["infected", "OBSERVATION_MODIFIER", 136, 144], ["pneumonia", "OBSERVATION", 145, 154], ["normal", "OBSERVATION", 160, 166]]], ["The hypothesis in this study is that instead of directly using the original chest X-ray images to train deep learning models, we can apply image processing algorithms to remove the majority of diaphragm regions, normalize image contrast and reduce image noise, and generate a pseudo color image to feed in 3 input channels of the existing deep learning models that were pre-trained using color (RGB) images in the transfer learning process.", [["diaphragm", "ANATOMY", 193, 202], ["diaphragm", "ORGAN", 193, 202], ["this study", "TEST", 18, 28], ["the original chest X-ray images", "TEST", 63, 94], ["image processing algorithms", "TREATMENT", 139, 166], ["image contrast", "TEST", 222, 236], ["image noise", "TEST", 248, 259], ["a pseudo color image", "TEST", 274, 294], ["the existing deep learning models", "TREATMENT", 326, 359], ["color (RGB) images", "TEST", 388, 406], ["chest", "ANATOMY", 76, 81], ["diaphragm", "ANATOMY", 193, 202], ["deep", "ANATOMY_MODIFIER", 339, 343]]], ["It may help significantly improve model performance and robustness in detecting COVID-19 cases and distinguishing them from other community-acquired non-COVID-19 infected pneumonia cases.", [["pneumonia", "DISEASE", 171, 180], ["robustness", "TEST", 56, 66], ["COVID", "TEST", 80, 85], ["acquired non-COVID-19 infected pneumonia cases", "PROBLEM", 140, 186], ["infected", "OBSERVATION_MODIFIER", 162, 170], ["pneumonia", "OBSERVATION", 171, 180]]], ["To test this study hypothesis and demonstrate the potential advantages of new approaches, we assemble a relatively large chest X-ray image dataset with 3 class cases.", [["this study hypothesis", "TEST", 8, 29], ["chest", "ANATOMY", 121, 126]]], ["Then, we select a well-trained VGG16 based CNN model as a transfer learning model used in our CAD scheme.", [["CAD", "DISEASE", 94, 97], ["VGG16 based CNN model", "CELL_LINE", 31, 52], ["a transfer learning model", "TREATMENT", 56, 81], ["our CAD scheme", "PROBLEM", 90, 104]]], ["The details of the study design and data analysis results are reported in the following sections of this article.DatasetIn this study, we utilize and assemble a dataset of chest X-ray radiography (CXR) images that are acquired from several different publicly available medical repositories [14] [15] [16] [17] [18] .", [["[14] [15] [16] [17] [18]", "CHEMICAL", 290, 314], ["[14] [15] [16] [17] [18]", "SIMPLE_CHEMICAL", 290, 314], ["the study", "TEST", 15, 24], ["data analysis", "TEST", 36, 49], ["this study", "TEST", 123, 133], ["chest X-ray radiography", "TEST", 172, 195], ["CXR) images", "TEST", 197, 208], ["chest", "ANATOMY", 172, 177]]], ["Specifically, the dataset used in this study includes 8,474 2D X-ray images in the posteroanterior (PA) chest view.", [["this study", "TEST", 34, 44], ["2D X-ray images", "TEST", 60, 75], ["the posteroanterior (PA) chest view", "TEST", 79, 114], ["chest", "ANATOMY", 104, 109]]], ["Among them, 415 images depict with the confirmed COVID-19 disease, 5,179 with other community-acquired non-COVID-19 infected pneumonia, and 2,880 normal (non-pneumonia) cases.", [["COVID-19 disease", "DISEASE", 49, 65], ["infected pneumonia", "DISEASE", 116, 134], ["non-pneumonia", "DISEASE", 154, 167], ["COVID", "TEST", 49, 54], ["non-COVID", "TEST", 103, 112], ["infected pneumonia", "PROBLEM", 116, 134], ["infected", "OBSERVATION_MODIFIER", 116, 124], ["pneumonia", "OBSERVATION", 125, 134]]], ["Figure 1 shows examples of three chest X-ray images acquired in three classes of normal, community-acquired non-COVID-19 infected pneumonia and COVID-19 pneumonia cases (from top to bottom).", [["pneumonia", "DISEASE", 130, 139], ["pneumonia", "DISEASE", 153, 162], ["three chest X-ray images", "TEST", 27, 51], ["non-COVID", "TEST", 108, 117], ["infected pneumonia", "PROBLEM", 121, 139], ["COVID", "TEST", 144, 149], ["pneumonia cases", "PROBLEM", 153, 168], ["chest", "ANATOMY", 33, 38], ["normal", "OBSERVATION", 81, 87], ["infected", "OBSERVATION_MODIFIER", 121, 129], ["pneumonia", "OBSERVATION", 130, 139], ["pneumonia", "OBSERVATION", 153, 162]]], ["It shows that the bottom part of images includes a diaphragm region with high-intensity (or bright pixels), which may have a negative effect on distinguishing and quantifying lung disease patterns using deep learning models.", [["diaphragm region", "ANATOMY", 51, 67], ["lung", "ANATOMY", 175, 179], ["diaphragm", "ORGAN", 51, 60], ["lung", "ORGAN", 175, 179], ["high-intensity (or bright pixels)", "PROBLEM", 73, 106], ["quantifying lung disease patterns", "PROBLEM", 163, 196], ["deep learning models", "TREATMENT", 203, 223], ["diaphragm", "ANATOMY", 51, 60], ["high", "OBSERVATION_MODIFIER", 73, 77], ["-intensity", "OBSERVATION_MODIFIER", 77, 87], ["negative effect", "OBSERVATION_MODIFIER", 125, 140], ["lung", "ANATOMY", 175, 179], ["disease", "OBSERVATION", 180, 187]]], ["Hence, an image pre-processing algorithm is applied to identify and remove diaphragm regions.", [["diaphragm regions", "ANATOMY", 75, 92], ["diaphragm", "ORGAN", 75, 84], ["an image pre-processing algorithm", "TEST", 7, 40], ["diaphragm", "ANATOMY", 75, 84]]], ["Specifically, the algorithm detects the maximum (the brightest -) and minimum (the darkest -) pixel value of the image, then uses a threshold = + 0.9 \u00d7 ( \u2212 ) to segment the original image into a binary image as shown in Figure 1 In the next step, we convert the segmented grayscale images ( ) to 3-channel images suitable for fine-tuning an existing CNN model pre-trained using color (RGB) images.", [["the algorithm", "TEST", 14, 27], ["a threshold", "TEST", 130, 141], ["a binary image", "TEST", 193, 207], ["the segmented grayscale images", "TEST", 258, 288], ["color (RGB) images", "TEST", 378, 396], ["maximum", "OBSERVATION_MODIFIER", 40, 47]]], ["To do so, we apply an image noise filtering method and a contrast normalization method to preprocess the image after removing the diaphragm region.", [["diaphragm region", "ANATOMY", 130, 146], ["diaphragm", "ORGAN", 130, 139], ["an image noise filtering method", "TREATMENT", 19, 50], ["a contrast normalization method", "TREATMENT", 55, 86], ["diaphragm", "ANATOMY", 130, 139]]], ["First, since the X-ray images often include additive noise, we apply a bilateral low-pass filter ( ) to .", [["the X-ray images", "TEST", 13, 29], ["additive noise", "PROBLEM", 44, 58], ["a bilateral low-pass filter", "TREATMENT", 69, 96]]], ["This filter is a non-linear filter and highly effective at noise removal while preserving textural information compared to the other low pass filters.", [["This filter", "TREATMENT", 0, 11], ["a non-linear filter", "TREATMENT", 15, 34], ["noise removal", "TREATMENT", 59, 72], ["the other low pass filters", "TREATMENT", 123, 149], ["filter", "OBSERVATION", 5, 11], ["non-linear filter", "OBSERVATION", 17, 34], ["effective", "OBSERVATION_MODIFIER", 46, 55]]], ["In other words, this filter J o u r n a l P r e -p r o o f analyzes intensity values locally and considers the intensity variation of the local area to replace the intensity value of each pixel with the averaged intensity value of the pixels in the local area.", [["a l P r e -p r o o f analyzes intensity values", "TEST", 38, 84], ["averaged", "OBSERVATION_MODIFIER", 203, 211], ["intensity", "OBSERVATION_MODIFIER", 212, 221], ["pixels", "OBSERVATION_MODIFIER", 235, 241], ["local", "ANATOMY_MODIFIER", 249, 254], ["area", "ANATOMY_MODIFIER", 255, 259]]], ["To calculate the weights, we apply a Gaussian low-pass filter in the space domain.", [["a Gaussian low-pass filter in the space domain", "TREATMENT", 35, 81]]], ["This step generates a noise-reduction image.", [["a noise-reduction image", "TREATMENT", 20, 43]]], ["Based on our experimental results, we select the following parameters in the bilateral filtering ( = 9 and = 75).", [["bilateral", "ANATOMY_MODIFIER", 77, 86]]], ["Second, chest X-ray images may have different image contrast or brightness due to the difference in patient body size and/or variation of X-ray dose.", [["body", "ANATOMY", 108, 112], ["patient", "ORGANISM", 100, 107], ["body", "ORGANISM_SUBDIVISION", 108, 112], ["patient", "SPECIES", 100, 107], ["chest X-ray images", "TEST", 8, 26], ["patient body size", "TEST", 100, 117], ["X-ray dose", "TEST", 138, 148], ["chest", "ANATOMY", 8, 13], ["size", "OBSERVATION_MODIFIER", 113, 117]]], ["To compensate such a potentially negative impact, we apply a histogram equalization ( ) method to normalize images.", [["a histogram equalization", "TEST", 59, 83], ["images", "TEST", 108, 114]]], ["This filter can enhance lung tissue patterns and characteristics associated with COVID-19Image Preprocessinginfection.", [["lung tissue", "ANATOMY", 24, 35], ["lung tissue", "TISSUE", 24, 35], ["This filter", "TREATMENT", 0, 11], ["COVID", "TEST", 81, 86], ["filter", "OBSERVATION", 5, 11], ["lung", "ANATOMY", 24, 28], ["tissue", "OBSERVATION", 29, 35]]], ["Then, as shown in Figure 2 , three preprocessed images namely, , = ( ) and = ( ) form a pseudo color image that is fed into 3 input (RGB) channels of the CNN model.Transfer LearningIn this study, we adopt a transfer learning approach since the previous studies have shown in order to avoid either overfitting or underfitting consequences using a small training dataset, a better approach is to take advantage of a CNN initially trained using a large-scale dataset [19] .", [["three preprocessed images", "TEST", 29, 54], ["a pseudo color image", "TEST", 86, 106], ["the CNN model", "TREATMENT", 150, 163], ["this study", "TEST", 184, 194], ["the previous studies", "TEST", 240, 260], ["overfitting or underfitting consequences", "PROBLEM", 297, 337], ["a small training dataset", "TREATMENT", 344, 368], ["a large-scale dataset", "TREATMENT", 442, 463]]], ["In this study, we select a VGG16 model, which was pre-trained on the ImageNet Large Scale VisualTransfer LearningRecognition Challenge (ILSVRC) using a large dataset with 14 million images [20] .", [["VGG16 model", "CELL_LINE", 27, 38], ["this study", "TEST", 3, 13], ["a VGG16 model", "TREATMENT", 25, 38], ["the ImageNet Large Scale VisualTransfer LearningRecognition Challenge (ILSVRC)", "TREATMENT", 65, 143], ["a large dataset", "TREATMENT", 150, 165]]], ["J o u r n a l P r e -p r o o f ILSVRC challenge [21] .", [["a l P r e", "TREATMENT", 10, 19], ["ILSVRC challenge", "TEST", 31, 47]]], ["As shown in Figure 3 , the VGG16 model has 13 convolutions, 5 max pooling and 3 fully connection layers in 6 blocks, which include over 138 million trainable parameters.Transfer LearningIn our transfer learning, the weights between all connected nodes in front or low layers of the VGG16 based CNN model maintain unchanged (blocks 1 to 5 as shown in Figure 3 ).", [["nodes", "ANATOMY", 246, 251], ["nodes", "MULTI-TISSUE_STRUCTURE", 246, 251], ["VGG16", "DNA", 282, 287], ["the VGG16 model", "TEST", 23, 38], ["5 max pooling", "PROBLEM", 60, 73], ["3 fully connection layers in 6 blocks", "PROBLEM", 78, 115], ["all connected nodes", "PROBLEM", 232, 251], ["6 blocks", "OBSERVATION_MODIFIER", 107, 115], ["nodes", "OBSERVATION", 246, 251], ["low layers", "OBSERVATION_MODIFIER", 264, 274], ["unchanged", "OBSERVATION_MODIFIER", 313, 322]]], ["Next, block 6 in the model is modified by replacing with one flatten layer and two fully connected layers, which include 256 and 128 nodes, respectively.", [["layers", "TISSUE", 99, 105], ["block", "TREATMENT", 6, 11], ["flatten", "OBSERVATION_MODIFIER", 61, 68], ["layer", "OBSERVATION_MODIFIER", 69, 74], ["layers", "OBSERVATION_MODIFIER", 99, 105], ["nodes", "OBSERVATION", 133, 138]]], ["In these layers, the rectified linear unit (ReLU) [22] is used as their activation function.", [["the rectified linear unit (ReLU)", "TREATMENT", 17, 49], ["layers", "OBSERVATION_MODIFIER", 9, 15]]], ["Then, all trainable weights in all connection nodes of the whole modified VGG16 model are fine-tuned using chest X-ray image data.", [["connection nodes", "MULTI-TISSUE_STRUCTURE", 35, 51], ["VGG16 model", "CELL_LINE", 74, 85], ["all trainable weights", "TREATMENT", 6, 27], ["chest X-ray image data", "TEST", 107, 129], ["chest", "ANATOMY", 107, 112]]], ["In this fine-tuning process, a small learning rate (learning rate = 10 \u22125 ) is used to make a small variation to the pre-trained parameters.", [["a small learning rate (learning rate", "TREATMENT", 29, 65], ["small", "OBSERVATION_MODIFIER", 31, 36]]], ["In this way, we will preserve the valuable parameters as much as possible by avoiding dramatic changes on the pre- Table 1 shows the complete architecture of the transfer learning VGG16 model built in this study.Model Training and TestingFirst, the original chest X-ray image has 1,024\u00d71,024 pixels, while the VGG16 model was pretrained using images of 224\u00d7224 pixels. and normal cases, the case partition or assignment is done on three classes independently.", [["VGG16 model", "CELL_LINE", 180, 191], ["VGG16 model", "DNA", 310, 321], ["dramatic changes", "PROBLEM", 86, 102], ["this study", "TEST", 201, 211], ["the original chest X-ray image", "TEST", 245, 275], ["the VGG16 model", "TEST", 306, 321], ["images", "TEST", 343, 349], ["chest", "ANATOMY", 258, 263]]], ["Table 2 shows the number of cases in each subset.Model Training and TestingJ o u r n a l P r e -p r o o f Second, there are different available techniques to deal with imbalanced data [24] .", [["Model Training", "TREATMENT", 49, 63]]], ["In this study, the class weight technique, as one possible way, is applied during training to reduce the potential consequences of imbalance data.", [["this study", "TEST", 3, 13], ["the class weight technique", "TREATMENT", 15, 41], ["imbalance data", "PROBLEM", 131, 145]]], ["In the class weigh technique, we adjust weights inversely proportional to class frequencies in the input data [25] .", [["the input data", "TEST", 95, 109]]], ["The weight, in class is computed using the following equation.Model Training and TestingThe weights of the classes are utilized while fitting the model.", [["The weight", "TEST", 0, 10], ["Model Training", "TREATMENT", 62, 76], ["Testing", "TEST", 81, 88]]], ["Hence, in the loss function, we assign higher values to the instances of smaller classes.", [["the loss function", "PROBLEM", 10, 27], ["smaller", "OBSERVATION_MODIFIER", 73, 80]]], ["Therefore, the calculated loss will be a weighted average, where the weights of each sample corresponding to each class during loss calculation are specified with .Model Training and TestingAdditionally, in the training data of minority cases (COVID-19 cases), a common augmentation technique [26] is applied to increase the training sample size.", [["the calculated loss", "PROBLEM", 11, 30], ["loss calculation", "PROBLEM", 127, 143], ["a common augmentation technique", "TREATMENT", 261, 292], ["size", "OBSERVATION_MODIFIER", 341, 345]]], ["First, using shearing factors (\u22640.2), image intensity is sheared based on the shearing angle in a counter-clockwise direction.", [["shearing factors", "TREATMENT", 13, 29], ["image intensity", "TEST", 38, 53]]], ["Second, using zooming factors (\u22640.2), images are randomly magnified.", [["zooming factors", "TEST", 14, 29], ["images", "TEST", 38, 44]]], ["Third, using rotation factors (within \u00b120\u00b0), To reduce the risk of potential bias in data partition into three subsets of training, validation, and testing, we repeat this model training and testing process three times by randomly dividing all cases into training, validation and testing subsets three times using the same case ratios or numbers as shown in Table 2 .", [["rotation factors", "PROTEIN", 13, 29], ["this model training", "TREATMENT", 167, 186], ["validation and testing subsets", "TEST", 265, 295]]], ["In addition, during these three times of case partition, the cases assigned to the validation and testing subsets are totally different (no duplication).", [["the validation", "TEST", 79, 93], ["testing subsets", "TEST", 98, 113]]], ["Three trained models are tested using totally different testing cases.", [["totally different testing cases", "TEST", 38, 69]]], ["Thus, the total number of testing cases increases (as shown in Table 2 ) to 2,544 (848\u00d7 3).", [["testing cases", "TEST", 26, 39]]], ["Figure 4 shows a schematic diagram that illustrates the complete architecture of this VGG16 transfer learning CNN model, as well as the training, validation, and testing phase.Performance AssessmentWe perform experiments to analyze two different accuracies.", [["a schematic diagram", "PROBLEM", 15, 34], ["validation, and testing phase", "TEST", 146, 175]]], ["The first one is accuracy for a threeclass classification to distinguish between COVID-19 infected pneumonia, community-acquired pneumonia, and normal (non-pneumonia) cases.", [["infected pneumonia", "DISEASE", 90, 108], ["pneumonia", "DISEASE", 129, 138], ["non-pneumonia", "DISEASE", 152, 165], ["COVID-19", "SPECIES", 81, 89], ["a threeclass classification", "TEST", 30, 57], ["COVID", "TEST", 81, 86], ["infected pneumonia", "PROBLEM", 90, 108], ["community-acquired pneumonia", "PROBLEM", 110, 138], ["infected", "OBSERVATION_MODIFIER", 90, 98], ["pneumonia", "OBSERVATION", 99, 108], ["pneumonia", "OBSERVATION", 129, 138], ["normal", "OBSERVATION", 144, 150]]], ["We compute accuracy values in detecting images in 3 classes.", [["accuracy values", "TEST", 11, 26], ["detecting images", "TEST", 30, 46]]], ["First, based on three confusion matrices as shown in Figure 5(a-c) To further evaluate the performance of our CAD scheme in detecting the COVID19 infected pneumonia cases using chest X-ray images, we place both normal and community-acquired pneumonia images into the negative class and COVID-19 infected pneumonia cases into the positive class.RESULTSCombining the data in the confusion matrix, as shown in Figure 5 (d), the CAD scheme yields 98.4% detection sensitivity (124/126) and 98.0% specificity (2,371/2,418).", [["confusion", "DISEASE", 22, 31], ["pneumonia", "DISEASE", 155, 164], ["pneumonia", "DISEASE", 241, 250], ["pneumonia", "DISEASE", 304, 313], ["confusion", "DISEASE", 377, 386], ["CAD", "DISEASE", 425, 428], ["our CAD scheme", "PROBLEM", 106, 120], ["the COVID19 infected pneumonia cases", "PROBLEM", 134, 170], ["chest X-ray images", "TEST", 177, 195], ["acquired pneumonia images", "PROBLEM", 232, 257], ["COVID", "TEST", 286, 291], ["infected pneumonia cases", "PROBLEM", 295, 319], ["the data", "TEST", 361, 369], ["the CAD scheme", "TEST", 421, 435], ["detection sensitivity", "TEST", 449, 470], ["specificity", "TEST", 491, 502], ["infected", "OBSERVATION_MODIFIER", 146, 154], ["pneumonia", "OBSERVATION", 155, 164], ["chest", "ANATOMY", 177, 182], ["normal", "OBSERVATION", 211, 217], ["pneumonia", "OBSERVATION", 241, 250], ["negative class", "OBSERVATION_MODIFIER", 267, 281], ["infected", "OBSERVATION_MODIFIER", 295, 303], ["pneumonia", "OBSERVATION", 304, 313], ["positive class", "OBSERVATION_MODIFIER", 329, 343]]], ["The overall accuracy is 98.1%RESULTS(2,495/2,544).RESULTSNext, Table 4 shows and compares (1) confusion matrixes generated by four models trained and tested using different input images and three data subsets generated from the data partition, as well as In addition, Table 5 compares our transfer learning VGG16 based CNN model and 10 state-of-art models recently reported in the literature to detect and classify COVID-19 cases.", [["confusion", "DISEASE", 94, 103], ["VGG16", "PROTEIN", 307, 312], ["The overall accuracy", "TEST", 0, 20], ["confusion matrixes", "PROBLEM", 94, 112], ["different input images", "TEST", 163, 185], ["COVID", "TEST", 415, 420]]], ["The Table shows the number of cases in the training and testing data subsets, imaging modality (CT or X-ray radiography), and reported classification performance including either 3-class or 2-class classification for these studies.", [["testing data subsets", "TEST", 56, 76], ["imaging modality", "TEST", 78, 94], ["CT or X-ray radiography", "TEST", 96, 119], ["these studies", "TEST", 217, 230]]], ["Although the reported performance of these studies cannot be directly compared due to the use of different image dataset and testing methods, the presented data clearly demonstrate that our model is tested using relatively large dataset and yields very comparable classification performance as comparing to the state-of-art models developed and tested in this research field. preprocessing approaches can also be adopted to develop new deep learning models for other medical images to detect and classify other types of diseases (i.e., cancers [30, 31] ).RESULTSDespite encouraging results, this study also has limitations.", [["cancers", "ANATOMY", 536, 543], ["cancers", "DISEASE", 536, 543], ["cancers", "CANCER", 536, 543], ["these studies", "TEST", 37, 50], ["different image dataset", "TEST", 97, 120], ["testing methods", "TEST", 125, 140], ["preprocessing approaches", "TREATMENT", 376, 400], ["other medical images", "TEST", 461, 481], ["diseases", "PROBLEM", 520, 528], ["cancers", "PROBLEM", 536, 543], ["this study", "TEST", 591, 601], ["diseases", "OBSERVATION", 520, 528]]], ["First, although we used a publicly available dataset of 8,474 cases, including 415 COVID-19 cases, due to the diversity or heterogeneity of COVID-19 cases, the performance and robustness of this CAD scheme need to be further tested and validated using other large and diverse image databases.", [["COVID", "TEST", 83, 88], ["COVID", "TEST", 140, 145], ["this CAD scheme", "PROBLEM", 190, 205]]], ["Second, this study only investigates and tests two image preprocessing methods to generate two filtered images, which may not be the best or optimal methods.", [["this study", "TEST", 8, 18], ["tests", "TEST", 41, 46], ["two filtered images", "TEST", 91, 110]]], ["New methods should also be investigated and compared in future studies.", [["New methods", "TREATMENT", 0, 11], ["future studies", "TEST", 56, 70]]], ["Third, to further improve model performance and robustness, it also needs to develop new image processing and segmentation algorithms to more accurately remove the diaphragm and other regions outside lung areas in the images.", [["diaphragm", "ANATOMY", 164, 173], ["lung areas", "ANATOMY", 200, 210], ["diaphragm", "ORGAN", 164, 173], ["lung", "ORGAN", 200, 204], ["new image processing", "TEST", 85, 105], ["segmentation algorithms", "TEST", 110, 133], ["the images", "TEST", 214, 224], ["diaphragm", "ANATOMY", 164, 173], ["lung", "ANATOMY", 200, 204]]], ["Therefore, more research work is needed to overcome these limitations in the future studies.CONCLUSIONIn this study, we proposed and investigated several new approaches to develop a transfer deep learning CNN model to detect and classify COVID-19 cases using chest X-ray images.", [["COVID", "DNA", 238, 243], ["the future studies", "TEST", 73, 91], ["this study", "TEST", 105, 115], ["COVID", "TEST", 238, 243], ["chest X-ray images", "TEST", 259, 277], ["chest", "ANATOMY", 259, 264]]], ["Study results demonstrate the added value of performing image preprocessing to generate better input image data to build deep learning models.", [["image preprocessing", "TEST", 56, 75]]], ["These include removing irrelevant regions, normalizing image contrastto-noise ratio, and generating pseudo color images to feed into all three channels of the CNN models in applying the transfer learning method.", [["the CNN models", "TREATMENT", 155, 169], ["the transfer learning method", "TREATMENT", 182, 210]]], ["The reported high classification performance is also promising, which provides a solid foundation to further optimize the deep learning models to detect COVID-19 cases and validate its performance and robustness using large and diverse image datasets in future studies.SUMMARY TABLEWhat was Already Known on the topic What this study adds to our knowledge \uf0b7 Due to the low cost, low radiation, wide accessibility, chest X-ray radiography is a good imaging modality to detect COVID-19.", [["COVID-19", "DNA", 475, 483], ["COVID", "TEST", 153, 158], ["future studies", "TEST", 254, 268], ["this study", "TEST", 323, 333], ["the low cost", "PROBLEM", 365, 377], ["low radiation", "TREATMENT", 379, 392], ["chest X-ray radiography", "TEST", 414, 437], ["COVID", "TEST", 475, 480], ["high", "OBSERVATION_MODIFIER", 13, 17], ["low", "OBSERVATION_MODIFIER", 369, 372], ["low radiation", "OBSERVATION_MODIFIER", 379, 392], ["chest", "ANATOMY", 414, 419]]], ["However, its sensitivity is lower than CT.SUMMARY TABLE\uf0b7 Developing deep learning model based CAD schemes of chest X-ray images may play a useful role in facilitating detection and diagnosis of COVID-19.SUMMARY TABLE\uf0b7 A few deep learning models using chest X-ray images to detect COVID-19 have been \uf0b7 Due to the diversity of image contrast and noise, adding image preprocessing steps is important and can help improve deep learning model performance.SUMMARY TABLE\uf0b7 In transfer learning, one should not only use original images.", [["COVID-19", "DNA", 194, 202], ["COVID-19", "DNA", 280, 288], ["its sensitivity", "TEST", 9, 24], ["CT", "TEST", 39, 41], ["Developing deep learning model based CAD schemes", "PROBLEM", 57, 105], ["chest X-ray images", "TEST", 109, 127], ["COVID", "TEST", 194, 199], ["chest X-ray images", "TEST", 251, 269], ["COVID", "TEST", 280, 285], ["image contrast", "TEST", 325, 339], ["image preprocessing steps", "TREATMENT", 358, 383], ["original images", "TEST", 511, 526], ["lower", "OBSERVATION_MODIFIER", 28, 33], ["deep", "ANATOMY_MODIFIER", 68, 72], ["chest", "ANATOMY", 109, 114], ["chest", "ANATOMY", 251, 256]]], ["It should add two additional filtered images to fill in 3 input channels of the deep learning model, which can enhance information learning and improve model performance.", [["filtered images", "TEST", 29, 44], ["the deep learning model", "TREATMENT", 76, 99], ["deep", "ANATOMY_MODIFIER", 80, 84]]]], "0c9c4ecf242b4ef2727cc93e098e00ec3822bff5": [["One of the reasons for this popularity is the support for automated analysis provided by the Alloy Analyzer, an easy to download and install selfcontained executable written in Java.", [["automated analysis", "TEST", 58, 76]]], ["Alloy is very effective in the specification and analysis of the static structures that pervade software design, but requires the employment of well-established idioms, that introduce an explicit notion of state or time, if mutability is to be considered and temporal properties analyzed.", [["very", "OBSERVATION_MODIFIER", 9, 13], ["effective", "OBSERVATION_MODIFIER", 14, 23]]], ["To avoid this cumbersome and error-prone process, several extensions to Alloy have been proposed, including one by authors of this paper -Electrum [7] -which extends the Alloy language with variable structures and linear temporal logic (including past operators), also adding bounded and unbounded model checking engines to the Analyzer.IntroductionDespite such streamlined toolkit, over the many years we taught and researched with Alloy we identified some missing features and functionalities that could further ease its adoption and its usage in an educational context.", [["this cumbersome", "TREATMENT", 9, 24], ["error-prone process", "TREATMENT", 29, 48], ["some missing features and functionalities", "PROBLEM", 453, 494]]], ["This would be particularly useful for students trying to get feedback from the tutors about specific counter-examples, or to submit exercise resolutions for evaluation.", [["evaluation", "TEST", 157, 167]]], ["Due to some limitations of the visualizer packaged with the Analyzer, we also felt the need for a more decoupled infrastructure to test alternative instance visualization features.IntroductionTo address these limitations we developed Alloy4Fun, a web application that enables online editing and sharing of Alloy and Electrum models 2 and instances, including simple specification challenges in the form of duels where students attempt to discover a secret specified by the tutors.", [["the Analyzer", "TEST", 56, 68], ["a web application", "TREATMENT", 245, 262]]], ["Such online platform also provided us the opportunity to collect information regarding Alloy usage patterns from an extended user base: one of the features of Alloy4Fun is thus the ability to record every interaction with the (anonymous) user, information that is made available to the creator of the challenges for subsequent analysis.", [["Alloy", "SIMPLE_CHEMICAL", 87, 92], ["subsequent analysis", "TEST", 316, 335]]], ["Over the last two years, Alloy4Fun has been used in 3 editions of graduate courses on formal methods and a tutorial at an international venue, which has allowed us to quickly obtain insight on how students use the language, namely identify typical mistakes or learning breakdowns in the class.", [["formal methods", "TREATMENT", 86, 100], ["learning breakdowns", "PROBLEM", 260, 279]]], ["3.2), and some preliminary insights on Alloy usage patterns and learning pitfalls (Sect.", [["Alloy", "SIMPLE_CHEMICAL", 39, 44], ["Alloy usage patterns", "TREATMENT", 39, 59]]], ["Knowledge of Alloy is not required to understand the paper, but can help better appreciate some of the features of Alloy4Fun.Alloy4Fun OverviewThe core of Alloy4Fun mimics in a web application the main features of the standalone Alloy Analyzer.", [["Alloy", "SIMPLE_CHEMICAL", 229, 234], ["Alloy4Fun", "PROTEIN", 115, 124]]], ["After accessing alloy4fun.inesctec.pt (the URL where Alloy4Fun is currently deployed) the user gets an empty online editor (with syntax highlighting) where Alloy models can be written.", [["alloy4fun", "GENE_OR_GENE_PRODUCT", 16, 25], ["alloy4fun", "DNA", 16, 25], ["accessing alloy4fun", "TREATMENT", 6, 25]]], ["For example, the Alloy4Fun screen capture shown in Fig. 1 shows a model of an online Curriculum Vitae (CV) platform, an example that was used as an exercise in classes.", [["Fun screen capture", "TEST", 23, 41]]], ["Two more signatures are declared in this example: Id and Work.", [["Id", "GENE_OR_GENE_PRODUCT", 50, 52], ["Id", "PROTEIN", 50, 52]]], ["We also have several fields that relate atoms of these signatures.", [["these signatures", "TEST", 49, 65]]], ["For example, ids is a binary relation that associates each atom of Work with its set of Ids.", [["Ids", "GENE_OR_GENE_PRODUCT", 88, 91], ["Ids", "PROTEIN", 88, 91]]], ["Signature and field declarations can have multiplicities attached to impose cardinality constraints.", [["cardinality constraints", "TREATMENT", 76, 99]]], ["For example, the some in the declaration of field ids imposes that each Work should have at least one Id.Alloy4Fun OverviewFormulas in facts, assertions, and predicates, are written in Relational Logic (RL), an extension of First-Order Logic (FOL) with operators that can be used to combine relations (aka predicates in FOL).", [["FOL", "CANCER", 320, 323], ["Id", "PROTEIN", 102, 104], ["operators", "TREATMENT", 253, 262], ["some", "OBSERVATION_MODIFIER", 17, 21]]], ["The most frequently used one is the relational composition (written as .), an operator that allows us to \"navigate\" through a relation: for example, in predicate Inv2 of Fig. 1 , expression u.profile denotes the set of atoms of signature Work associated with User u.", [["Inv2", "PROTEIN", 162, 166]]], ["With the Electrum extension they can be declared as mutable, and formulas can also be specified with Linear Temporal Logic (LTL) operators.Alloy4Fun OverviewA distinctive feature of Alloy is that analysis commands can also be declared as paragraphs in a model.", [["Linear Temporal Logic (LTL) operators", "TREATMENT", 101, 138]]], ["All the analysis commands operate in a bounded domain: there is a user-defined scope imposed on every signature that limits the maximum number of elements that will be considered by the automatic verification procedures.", [["the automatic verification procedures", "TEST", 182, 219]]], ["If witnesses (in the case of run) or counter-examples (in the case of a check) are found, they are depicted below the editor as graphs that, likewise in Analyzer, can be customised with user-defined themes.Alloy4Fun OverviewBesides these core functionalities, Alloy4Fun has some new features (and some improvements to existing ones) when compared to the Analyzer, as described in the sequel.", [["some new features", "PROBLEM", 274, 291], ["the Analyzer", "TEST", 350, 362], ["some", "OBSERVATION_MODIFIER", 274, 278], ["new", "OBSERVATION_MODIFIER", 279, 282]]], ["Currently, it also has some limitations, most notably the inability to choose the underlying SAT solver used to perform a given analysis, not being able to display an unsatisfiable core, and lack of support for Alloy's module system (except for the standard modules distributed with Alloy, which can be used).", [["SAT", "TISSUE", 93, 96], ["Alloy", "PROTEIN", 211, 216], ["the underlying SAT solver", "PROBLEM", 78, 103], ["a given analysis", "TEST", 120, 136], ["Alloy's module system", "TREATMENT", 211, 232]]], ["When compared to the Analyzer, Alloy4Fun follows a more lightweight approach to the user interface, allowing the most common theme customizations (like changing the color of the atoms of a given signature) to be performed quickly through a right-click menu on atoms or edges.", [["a more lightweight approach", "TREATMENT", 49, 76], ["right", "ANATOMY_MODIFIER", 240, 245]]], ["Alloy4Fun themes allow color, shape, stroke, and visibility parametrization for signatures and fields, signature projection, and the display of fields as attributes inside atoms.", [["stroke", "DISEASE", 37, 43], ["stroke", "PROBLEM", 37, 43], ["visibility parametrization", "TEST", 49, 75], ["signatures and fields, signature projection", "TEST", 80, 123], ["shape", "OBSERVATION_MODIFIER", 30, 35], ["stroke", "OBSERVATION", 37, 43]]], ["A new feature is the ability to select different layout algorithms to automatically organize nodes, which the user can then manually move.", [["nodes", "ANATOMY", 93, 98], ["nodes", "MULTI-TISSUE_STRUCTURE", 93, 98], ["new", "OBSERVATION_MODIFIER", 2, 5], ["nodes", "OBSERVATION", 93, 98]]], ["In Fig. 1 a counter-example of a check command named Inv2OK is being depicted with a user-defined theme.", [["Inv2OK", "DNA", 53, 59]]], ["In the case of Electrum, Alloy4Fun only allows one state of an instance trace to be visualised at a time (the Electrum Analyzer depicts two states side by side), and it is only possible to ask for a different next trace (the Electrum Analyzer has more sophisticated trace exploration options, for example it is possible to ask for trace with the same prefix up to the displayed state, but a different next state).Alloy4Fun OverviewSharing Models and Instances.", [["the Electrum Analyzer", "TEST", 106, 127], ["the Electrum Analyzer", "TEST", 221, 242]]], ["Alloy4Fun provides the ability to easily share models and instances.", [["Fun", "PROTEIN", 6, 9]]], ["The theme and positions of the depicted atoms and relations at the time of sharing are also preserved.", [["preserved", "OBSERVATION", 92, 101]]], ["One way to overcome this difficulty is by independently solving exercises proposed by tutors, but, even with automated analysis and visual feedback, it is often difficult for students to assess whether they reached the correct answer, and tutors are required to inspect and interpret the solutions (something not scalable for large classes).", [["automated analysis", "TEST", 109, 127]]], ["These problems could be mitigated with automatic assessment functionalities, allowing students to solve exercises at their own pace and without the constant need for face-to-face time with tutors.", [["automatic assessment functionalities", "TEST", 39, 75]]], ["Using a comment instead of a new keyword to mark secret paragraphs ensures compatibility with Alloy's default syntax, allowing users to copy and paste models from Alloy4Fun to the standalone Analyzer, and vice versa.", [["Alloy4Fun", "CELL_LINE", 163, 172], ["Alloy's default syntax", "TREATMENT", 94, 116]]], ["The instance shown in Fig. 1 was obtained precisely by accessing the public permalink of an exercise, and failing to solve a challenge, for which a counter-example was returned.Mining Derivation Trees.A possible way to gain insight about the students' learning process is to have access to their attempts at solving the proposed exercises, and tool support to mine this corpus for useful data [8] .", [["the proposed exercises", "TREATMENT", 316, 338], ["tool support", "TREATMENT", 344, 356], ["Derivation Trees", "OBSERVATION", 184, 200]]], ["Again, such feature would also be useful for research, and was one of the reasons that led Microsoft to develop the www.rise4fun.com web service, that allows researchers to easily deploy their tools on the web and collect human-tool interactions for posterior mining [1] (besides other advantages of web tools, like increased exposure, since the need for downloading and installing is eliminated, and promoting reliability given the large amount of test cases that can be collected).", [["human", "ORGANISM", 222, 227], ["human", "SPECIES", 222, 227], ["human", "SPECIES", 222, 227]]], ["One of the most popular examples available via Rise4Fun, and the inspiration for developing Alloy4Fun, is www.pex4fun.com, a web-based educational gaming environment for learning programming, where students can engage in coding duels where they attempt to write code equivalent to a tutor's secret implementation [12] .", [["learning programming", "TREATMENT", 170, 190]]], ["Pex [11] , an advanced white box test-generation tool, is used on the background to find inputs that show discrepancies between the student's code and the secret implementation.", [["Pex", "TEST", 0, 3], ["an advanced white box test", "TEST", 11, 37]]], ["This has led us to implement our own solution rather than integrate Alloy in this service.Mining Derivation Trees.Every shared model and instance is stored by Alloy4Fun in its database.", [["Alloy", "SIMPLE_CHEMICAL", 68, 73], ["our own solution", "TREATMENT", 29, 45], ["Derivation Trees", "OBSERVATION", 97, 113]]], ["This means that all the models that are developed after accessing a shared permalink end up forming a derivation tree.Mining Derivation Trees.In the case of a permalink with secrets/challenges, a branch in this tree typically corresponds to an interactive session where one user/student is trying to solve the different challenges defined inside, and can be analyzed to determine, for example, how many challenges were solved or how many attempts were needed to solve each one.", [["permalink end", "DNA", 75, 88], ["derivation tree", "OBSERVATION", 102, 117], ["Derivation Trees", "OBSERVATION", 125, 141], ["branch", "ANATOMY_MODIFIER", 196, 202]]], ["Every fork in branch represents a point where a user generated a new permalink for a model which was subsequently accessed multiple times.", [["a new permalink", "TREATMENT", 63, 78], ["a model", "TREATMENT", 83, 90], ["branch", "ANATOMY_MODIFIER", 14, 20]]], ["Alloy4Fun allows anyone in possession of the secret permalink of a model to download the respective derivation tree in an easy to process JSON format.Mining Derivation Trees.Implementation.", [["JSON", "CANCER", 138, 142], ["Derivation Trees", "OBSERVATION", 157, 173]]], ["Alloy4Fun was developed [9] with Meteor, a full-stack isomorphic JavaScript framework for developing web applications based on Node.js.", [["Alloy4Fun", "CHEMICAL", 0, 9], ["Alloy4Fun", "SIMPLE_CHEMICAL", 0, 9]]], ["The client uses CodeMirror as text editor and the Cytoscape.js graph visualization library to depict instances.", [["CodeMirror", "TREATMENT", 16, 26]]], ["All the Alloy4Fun code is open-source and available at github.com/haslab/Alloy4Fun.Experiences on Teaching with Alloy4FunIn the first semester of the 2018/19 academic year we did a preliminary evaluation of Alloy4Fun in two graduate formal methods courses at UM and UP.", [["Alloy4Fun code", "DNA", 8, 22], ["Alloy4Fun", "TREATMENT", 73, 82], ["a preliminary evaluation", "TEST", 179, 203]]], ["One major identified design improvement regarded a special \"lock\" comment available in the beta version to prevent the accidental editing of certain paragraphs that could render the challenges unsolvable (or trivially solvable).", [["the beta version", "TREATMENT", 87, 103]]], ["These first experiences also allowed us to identify which classes of exercises are better suited to be explored in Alloy4Fun, as well as how the visualization features can be explored to provide more intuitive feedback to the students.Experiences on Teaching with Alloy4FunFrom this process resulted the first official release of Alloy4Fun, which has been used in the 2019/20 academic year in the UM graduate course and on an Alloy/Electrum tutorial at the World Congress on Formal Methods 5 , with a refined set of specification exercises with challenges.", [["an Alloy/Electrum tutorial", "TREATMENT", 423, 449], ["Formal Methods", "TREATMENT", 475, 489]]], ["Although useful for practicing the usage of logic (either relational or temporal) in the specification of properties, there are certain classes of problems for which the approach based on secret specifications is not well-suited, namely modeling exercises where the student is expected to freely declare signatures and fields.Alloy4Fun ExercisesThe model shown in Fig. 1 was obtained precisely by accessing the public permalink of the CV exercise, which contains 4 challenges (in this case, simple problems where a natural language description of a desired property of the model is given for each of them).", [["simple problems", "PROBLEM", 491, 506]]], ["After filling the empty predicate (e.g., Inv2), the student can check whether it is a valid solution (e.g., by running secret command Inv2OK, for the case of Inv2), which will either return a \"no counter-example found\" message, meaning the challenge is solved, or a counter-example otherwise (as is the case in Fig. 1 , showing that the specification of Inv2 is still not correct).", [["Inv2", "GENE_OR_GENE_PRODUCT", 158, 162], ["Inv2", "GENE_OR_GENE_PRODUCT", 354, 358], ["Inv2OK", "PROTEIN", 134, 140], ["Inv2", "PROTEIN", 158, 162], ["Inv2", "PROTEIN", 354, 358], ["a valid solution", "TREATMENT", 84, 100], ["empty", "OBSERVATION", 18, 23]]], ["Figure 2 shows the secret implementation of challenge Inv2: predicate Inv2o specifies a correct solution for the challenge and command Inv2OK checks the equivalence between both.", [["Inv2o", "PROTEIN", 70, 75], ["Inv2OK", "PROTEIN", 135, 141], ["a correct solution", "TREATMENT", 86, 104], ["the challenge", "TREATMENT", 109, 122]]], ["In exercises such as CV where several desired (and natural) properties of the model are solved in different challenges, we opted to check this equivalence assuming that the remaining properties hold: if that was not the case the student would get many counter-examples where it would not be clear why their specification failed, since they would be \"polluted\" with distracting problems corresponding to failures of other properties.", [["distracting problems", "PROBLEM", 365, 385], ["failures of other properties", "PROBLEM", 403, 431]]], ["This conditional check is the reason to include Inv1o, Inv3o, and Inv4o as assumptions in the equivalence check Inv2OK.", [["Inv1o", "GENE_OR_GENE_PRODUCT", 48, 53], ["Inv3o", "GENE_OR_GENE_PRODUCT", 55, 60], ["Inv4o", "GENE_OR_GENE_PRODUCT", 66, 71], ["Inv1o", "PROTEIN", 48, 53], ["Inv3o", "PROTEIN", 55, 60], ["Inv4o", "PROTEIN", 66, 71], ["Inv2OK", "DNA", 112, 118], ["This conditional check", "TEST", 0, 22], ["Inv1o", "TREATMENT", 48, 53], ["Inv3o", "TREATMENT", 55, 60]]], ["As seen in Fig. 2 this can be achieved by introducing a singleton signature whose possible values are either ShouldBeRejected or ShouldBeAccepted and through a simple trick in the equivalence check, namely making the verification conditional to the existence of the ShouldBeRejected atom when the student solution incorrectly holds (or vice-versa).Alloy4Fun ExercisesThe challenges used in this course were based on 6 different problems:Alloy4Fun Exercises-Trash, a model of a file system trash bin.Alloy4Fun Exercises-Classroom, a model a classroom management system. -Graph, a specification of several standard properties of unlabeled graphs.Alloy4Fun Exercises-LTL, a specification of several standard properties of labeled transition systems. -Production, a model of an automated production line in a factory. -CV, the Curriculum Vitae model used as running example in this paper.Alloy4Fun ExercisesFor some of these problems we developed more than one variant (or exercise) focusing on different features of the language.", [["a singleton signature", "PROBLEM", 54, 75], ["the equivalence check", "TEST", 176, 197], ["a model a classroom management system", "TREATMENT", 530, 567], ["these problems", "PROBLEM", 915, 929], ["Fig", "OBSERVATION", 11, 14], ["production line", "OBSERVATION", 784, 799]]], ["The table lists the permalink and total number of challenges of each exercise (the columns F1 to F9 will be discussed in Sect.", [["F9", "CELL", 97, 99], ["the columns F1", "TREATMENT", 79, 93]]], ["3.3).Alloy4Fun ExercisesChallenges in these exercises range from trivial (e.g., asking to enforce simple inclusion dependencies or multiplicities), to more complex ones requiring the use of nested quantifiers or closures.", [["simple inclusion dependencies", "PROBLEM", 98, 127], ["nested quantifiers", "TREATMENT", 190, 208], ["closures", "TREATMENT", 212, 220]]], ["As expected, the introduction of the Alloy (and Electrum) language and underlying logics in classes was gradual: FOL constructs were first presented, followed by the full set of RL operators, and finally the LTL operators specific to Electrum.", [["FOL constructs", "DNA", 113, 127], ["the Alloy (and Electrum) language", "TREATMENT", 33, 66]]], ["To try to understand the impact of using relational operators, we introduced two variants of the first two problems: one where challenges were to be solved using only the FOL subset of Alloy, and another, introduced when students already had knowledge of RL, where they could use all the standard Alloy operators to solve the challenges.", [["the standard Alloy operators", "TREATMENT", 284, 312]]], ["For the Trash problem we also created a mutable variant, where challenges required the usage of the LTL operators of Electrum to be solved.", [["the LTL operators", "TREATMENT", 96, 113]]], ["Hence the total of 9 exercises described in Table 1 .", [["the total of 9 exercises", "TREATMENT", 6, 30]]], ["As an example, exercise CV (containing 4 challenges) is the one shown in Fig. 1 .Student Usage and AdoptionIn the 2019/20 edition 17 students attended the UM course.", [["exercise CV (containing 4 challenges", "TREATMENT", 15, 51]]], ["Alloy4Fun was used in the lab sessions that followed the lectures that introduced FOL, RL, and LTL, mainly as a way to practice the usage of these logics to specify natural language requirements.", [["Alloy4Fun", "CHEMICAL", 0, 9], ["Alloy4Fun", "SIMPLE_CHEMICAL", 0, 9], ["these logics", "TREATMENT", 141, 153]]], ["In the lab sessions that addressed other aspects of the Alloy language and analysis not amenable for automated assessment, such as solving problems that required the development of a full model from scratch, students were expected to still use the Alloy Analyzer and locally manage their models.", [["automated assessment", "TEST", 101, 121], ["solving problems", "PROBLEM", 131, 147], ["the Alloy Analyzer", "TREATMENT", 244, 262]]], ["2, such as the lack of module support or the lack of sophisticated trace exploration options in the case of Electrum) might prove problematic for some more realistic problems.", [["module support", "TREATMENT", 23, 37], ["sophisticated trace exploration options", "TREATMENT", 53, 92]]], ["Thus, Alloy4Fun was only used in 4 lab sessions, each introducing a particular set of exercises -1 session with Trash FOL and Classroom FOL after the FOL lecture, 2 sessions with Trash RL, Classroom RL and Graphs after the RL lecture, and 1 session with Trash LTL after the LTL lecture.", [["Trash FOL", "TREATMENT", 112, 121], ["Trash RL", "TREATMENT", 179, 187], ["Trash LTL", "TREATMENT", 254, 263]]], ["Extra exercises (namely LTS, Production, and CV) were made available in the course website for the students to freely explore.", [["Extra exercises", "TREATMENT", 0, 15]]], ["During the course there were 3 evaluation points involving Alloy: a medium-size modeling project (developed with the standard Analyzer outside of the classes in groups of two students), an individual written exam, and finally a supplementary exam for students failing the first attempt.Student Usage and AdoptionAfter concluding the course, the main question we tried to answer was whether students found Alloy4Fun useful as an automated assessment platform while learning Alloy.", [["Alloy4", "CHEMICAL", 405, 411], ["Alloy4", "CHEMICAL", 405, 411], ["3 evaluation", "TEST", 29, 41], ["an individual written exam", "TEST", 186, 212], ["a supplementary exam", "TEST", 226, 246], ["an automated assessment", "TEST", 425, 448], ["size", "OBSERVATION_MODIFIER", 75, 79]]], ["More specifically: 1) have the students used Alloy4Fun regularly outside classes? 2) in particular, have they used it when studying for the exams? 3) have they found the sharing feature useful? 4) were the counterexamples useful to reach the correct solution?", [["the exams", "TEST", 136, 145]]], ["The questionnaire was answered by 13 of the 17 students, and, over the duration of the course, we collected almost 11000 interactions with the exercises, most of them resulting from the execution of commands (checking the correctness of challenges) and a small portion from sharing of models 6 .Student Usage and AdoptionConcerning the first question, of the 13 students that answered the questionnaire, 9 said they used Alloy4Fun frequently outside classes, 3 only used it rarely, and 1 never used it.", [["Alloy4", "CHEMICAL", 421, 427], ["the exercises", "TREATMENT", 139, 152]]], ["To the second question all of the 12 students that used it outside classes answered that they used it to study for the exam.", [["the exam", "TEST", 115, 123]]], ["Of these, 9 mentioned that when studying for the exam they actually repeated some of the exercises they had already solved before.", [["the exam", "TEST", 45, 53]]], ["The data collected throughout the semester, shown in Fig. 3 , seems to corroborate these answers.", [["The data", "TEST", 0, 8]]], ["Figure 3a depicts the usage of the platform over time, highlighting the classes where Alloy4Fun was mandatory and the evaluation points (first the project deadline, and later in the semester the two exams).", [["the evaluation", "TEST", 114, 128], ["two exams", "TEST", 195, 204]]], ["Each entry in the dataset is either a correct (unsatisfiable) check, a wrong (satisfiable) check, an analysis that threw an error (e.g., parsing) or a model stored for sharing.", [["a wrong (satisfiable) check", "TEST", 69, 96], ["an analysis", "TEST", 98, 109]]], ["Despite the peak of usage during the Alloy4Fun classes, we can see that the students have indeed relied on Alloy4Fun outside the classes, and in particular when studying for the written exam.Student Usage and AdoptionFigures 3b and 3c present statistics per exercise (below each exercise number we recall the number of challenges inside).", [["the written exam", "TEST", 174, 190], ["AdoptionFigures", "TREATMENT", 209, 224]]], ["This information is normalised taking into account the number of challenges in each exercise (i.e., the graph shows the average number of executions per challenge).", [["the graph", "TEST", 100, 109]]], ["Even with all the uncertainty, it is safe to say that indeed most students should have used Alloy4Fun frequently outside the classes (from our observation, during classes students mainly used a single session per exercise), including repeated attempts to solve exercises already previously solved (as reported in the questionnaire): for example, for Trash FOL around 50 sessions were recorded where all the challenges were solved, a strong indicator that each student should have solved it at least twice.Student Usage and AdoptionConcerning permalinks, 7 students mentioned that they generated them frequently to store their own solutions for later access, 3 did it rarely, and, somehow surprising, 3 never did it.", [["Alloy4", "CHEMICAL", 92, 98]]], ["These results seem to suggest that one of our main goals for Alloy4Fun -to simplify the sharing of models and instances -may actually not be that popular in an educational setting, but of course a more comprehensive study must be conducted to clarify that.Student Usage and AdoptionConcerning the last question, 10 students mentioned that counter-examples were frequently useful to help find the correct answer, but of these 4 only found them useful if they had the atoms that signal whether the shown counter-example should have been rejected or accepted by a correct specification.", [["comprehensive study", "TEST", 202, 221]]], ["This is one of the studies we intend to conduct in the near future.Student Usage and AdoptionFinally we also asked the students the overall question of whether they found Alloy4Fun useful for learning Alloy and Electrum: all of them agreed that was the case, with 8 of the 13 strongly agreeing.Insights on Learning AlloyTaking advantage of the collected data, we also tried to get some insights about how students learn Alloy, and in particular determine which features of the language pose more difficulties and should thus be addressed more carefully in lectures.", [["the studies", "TEST", 15, 26]]], ["To this end, we started by classifying a normalized version 7 of each challenge according to a set of required concepts, namely whether it requires: F1 using more than 10 logic or relational operators F2 a simple restriction of the multiplicity of a relation F3 nested quantifications (ignoring multi-variable quantifications) F4 manipulating ternary relations F5 transitive closure over fields F6 transitive closure over expressions (either relational expressions or relations by comprehension) F7 reasoning about total orders (i.e, using the ordering module) F8 a single temporal operator F9 nested temporal operators For each exercise, Table 1 presents the number of challenges that fall into each of these (non-exclusive) categories.", [["transitive closure over fields", "TREATMENT", 364, 394], ["transitive closure over expressions", "TREATMENT", 398, 433], ["a single temporal operator F9", "TREATMENT", 564, 593]]], ["Figure 4 compares the results of challenge execution classified under each category (also listing the total number of challenges for each).", [["challenge execution", "TREATMENT", 33, 52]]], ["For each of the 9 categories, the number of correct (green) and wrong (red) executions are presented.", [["wrong (red) executions", "PROBLEM", 64, 86]]], ["Contrary to our expectations, given that Alloy has special syntax for that purpose, challenges that required restricting the multiplicity of relations (F2) were only slightly easier than average (52%).", [["Alloy", "CHEMICAL", 41, 46], ["special syntax", "TREATMENT", 51, 65]]], ["As expected, the need to use nested quantifiers (F3) increases the difficulty of challenges (33% success rate).", [["nested quantifiers (F3", "TREATMENT", 29, 51]]], ["Concerning closures, usage of a closure operator over a relation (F5) was not very problematic (41% success rate), but challenges that required applying a closure operator to a relational expression (F6) were the most difficult to solve (8% success rate).", [["a closure operator", "TREATMENT", 30, 48], ["a closure operator", "TREATMENT", 153, 171]]], ["We had some anecdotal evidence that closures were difficult for students, but this discrepancy between the two cases was rather surprising, meaning that special attention should be given to the later case in lectures.", [["closures", "OBSERVATION", 36, 44]]], ["Other problematic concepts were the manipulation of ternary relations (F4) (19% success rate), and usage of the standard ordering module (F7) (16% success rate), both frequently used in Alloy specifications.", [["the standard ordering module (F7)", "TREATMENT", 108, 141]]], ["The first result is aligned with our anecdotal evidence, and we already had special care with higher arity relations in lectures.", [["special care", "TREATMENT", 76, 88]]], ["The second is a bit more surprising, meaning that, likewise to closures of relational expressions, we should invest more lecture time in explaining how to use this module.", [["this module", "TREATMENT", 159, 170], ["bit more", "OBSERVATION_MODIFIER", 16, 24]]], ["Concerning Electrum, students seem to understand well the usage of a single temporal operator (F8) (58% success rate), but, as expected and likewise quantifiers, specifications requiring nesting of several temporal operators (F9) were more difficult (32% success rate).Insights on Learning AlloyWe also collected statistics about typical errors and warnings, with Tables 2 and 3 presenting the 10 most commonly found error and warning messages, respectively.", [["F9", "ANATOMY", 226, 228]]], ["Of the remaining, the most frequent are incorrectly applying logic operators to relational expressions and vice-versa (messages 3, 5, and 7), in total 28% of the errors, and simple typing errors related to arity (messages 4, 6, 9, and 10), in total 26% of the errors.", [["simple typing errors", "PROBLEM", 174, 194]]], ["The reader unacquainted with Alloy could find the frequency of the former rather surprising, but this is a rather frequent error due to the syntactic similarity between some logical and relational operators (for example, not for negation vs. no for emptiness check or && for conjunction vs. & for intersection).", [["emptiness check", "TEST", 249, 264]]], ["Fortunately, Alloy has alternative syntax for many logic operators (for example, and for conjunction) and maybe instructors should recommend using that alternative instead.", [["Alloy", "CHEMICAL", 13, 18], ["Alloy", "SIMPLE_CHEMICAL", 13, 18]]], ["Concerning warnings, all but the third most common message (unused variables, 23% of the total warnings) are warnings about potentially irrelevant expressions -formulas that are trivially true or false or expressions that always denote an empty set -a testimony to the usefulness of Alloy's sophisticated type system [5] .Concluding Remarks and Future WorkWe briefly presented Alloy4Fun, a web application for online editing and sharing of Alloy models and instances, that also allows the automated assessment of simple specification challenges.", [["a web application", "TREATMENT", 388, 405], ["the automated assessment", "TEST", 485, 509]]], ["Its main intended use is in an educational context, and our preliminary evaluation in a graduate formal methods course provided evidence that students found the automated assessment feature useful for learning Alloy and Electrum (and the sharing feature less so).", [["our preliminary evaluation", "TEST", 56, 82], ["the automated assessment", "TEST", 157, 181], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Concerning the application itself, we intend to develop tools to simplify the mining of useful data from the derivation trees, possibly to be run server-side at the click of a button (with results visualized in the browser), to enable the timely identification of learning breakdowns.", [["learning breakdowns", "PROBLEM", 264, 283]]]], "PMC7283824": [["The Covid\u201019 Pandemic has thrown global economies into turmoil, necessitating hugely expensive economic stabilisation programmes.", [["hugely expensive economic stabilisation programmes", "TREATMENT", 78, 128], ["economic stabilisation", "OBSERVATION", 95, 117]]], ["The crisis has brought into sharp focus the fundamental strategic importance of agri\u2010food sectors in sustaining the health and general wellbeing of societies across the globe.", [["The crisis", "PROBLEM", 0, 10], ["crisis", "OBSERVATION", 4, 10], ["globe", "ANATOMY", 169, 174]]], ["In more stable and peaceful times it is easy to lose sight of the significance of this key role.", [["stable", "OBSERVATION_MODIFIER", 8, 14]]], ["The crisis will surely have an impact on the aims and outcomes of the negotiations; perhaps above all the importance of ensuring free and open trading relationships.", [["The crisis", "PROBLEM", 0, 10], ["crisis", "OBSERVATION", 4, 10]]]], "bb8fcfbe598f6820e9fe243a67314aff31727295": [["The best advantage of that form of contact is that it is a means of mass communication and offers the ability to facilitate disease surveillance [12] , [14] .", [["mass communication", "PROBLEM", 68, 86], ["disease surveillance", "TEST", 124, 144]]]], "PMC7159720": [["Experimental SectionThe GO sheets were prepared according to previously reported methods.15 SARS\u2010CoV helicase was overexpressed in Escherichia coli and purified as described previously.19 Then upper\u2010strand DNA (12 \u03bcL, 10 \u03bcm; 5\u2032\u2010TTT TTT TTT TTT TTT GAG CGG ATT ACT ATA CTA CAT TAG AAT TCC\u20103\u2032, Genotech, Seoul, Korea) and fluorescent\u2010dye\u2010conjugated bottom\u2010strand DNA (6 \u03bcL, 10 \u03bcm; 5\u2032\u2010FAM\u2010GGA ATT CTA ATG TAG TAT AGT AAT CCG CTC\u20103\u2032, Genotech) were mixed and annealed in pH 8.0 buffer containing 50 mm Tris\u2013HCl and 50 mm NaCl (1\u00d7buffer).", [["Tris\u2013HCl", "CHEMICAL", 498, 506], ["NaCl", "CHEMICAL", 517, 521], ["NaCl", "CHEMICAL", 517, 521], ["CoV", "GENE_OR_GENE_PRODUCT", 97, 100], ["Escherichia coli", "ORGANISM", 131, 147], ["DNA", "CELLULAR_COMPONENT", 206, 209], ["DNA", "CELLULAR_COMPONENT", 361, 364], ["Tris\u2013HCl", "SIMPLE_CHEMICAL", 498, 506], ["SARS\u2010CoV helicase", "PROTEIN", 92, 109], ["upper\u2010strand DNA", "DNA", 193, 209], ["TTT TTT TTT TTT GAG CGG ATT ACT ATA CTA CAT", "DNA", 232, 275], ["fluorescent\u2010dye\u2010conjugated bottom\u2010strand DNA", "DNA", 320, 364], ["FAM\u2010GGA ATT CTA ATG TAG TAT AGT AAT", "DNA", 382, 417], ["Escherichia coli", "SPECIES", 131, 147], ["SARS\u2010CoV", "SPECIES", 92, 100], ["Escherichia coli", "SPECIES", 131, 147], ["CoV helicase", "TREATMENT", 97, 109], ["Escherichia coli", "PROBLEM", 131, 147], ["TTT", "TEST", 228, 231], ["TTT", "TEST", 232, 235], ["TTT", "TEST", 236, 239], ["TTT", "TEST", 240, 243], ["TTT", "TEST", 244, 247], ["GAG", "TEST", 248, 251], ["CGG", "TEST", 252, 255], ["ATT", "TEST", 256, 259], ["ACT", "TEST", 260, 263], ["ATA", "TEST", 264, 267], ["CTA", "TEST", 268, 271], ["CAT", "TEST", 272, 275], ["TAG", "TEST", 276, 279], ["TCC", "TEST", 284, 287], ["\u2010", "TEST", 287, 288], ["Genotech", "TEST", 292, 300], ["FAM", "TEST", 382, 385], ["GGA", "TEST", 386, 389], ["ATT", "TEST", 390, 393], ["CTA", "TEST", 394, 397], ["ATG", "TEST", 398, 401], ["TAG", "TEST", 402, 405], ["TAT", "TEST", 406, 409], ["AGT", "TEST", 410, 413], ["AAT", "TEST", 414, 417], ["CCG", "TEST", 418, 421], ["CTC", "TEST", 422, 425], ["\u2010", "TEST", 425, 426], ["Genotech", "TEST", 430, 438], ["pH", "TEST", 467, 469], ["Escherichia coli", "OBSERVATION", 131, 147]]], ["Substrate solution was prepared by mixing annealed substrate (0.2 \u03bcm), EDTA (0.5 mm; Bio\u2010Rad, Hercules, CA, USA), ATP disodium (20 mm; Sigma\u2013Aldrich, St. Louis, MO, USA), and MgCl2 (1.3 mm; Junsei, Tokyo, Japan) in 1\u00d7 buffer containing 10 % glycerol solution.", [["ATP disodium", "CHEMICAL", 114, 126], ["MgCl2", "CHEMICAL", 175, 180], ["glycerol", "CHEMICAL", 241, 249], ["EDTA", "CHEMICAL", 71, 75], ["ATP disodium", "CHEMICAL", 114, 126], ["MgCl2", "CHEMICAL", 175, 180], ["glycerol", "CHEMICAL", 241, 249], ["EDTA", "SIMPLE_CHEMICAL", 71, 75], ["ATP disodium", "SIMPLE_CHEMICAL", 114, 126], ["MgCl2", "SIMPLE_CHEMICAL", 175, 180], ["glycerol", "SIMPLE_CHEMICAL", 241, 249], ["Substrate solution", "TREATMENT", 0, 18], ["mixing annealed substrate", "TREATMENT", 35, 60], ["EDTA", "TEST", 71, 75], ["Hercules", "TEST", 94, 102], ["CA", "TEST", 104, 106], ["ATP disodium", "TEST", 114, 126], ["MgCl2", "TREATMENT", 175, 180], ["Junsei", "TREATMENT", 190, 196], ["10 % glycerol solution", "TREATMENT", 236, 258]]], ["GO solution was prepared in 1\u00d7 buffer (1 mg mL\u22121); the substrate solution (30 \u03bcL) and GO solution (30 \u03bcL) were mixed, and then the helicase reaction was initiated by addition of various amounts of helicase stock solution (200 nm).", [["the substrate solution", "TREATMENT", 51, 73], ["the helicase reaction", "TREATMENT", 127, 148], ["helicase stock solution", "TREATMENT", 197, 220]]], ["After the addition of helicase, the fluorescence intensity was measured by using a Synergy Mx fluorometer (BioTek, Potton, UK) at 520 nm for 30 min.", [["helicase", "PROTEIN", 22, 30], ["helicase", "TREATMENT", 22, 30], ["the fluorescence intensity", "TEST", 32, 58], ["a Synergy Mx fluorometer", "TREATMENT", 81, 105]]]], "PMC7223162": [["IntroductionThe World Health Organization estimates that annually there are approximately 1 billion human influenza cases of which 3 to 5 million are considered severe (especially in children, the elderly and in the immunocompromised) and result in 290,000 to 650,000 deaths [1].IntroductionInfluenza can be transmitted through the following routes:Respiratory droplets (> 5 \u03bcm) generated e.g. by coughing and sneezing.", [["influenza", "DISEASE", 106, 115], ["deaths", "DISEASE", 268, 274], ["Influenza", "DISEASE", 291, 300], ["coughing", "DISEASE", 397, 405], ["sneezing", "DISEASE", 410, 418], ["human", "ORGANISM", 100, 105], ["children", "ORGANISM", 183, 191], ["Influenza", "ORGANISM", 291, 300], ["human", "SPECIES", 100, 105], ["children", "SPECIES", 183, 191], ["human", "SPECIES", 100, 105], ["IntroductionInfluenza", "PROBLEM", 279, 300], ["Respiratory droplets", "TREATMENT", 349, 369], ["coughing", "PROBLEM", 397, 405], ["sneezing", "PROBLEM", 410, 418], ["severe", "OBSERVATION_MODIFIER", 161, 167]]], ["These do not remain suspended in the air and settle to the ground within 1\u20132 mContact transmission either through direct transfer of infectious particles from an infected to an uninfected individual or indirectly via contaminated surfaces or objects (i.e. fomites) and influenza can survive for hours on nonporous surfacesPossibly by airborne transmission via small aerosols (< 5 \u03bcm) generated from breathing/talking (and can remain suspended in the air for minutes to hours) [2]; however, there is limited data to suggest that infectious particles can be transmitted over long distances (and special air handling and ventilation systems are not considered necessary to prevent spread)IntroductionInfluenza belongs to the orthomyxovirus family and there are four influenza types A to D of which only influenza A, B and C can infect humans (influenza C is rare and usually causes a mild upper respiratory tract illness) [3].", [["upper respiratory tract", "ANATOMY", 886, 909], ["influenza", "DISEASE", 269, 278], ["Influenza belongs to the orthomyxovirus", "DISEASE", 697, 736], ["influenza", "DISEASE", 800, 809], ["influenza C", "DISEASE", 840, 851], ["upper respiratory tract illness", "DISEASE", 886, 917], ["Influenza", "ORGANISM", 697, 706], ["influenza", "ORGANISM", 800, 809], ["B", "GENE_OR_GENE_PRODUCT", 813, 814], ["C", "GENE_OR_GENE_PRODUCT", 819, 820], ["humans", "ORGANISM", 832, 838], ["influenza C", "ORGANISM", 840, 851], ["upper", "ORGANISM_SUBDIVISION", 886, 891], ["respiratory tract", "ORGANISM_SUBDIVISION", 892, 909], ["humans", "SPECIES", 832, 838], ["humans", "SPECIES", 832, 838], ["infectious particles", "PROBLEM", 133, 153], ["influenza", "PROBLEM", 269, 278], ["small aerosols", "PROBLEM", 360, 374], ["infectious particles", "PROBLEM", 528, 548], ["special air handling", "TREATMENT", 593, 613], ["ventilation systems", "TREATMENT", 618, 637], ["Influenza", "PROBLEM", 697, 706], ["influenza", "PROBLEM", 800, 809], ["A, B and C can infect humans (influenza C", "PROBLEM", 810, 851], ["a mild upper respiratory tract illness", "PROBLEM", 879, 917], ["suspended", "OBSERVATION", 20, 29], ["air", "OBSERVATION", 37, 40], ["infectious", "OBSERVATION", 133, 143], ["infected", "OBSERVATION", 162, 170], ["small", "OBSERVATION_MODIFIER", 360, 365], ["aerosols", "OBSERVATION", 366, 374], ["infectious", "OBSERVATION", 528, 538], ["mild", "OBSERVATION_MODIFIER", 881, 885], ["upper", "ANATOMY_MODIFIER", 886, 891], ["respiratory tract", "ANATOMY", 892, 909]]], ["Influenza A and B contain 8 pieces of segmented single-stranded RNA which encode various proteins including haemagglutinin (which facilitates attachment to the host cell) and neuraminidase (which facilitates release of new virus particles from the host cell).", [["cell", "ANATOMY", 165, 169], ["cell", "ANATOMY", 253, 257], ["Influenza A", "ORGANISM", 0, 11], ["B", "CANCER", 16, 17], ["haemagglutinin", "GENE_OR_GENE_PRODUCT", 108, 122], ["host cell", "CELL", 160, 169], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 175, 188], ["cell", "CELL", 253, 257], ["segmented single-stranded RNA", "RNA", 38, 67], ["haemagglutinin", "PROTEIN", 108, 122], ["neuraminidase", "PROTEIN", 175, 188], ["Influenza", "PROBLEM", 0, 9], ["segmented single-stranded RNA", "TREATMENT", 38, 67], ["various proteins", "PROBLEM", 81, 97], ["haemagglutinin", "TREATMENT", 108, 122], ["neuraminidase", "TREATMENT", 175, 188], ["new virus particles", "TREATMENT", 219, 238], ["stranded RNA", "OBSERVATION_MODIFIER", 55, 67], ["host cell", "OBSERVATION", 248, 257]]], ["Influenza A has the broadest host range of the influenza viruses and significant interspecies transmission occurs [4].", [["influenza", "DISEASE", 47, 56], ["Influenza A", "ORGANISM", 0, 11], ["influenza viruses", "ORGANISM", 47, 64], ["Influenza A", "SPECIES", 0, 11], ["Influenza", "PROBLEM", 0, 9], ["the influenza viruses", "PROBLEM", 43, 64], ["influenza viruses", "OBSERVATION", 47, 64]]], ["Eighteen haemagglutinin (H) and 11 neuraminidase (N) subtypes have been described in influenza A (of which 16 H and 9 N subtypes have also been detected within avian species) [5].", [["influenza A", "DISEASE", 85, 96], ["haemagglutinin (H)", "GENE_OR_GENE_PRODUCT", 9, 27], ["influenza A", "ORGANISM", 85, 96], ["haemagglutinin", "PROTEIN", 9, 23], ["H", "PROTEIN", 25, 26], ["neuraminidase (N) subtypes", "PROTEIN", 35, 61], ["Eighteen haemagglutinin (H)", "TREATMENT", 0, 27], ["11 neuraminidase (N) subtypes", "PROBLEM", 32, 61], ["influenza A", "PROBLEM", 85, 96]]], ["Influenza B is far less genetically diverse than influenza A and has no distinct antigenic subtypes (mutates 2 to 3 times slower than influenza A and apart from humans, only seals and ferrets have demonstrated susceptibility) [6\u20138].IntroductionInfluenza achieves antigenic diversity via two main mechanisms:Antigenic drift where mutations readily occur in HA and NA resulting in new antigenic variants (thus avoiding pre-existing host immunity); the error prone nature of the viral polymerase is a significant factor in thisAntigenic shift due to reassortment of gene segments between two distinct influenza viruses within the same host giving rise to a novel strainIntroductionThe 1918 influenza A H1N1 pandemic is thought to have arisen from reassortment between human and avian strains (based on sequencing of fixed, frozen lung tissue from victims) and similarly, the most recent \u2018swine flu\u2019 influenza A H1N1 pandemic was thought to arise from a series of reassortment events between human influenza A H3N2, swine influenza A H1N1 and avian influenza A H1N2 [9, 10].", [["lung tissue", "ANATOMY", 827, 838], ["Influenza B", "DISEASE", 0, 11], ["Influenza", "DISEASE", 244, 253], ["NA", "CHEMICAL", 363, 365], ["influenza viruses", "DISEASE", 598, 615], ["influenza A H1N1 pandemic", "DISEASE", 687, 712], ["H1N1 pandemic", "DISEASE", 908, 921], ["influenza A H3N2", "DISEASE", 994, 1010], ["influenza A H1N1", "DISEASE", 1018, 1034], ["Influenza B", "ORGANISM", 0, 11], ["influenza A", "CANCER", 49, 60], ["humans", "ORGANISM", 161, 167], ["ferrets", "ORGANISM", 184, 191], ["influenza viruses", "ORGANISM", 598, 615], ["1918 influenza A H1N1", "ORGANISM", 682, 703], ["human", "ORGANISM", 765, 770], ["avian strains", "ORGANISM", 775, 788], ["lung tissue", "TISSUE", 827, 838], ["\u2018", "ORGANISM", 884, 885], ["swine flu\u2019 influenza A H1N1", "ORGANISM", 885, 912], ["human", "ORGANISM", 988, 993], ["influenza A H3N2", "ORGANISM", 994, 1010], ["swine influenza A H1N1", "ORGANISM", 1012, 1034], ["avian influenza A H1N2", "ORGANISM", 1039, 1061], ["viral polymerase", "PROTEIN", 476, 492], ["humans", "SPECIES", 161, 167], ["ferrets", "SPECIES", 184, 191], ["influenza A H1N1 pandemic", "SPECIES", 687, 712], ["human", "SPECIES", 765, 770], ["swine flu\u2019 influenza A H1N1 pandemic", "SPECIES", 885, 921], ["human", "SPECIES", 988, 993], ["influenza A H3N2", "SPECIES", 994, 1010], ["swine influenza A H1N1", "SPECIES", 1012, 1034], ["avian influenza A H1N2", "SPECIES", 1039, 1061], ["influenza A", "SPECIES", 49, 60], ["humans", "SPECIES", 161, 167], ["human", "SPECIES", 765, 770], ["swine flu\u2019 influenza A H1N1 pandemic", "SPECIES", 885, 921], ["human influenza A H3N2", "SPECIES", 988, 1010], ["swine influenza A H1N1", "SPECIES", 1012, 1034], ["Influenza B", "PROBLEM", 0, 11], ["influenza", "PROBLEM", 49, 58], ["distinct antigenic subtypes", "PROBLEM", 72, 99], ["influenza", "PROBLEM", 134, 143], ["Antigenic drift", "PROBLEM", 307, 322], ["mutations", "PROBLEM", 329, 338], ["HA", "PROBLEM", 356, 358], ["NA", "PROBLEM", 363, 365], ["new antigenic variants", "PROBLEM", 379, 401], ["pre-existing host immunity", "TREATMENT", 417, 443], ["the viral polymerase", "PROBLEM", 472, 492], ["a significant factor", "PROBLEM", 496, 516], ["gene segments between two distinct influenza viruses", "PROBLEM", 563, 615], ["a novel strain", "PROBLEM", 652, 666], ["A H1N1 pandemic", "PROBLEM", 697, 712], ["human and avian strains", "TREATMENT", 765, 788], ["fixed, frozen lung tissue", "PROBLEM", 813, 838], ["A H1N1 pandemic", "PROBLEM", 906, 921], ["human influenza A H3N2", "PROBLEM", 988, 1010], ["swine influenza A H1N1", "PROBLEM", 1012, 1034], ["avian influenza A H1N2", "PROBLEM", 1039, 1061], ["no", "UNCERTAINTY", 69, 71], ["distinct", "OBSERVATION_MODIFIER", 72, 80], ["antigenic subtypes", "OBSERVATION", 81, 99], ["drift", "OBSERVATION", 317, 322], ["new", "OBSERVATION_MODIFIER", 379, 382], ["antigenic variants", "OBSERVATION", 383, 401], ["distinct", "OBSERVATION_MODIFIER", 589, 597], ["influenza viruses", "OBSERVATION", 598, 615], ["lung", "ANATOMY", 827, 831]]], ["Lack of influenza B infection in several other species may explain why antigenic shift is not seen with influenza B [11].IntroductionThis potential for vast genetic variability within influenza viruses and their highly error-prone RNA dependent RNA polymerase does raise concerns regarding the possible emergence of treatment resistant strains and generates further questions regarding their viral fitness and transmissibility as well as which strategies to employ in rapidly identifying and effectively treating these resistance variants.", [["influenza B infection", "DISEASE", 8, 29], ["influenza", "DISEASE", 184, 193], ["influenza B", "ORGANISM", 8, 19], ["influenza viruses", "ORGANISM", 184, 201], ["RNA polymerase", "PROTEIN", 245, 259], ["influenza B infection", "PROBLEM", 8, 29], ["several other species", "PROBLEM", 33, 54], ["antigenic shift", "PROBLEM", 71, 86], ["influenza B", "PROBLEM", 104, 115], ["vast genetic variability", "PROBLEM", 152, 176], ["influenza viruses", "PROBLEM", 184, 201], ["their highly error-prone RNA dependent RNA polymerase", "PROBLEM", 206, 259], ["treatment resistant strains", "PROBLEM", 316, 343], ["these resistance variants", "PROBLEM", 513, 538], ["influenza", "OBSERVATION", 8, 17], ["infection", "OBSERVATION", 20, 29]]], ["This article discusses these issues including novel agents and experimental strategies that have been used in an attempt to treat as well as prevent the emergence of resistant influenza viruses in humans.Earlier influenza treatment with the adamantanesThe mechanism of action of the adamantanes is by blocking the M2 ion channel of influenza A thus preventing viral uncoating and the subsequent release of influenza A viral RNA into the host cell.", [["cell", "ANATOMY", 442, 446], ["influenza viruses", "DISEASE", 176, 193], ["influenza", "DISEASE", 212, 221], ["adamantanes", "CHEMICAL", 241, 252], ["adamantanes", "CHEMICAL", 283, 294], ["adamantanes", "CHEMICAL", 241, 252], ["adamantanes", "CHEMICAL", 283, 294], ["influenza viruses", "ORGANISM", 176, 193], ["humans", "ORGANISM", 197, 203], ["adamantanes", "SIMPLE_CHEMICAL", 283, 294], ["influenza A", "ORGANISM", 332, 343], ["influenza A viral", "ORGANISM", 406, 423], ["host cell", "CELL", 437, 446], ["M2 ion channel", "PROTEIN", 314, 328], ["influenza A viral RNA", "RNA", 406, 427], ["host cell", "CELL_TYPE", 437, 446], ["humans", "SPECIES", 197, 203], ["humans", "SPECIES", 197, 203], ["novel agents", "TREATMENT", 46, 58], ["experimental strategies", "TREATMENT", 63, 86], ["resistant influenza viruses in humans", "PROBLEM", 166, 203], ["Earlier influenza treatment", "TREATMENT", 204, 231], ["the adamantanes", "TREATMENT", 237, 252], ["influenza", "PROBLEM", 332, 341], ["viral uncoating", "PROBLEM", 360, 375], ["influenza A viral RNA into the host cell", "PROBLEM", 406, 446], ["influenza", "OBSERVATION", 176, 185], ["influenza", "OBSERVATION", 332, 341], ["host cell", "OBSERVATION", 437, 446]]], ["They have activity against influenza A but not influenza B (due to their lack of the M2 protein, influenza B has an alternative ion channel called BM2) [12].", [["influenza A", "DISEASE", 27, 38], ["influenza B", "DISEASE", 47, 58], ["influenza A", "ORGANISM", 27, 38], ["influenza B", "ORGANISM", 47, 58], ["M2", "GENE_OR_GENE_PRODUCT", 85, 87], ["influenza B", "ORGANISM", 97, 108], ["M2 protein", "PROTEIN", 85, 95], ["influenza B", "PROTEIN", 97, 108], ["BM2", "PROTEIN", 147, 150], ["influenza A", "PROBLEM", 27, 38], ["influenza B", "PROBLEM", 47, 58], ["influenza", "PROBLEM", 97, 106]]], ["Amantadine was approved for clinical use in 1966 and subsequently rimantadine in 1993.", [["Amantadine", "CHEMICAL", 0, 10], ["rimantadine", "CHEMICAL", 66, 77], ["Amantadine", "CHEMICAL", 0, 10], ["rimantadine", "CHEMICAL", 66, 77], ["Amantadine", "SIMPLE_CHEMICAL", 0, 10], ["rimantadine", "SIMPLE_CHEMICAL", 66, 77], ["Amantadine", "TREATMENT", 0, 10], ["rimantadine", "TREATMENT", 66, 77]]], ["Both drugs were initially very effective in treating and preventing influenza A infection with efficacy rates of up to 90%.", [["influenza A infection", "DISEASE", 68, 89], ["influenza A", "SPECIES", 68, 79], ["Both drugs", "TREATMENT", 0, 10], ["influenza A infection", "PROBLEM", 68, 89], ["efficacy rates", "TEST", 95, 109], ["infection", "OBSERVATION", 80, 89]]], ["The resistance of influenza A to amantadine was first recognised during the 1980 influenza A epidemic [12].", [["influenza A", "CHEMICAL", 18, 29], ["amantadine", "CHEMICAL", 33, 43], ["amantadine", "CHEMICAL", 33, 43], ["influenza A", "ORGANISM", 18, 29], ["amantadine", "SIMPLE_CHEMICAL", 33, 43], ["influenza", "PROBLEM", 18, 27], ["amantadine", "TREATMENT", 33, 43], ["influenza", "OBSERVATION", 18, 27]]], ["However, resistance to both drugs in seasonal influenza A subtypes was rare (1\u20132% frequency) until after 2000 when there was a dramatic rise in rates of resistance.", [["influenza", "DISEASE", 46, 55], ["seasonal influenza A", "ORGANISM", 37, 57], ["both drugs", "TREATMENT", 23, 33], ["seasonal influenza A subtypes", "PROBLEM", 37, 66], ["a dramatic rise in rates of resistance", "PROBLEM", 125, 163], ["dramatic", "OBSERVATION_MODIFIER", 127, 135], ["rise", "OBSERVATION_MODIFIER", 136, 140]]], ["By 2013, approximately 45% of all influenza A subtypes in circulation globally were resistant to the adamantanes (> 69% of H1 subtypes and 43% of H3 subtypes) [11].", [["adamantanes", "CHEMICAL", 101, 112], ["adamantanes", "CHEMICAL", 101, 112], ["all influenza A subtypes in circulation globally", "PROBLEM", 30, 78], ["the adamantanes", "TEST", 97, 112], ["H1 subtypes", "TEST", 123, 134]]], ["Resistance (as a result of the S31N mutation in the M2 protein) to the adamantanes occurs rapidly within 3\u20135 days of use and occurs in 30\u201350% of both immunocompetent and immunocompromised patients [13, 14].", [["adamantanes", "CHEMICAL", 71, 82], ["adamantanes", "CHEMICAL", 71, 82], ["S31N", "GENE_OR_GENE_PRODUCT", 31, 35], ["M2", "GENE_OR_GENE_PRODUCT", 52, 54], ["adamantanes", "SIMPLE_CHEMICAL", 71, 82], ["patients", "ORGANISM", 188, 196], ["M2 protein", "PROTEIN", 52, 62], ["patients", "SPECIES", 188, 196], ["the S31N mutation", "PROBLEM", 27, 44]]], ["Due to such high levels of resistance, the adamantanes are no longer recommended for treatment of influenza A [15].Neuraminidase inhibitorsNeuraminidase inhibitors are currently first-line treatment for both influenza A and B in the United Kingdom (UK) and most (if not all) parts of the world.", [["adamantanes", "CHEMICAL", 43, 54], ["influenza", "DISEASE", 98, 107], ["influenza A and B", "DISEASE", 208, 225], ["adamantanes", "CHEMICAL", 43, 54], ["adamantanes", "SIMPLE_CHEMICAL", 43, 54], ["Neuraminidase", "GENE_OR_GENE_PRODUCT", 115, 128], ["Neuraminidase", "SIMPLE_CHEMICAL", 139, 152], ["such high levels of resistance", "PROBLEM", 7, 37], ["the adamantanes", "TREATMENT", 39, 54], ["influenza", "PROBLEM", 98, 107], ["Neuraminidase inhibitors", "TREATMENT", 115, 139], ["Neuraminidase inhibitors", "TREATMENT", 139, 163], ["first-line treatment", "TREATMENT", 178, 198], ["influenza", "PROBLEM", 208, 217], ["no longer", "UNCERTAINTY", 59, 68]]], ["They competitively inhibit neuraminidase on the surface of influenza A and B. They act by preventing cleavage of sialic acid residues on budding newly formed virus particles thus preventing release of new virus particles from infected host (ciliated epithelial) cells.", [["surface", "ANATOMY", 48, 55], ["ciliated epithelial) cells", "ANATOMY", 241, 267], ["sialic acid", "CHEMICAL", 113, 124], ["sialic acid", "CHEMICAL", 113, 124], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 27, 40], ["surface", "CELLULAR_COMPONENT", 48, 55], ["influenza A", "ORGANISM", 59, 70], ["sialic acid", "SIMPLE_CHEMICAL", 113, 124], ["ciliated epithelial) cells", "CELL", 241, 267], ["neuraminidase", "PROTEIN", 27, 40], ["infected host (ciliated epithelial) cells", "CELL_TYPE", 226, 267], ["neuraminidase", "PROBLEM", 27, 40], ["influenza", "PROBLEM", 59, 68], ["sialic acid residues", "PROBLEM", 113, 133], ["budding newly formed virus particles", "PROBLEM", 137, 173], ["new virus particles", "PROBLEM", 201, 220], ["infected host (ciliated epithelial) cells", "PROBLEM", 226, 267], ["epithelial", "ANATOMY_MODIFIER", 250, 260]]], ["Resistance occurs much less readily in comparison with the adamantanes [16].", [["adamantanes", "CHEMICAL", 59, 70], ["adamantanes", "CHEMICAL", 59, 70]]], ["The neuraminidase inhibitors, if given within 36 h of onset, have been shown to reduce the duration of illness by 30% (with an approximately 40% reduction in illness severity) and, if given within 24 h of symptom onset, even greater reductions in the duration of illness attributable to influenza (approximately 44% reduction) have been observed [17, 18].", [["illness", "DISEASE", 103, 110], ["illness", "DISEASE", 158, 165], ["illness", "DISEASE", 263, 270], ["influenza", "DISEASE", 287, 296], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 4, 17], ["The neuraminidase inhibitors", "TREATMENT", 0, 28], ["illness severity", "PROBLEM", 158, 174], ["symptom onset", "PROBLEM", 205, 218], ["illness", "PROBLEM", 263, 270], ["influenza", "PROBLEM", 287, 296], ["greater", "OBSERVATION_MODIFIER", 225, 232], ["reductions", "OBSERVATION_MODIFIER", 233, 243]]], ["A decrease in the incidence of secondary complications, such as otitis media, sinusitis and pneumonia, with the use of neuraminidase inhibitors was also demonstrated [17].", [["otitis media", "DISEASE", 64, 76], ["sinusitis", "DISEASE", 78, 87], ["pneumonia", "DISEASE", 92, 101], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 119, 132], ["A decrease", "PROBLEM", 0, 10], ["secondary complications", "PROBLEM", 31, 54], ["otitis media", "PROBLEM", 64, 76], ["sinusitis", "PROBLEM", 78, 87], ["pneumonia", "PROBLEM", 92, 101], ["neuraminidase inhibitors", "TREATMENT", 119, 143], ["decrease", "OBSERVATION_MODIFIER", 2, 10], ["secondary", "OBSERVATION_MODIFIER", 31, 40], ["complications", "OBSERVATION", 41, 54], ["otitis", "OBSERVATION", 64, 70], ["sinusitis", "OBSERVATION", 78, 87], ["pneumonia", "OBSERVATION", 92, 101]]], ["Additionally, when used as prophylaxis (before or shortly after exposure), neuraminidase inhibitors can reduce the incidence of infection by approximately 70\u201390% [19].", [["infection", "DISEASE", 128, 137], ["prophylaxis", "TREATMENT", 27, 38], ["neuraminidase inhibitors", "TREATMENT", 75, 99], ["infection", "PROBLEM", 128, 137], ["infection", "OBSERVATION", 128, 137]]], ["In the UK, oseltamivir (oral agent; typically first line for influenza A and B treatment) and zanamivir (inhaled and also available as an aqueous solution which can be administered intravenously or via nebuliser) are licensed for the treatment of influenza A and B and also for prophylaxis.", [["oral", "ANATOMY", 24, 28], ["intravenously", "ANATOMY", 181, 194], ["oseltamivir", "CHEMICAL", 11, 22], ["influenza A and B", "CHEMICAL", 61, 78], ["zanamivir", "CHEMICAL", 94, 103], ["influenza A and B", "DISEASE", 247, 264], ["oseltamivir", "CHEMICAL", 11, 22], ["zanamivir", "CHEMICAL", 94, 103], ["UK", "GENE_OR_GENE_PRODUCT", 7, 9], ["oseltamivir", "SIMPLE_CHEMICAL", 11, 22], ["oral", "ORGANISM_SUBDIVISION", 24, 28], ["zanamivir", "SIMPLE_CHEMICAL", 94, 103], ["B", "CANCER", 263, 264], ["oseltamivir (oral agent", "TREATMENT", 11, 34], ["influenza A", "TREATMENT", 61, 72], ["B treatment)", "TREATMENT", 77, 89], ["zanamivir", "TREATMENT", 94, 103], ["an aqueous solution", "TREATMENT", 135, 154], ["influenza", "PROBLEM", 247, 256], ["prophylaxis", "TREATMENT", 278, 289]]], ["Oseltamivir is licensed in the UK for use in all ages including neonates, whereas zanamivir is not licensed for children under the age of 5 years.", [["Oseltamivir", "CHEMICAL", 0, 11], ["zanamivir", "CHEMICAL", 82, 91], ["Oseltamivir", "CHEMICAL", 0, 11], ["zanamivir", "CHEMICAL", 82, 91], ["Oseltamivir", "SIMPLE_CHEMICAL", 0, 11], ["UK", "GENE_OR_GENE_PRODUCT", 31, 33], ["neonates", "ORGANISM", 64, 72], ["zanamivir", "SIMPLE_CHEMICAL", 82, 91], ["children", "ORGANISM", 112, 120], ["children", "SPECIES", 112, 120], ["Oseltamivir", "TREATMENT", 0, 11], ["zanamivir", "TREATMENT", 82, 91]]], ["Peramivir (a single-dose intravenous infusion) was licensed in the UK in 2018 but has not been marketed/launched (it is used in the USA, Japan and South Korea).", [["intravenous", "ANATOMY", 25, 36], ["Peramivir", "CHEMICAL", 0, 9], ["Peramivir", "CHEMICAL", 0, 9], ["Peramivir", "SIMPLE_CHEMICAL", 0, 9], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 25, 36], ["Peramivir", "TREATMENT", 0, 9], ["a single-dose intravenous infusion", "TREATMENT", 11, 45]]], ["Laninamivir (an inhaled neuraminidase inhibitor) is licensed for use in Japan.Neuraminidase inhibitorsBased on the data from animal models which demonstrated that oseltamivir-resistant viruses were unfit and poorly transmissible, resistance to neuraminidase inhibitors was not envisaged to become an important clinical issue [20].", [["Laninamivir", "CHEMICAL", 0, 11], ["oseltamivir", "CHEMICAL", 163, 174], ["Laninamivir", "CHEMICAL", 0, 11], ["oseltamivir", "CHEMICAL", 163, 174], ["Laninamivir", "SIMPLE_CHEMICAL", 0, 11], ["Neuraminidase", "GENE_OR_GENE_PRODUCT", 78, 91], ["oseltamivir", "SIMPLE_CHEMICAL", 163, 174], ["Laninamivir", "TREATMENT", 0, 11], ["an inhaled neuraminidase inhibitor", "TREATMENT", 13, 47], ["Neuraminidase inhibitors", "TREATMENT", 78, 102], ["the data", "TEST", 111, 119], ["animal models", "TEST", 125, 138], ["oseltamivir", "TREATMENT", 163, 174], ["resistant viruses", "PROBLEM", 175, 192], ["neuraminidase inhibitors", "TREATMENT", 244, 268]]], ["Prior to 2007, oseltamivir resistance was rarely seen in clinical practice (and low resistance rates of 1\u20135% were reported in clinical trials) [21].", [["oseltamivir", "CHEMICAL", 15, 26], ["oseltamivir", "CHEMICAL", 15, 26], ["oseltamivir", "SIMPLE_CHEMICAL", 15, 26], ["oseltamivir resistance", "TREATMENT", 15, 37], ["low resistance rates", "TREATMENT", 80, 100]]], ["Human cases of oseltamivir-resistant influenza A H1N1 began emerging during the 2007\u20132008 influenza season.", [["oseltamivir", "CHEMICAL", 15, 26], ["influenza A H1N1", "DISEASE", 37, 53], ["influenza", "DISEASE", 90, 99], ["oseltamivir", "CHEMICAL", 15, 26], ["Human", "ORGANISM", 0, 5], ["oseltamivir-resistant", "ORGANISM", 15, 36], ["influenza A H1N1", "ORGANISM", 37, 53], ["Human", "SPECIES", 0, 5], ["influenza A H1N1", "SPECIES", 37, 53], ["Human", "SPECIES", 0, 5], ["oseltamivir", "TREATMENT", 15, 26], ["resistant influenza A H1N1", "PROBLEM", 27, 53]]], ["Many of the cases reported were individuals who had not taken oseltamivir demonstrating that resistant virus could be efficiently transmitted between humans [22].", [["oseltamivir", "CHEMICAL", 62, 73], ["oseltamivir", "CHEMICAL", 62, 73], ["oseltamivir", "SIMPLE_CHEMICAL", 62, 73], ["humans", "ORGANISM", 150, 156], ["humans", "SPECIES", 150, 156], ["humans", "SPECIES", 150, 156], ["oseltamivir", "TREATMENT", 62, 73], ["resistant virus", "PROBLEM", 93, 108]]], ["During the 2008\u20132009 influenza season, in some parts of the world, such as the USA, Canada, the UK and Australia, very high rates (> 90%) of oseltamivir-resistant seasonal influenza A H1N1 strains were seen [23, 24].", [["influenza", "DISEASE", 21, 30], ["oseltamivir", "CHEMICAL", 141, 152], ["oseltamivir", "CHEMICAL", 141, 152], ["oseltamivir", "ORGANISM", 141, 152], ["seasonal influenza A H1N1", "ORGANISM", 163, 188], ["seasonal influenza A H1N1", "SPECIES", 163, 188], ["oseltamivir", "TREATMENT", 141, 152], ["resistant seasonal influenza A H1N1 strains", "PROBLEM", 153, 196]]], ["In 2009, the pandemic (pdm09) influenza A H1N1 strain emerged worldwide but in the majority of cases (< 1.5% resistance) remained oseltamivir susceptible initially.", [["oseltamivir", "CHEMICAL", 130, 141], ["oseltamivir", "CHEMICAL", 130, 141], ["pdm09) influenza A H1N1", "ORGANISM", 23, 46], ["influenza A H1N1", "SPECIES", 30, 46], ["influenza", "PROBLEM", 30, 39], ["A H1N1 strain", "PROBLEM", 40, 53], ["oseltamivir", "TREATMENT", 130, 141]]], ["Oseltamivir resistant H1N1 pdm09 cases did emerge but this was mostly immunocompromised patients that had received oseltamivir.", [["Oseltamivir", "CHEMICAL", 0, 11], ["oseltamivir", "CHEMICAL", 115, 126], ["Oseltamivir", "CHEMICAL", 0, 11], ["oseltamivir", "CHEMICAL", 115, 126], ["H1N1 pdm09", "ORGANISM", 22, 32], ["patients", "ORGANISM", 88, 96], ["oseltamivir", "SIMPLE_CHEMICAL", 115, 126], ["patients", "SPECIES", 88, 96], ["Oseltamivir resistant H1N1 pdm09 cases", "PROBLEM", 0, 38], ["oseltamivir", "TREATMENT", 115, 126], ["immunocompromised", "OBSERVATION", 70, 87]]], ["Subsequently, however, in the 2010\u20132011 influenza season in the UK (and other parts of the world), increasing numbers of oseltamivir resistant cases were identified with no previous oseltamivir exposure [25].", [["influenza", "DISEASE", 40, 49], ["oseltamivir", "CHEMICAL", 121, 132], ["oseltamivir", "CHEMICAL", 182, 193], ["oseltamivir", "CHEMICAL", 121, 132], ["oseltamivir", "CHEMICAL", 182, 193], ["oseltamivir resistant cases", "TREATMENT", 121, 148], ["previous oseltamivir exposure", "TREATMENT", 173, 202]]], ["Resistance to oseltamivir was still seen with much greater frequency in immunocompromised individuals receiving oseltamivir (with very little cross-resistance seen with zanamivir).Neuraminidase inhibitorsThe neuraminidase mutation responsible for the oseltamivir resistance that emerged in the seasonal influenza A H1N1 (A/Brisbane/59/2007-like) strain in 2007 and then in the 2009 H1N1 pdm09 and also subsequent H1N1 strains is the H275Y mutation; a histidine to tyrosine substitution at amino acid 275 of the influenza A N1 neuraminidase [26, 27].", [["oseltamivir", "CHEMICAL", 14, 25], ["oseltamivir", "CHEMICAL", 112, 123], ["zanamivir", "CHEMICAL", 169, 178], ["oseltamivir", "CHEMICAL", 251, 262], ["histidine", "CHEMICAL", 451, 460], ["tyrosine", "CHEMICAL", 464, 472], ["amino acid 275", "CHEMICAL", 489, 503], ["oseltamivir", "CHEMICAL", 14, 25], ["oseltamivir", "CHEMICAL", 112, 123], ["zanamivir", "CHEMICAL", 169, 178], ["oseltamivir", "CHEMICAL", 251, 262], ["histidine", "CHEMICAL", 451, 460], ["tyrosine", "CHEMICAL", 464, 472], ["amino acid", "CHEMICAL", 489, 499], ["oseltamivir", "SIMPLE_CHEMICAL", 14, 25], ["oseltamivir", "SIMPLE_CHEMICAL", 112, 123], ["zanamivir", "SIMPLE_CHEMICAL", 169, 178], ["Neuraminidase", "GENE_OR_GENE_PRODUCT", 180, 193], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 208, 221], ["influenza A H1N1", "ORGANISM", 303, 319], ["A/Brisbane/59/2007-like", "ORGANISM", 321, 344], ["2009 H1N1 pdm09", "ORGANISM", 377, 392], ["histidine", "AMINO_ACID", 451, 460], ["tyrosine", "AMINO_ACID", 464, 472], ["amino acid", "AMINO_ACID", 489, 499], ["275", "AMINO_ACID", 500, 503], ["influenza A H1N1", "SPECIES", 303, 319], ["A H1N1 (A/Brisbane/59/2007", "SPECIES", 313, 339], ["2009 H1N1 pdm09", "SPECIES", 377, 392], ["oseltamivir", "TREATMENT", 14, 25], ["oseltamivir", "TREATMENT", 112, 123], ["zanamivir", "TREATMENT", 169, 178], ["Neuraminidase inhibitors", "TREATMENT", 180, 204], ["The neuraminidase mutation", "PROBLEM", 204, 230], ["the oseltamivir resistance", "PROBLEM", 247, 273], ["the seasonal influenza A H1N1", "PROBLEM", 290, 319], ["strain", "PROBLEM", 346, 352], ["pdm09", "PROBLEM", 387, 392], ["subsequent H1N1 strains", "PROBLEM", 402, 425], ["the H275Y mutation", "PROBLEM", 429, 447], ["a histidine to tyrosine substitution", "TREATMENT", 449, 485], ["amino acid", "TEST", 489, 499], ["the influenza A N1 neuraminidase", "TREATMENT", 507, 539], ["oseltamivir", "OBSERVATION", 14, 25], ["immunocompromised", "OBSERVATION", 72, 89], ["neuraminidase mutation", "OBSERVATION", 208, 230]]], ["Normally when oseltamivir binds to the neuraminidase on the influenza virion, the neuraminidase active site changes shape to accommodate oseltamivir.", [["oseltamivir", "CHEMICAL", 14, 25], ["oseltamivir", "CHEMICAL", 137, 148], ["oseltamivir", "CHEMICAL", 14, 25], ["oseltamivir", "CHEMICAL", 137, 148], ["oseltamivir", "SIMPLE_CHEMICAL", 14, 25], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 39, 52], ["influenza virion", "ORGANISM", 60, 76], ["oseltamivir", "SIMPLE_CHEMICAL", 137, 148], ["neuraminidase", "PROTEIN", 39, 52], ["neuraminidase active site", "DNA", 82, 107], ["oseltamivir binds", "TREATMENT", 14, 31], ["the neuraminidase", "TREATMENT", 35, 52], ["the influenza virion", "TREATMENT", 56, 76], ["the neuraminidase active", "TREATMENT", 78, 102], ["oseltamivir", "TREATMENT", 137, 148]]], ["A neuraminidase mutation, such as H275Y, prevents this conformational change in the active site and therefore, oseltamivir is unable to bind.", [["oseltamivir", "CHEMICAL", 111, 122], ["oseltamivir", "CHEMICAL", 111, 122], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 2, 15], ["oseltamivir", "SIMPLE_CHEMICAL", 111, 122], ["A neuraminidase mutation", "PROBLEM", 0, 24], ["this conformational change in the active site", "PROBLEM", 50, 95], ["oseltamivir", "TREATMENT", 111, 122], ["neuraminidase mutation", "OBSERVATION", 2, 24]]], ["Zanamivir, however, does not require this structural change in the neuraminidase active site in order to bind [28].", [["Zanamivir", "CHEMICAL", 0, 9], ["Zanamivir", "CHEMICAL", 0, 9], ["Zanamivir", "SIMPLE_CHEMICAL", 0, 9], ["neuraminidase active site", "PROTEIN", 67, 92], ["Zanamivir", "TREATMENT", 0, 9], ["this structural change", "TREATMENT", 37, 59], ["the neuraminidase active site", "TREATMENT", 63, 92]]], ["The H275Y mutation reduces the susceptibility (IC50; the half maximal inhibitory concentration) of influenza A H1N1 to oseltamivir by approximately 400-fold but not zanamivir [13, 29].", [["oseltamivir", "CHEMICAL", 119, 130], ["zanamivir", "CHEMICAL", 165, 174], ["oseltamivir", "CHEMICAL", 119, 130], ["zanamivir", "CHEMICAL", 165, 174], ["H275Y", "GENE_OR_GENE_PRODUCT", 4, 9], ["influenza A H1N1", "ORGANISM", 99, 115], ["oseltamivir", "SIMPLE_CHEMICAL", 119, 130], ["zanamivir", "SIMPLE_CHEMICAL", 165, 174], ["influenza A H1N1", "SPECIES", 99, 115], ["influenza A H1N1", "SPECIES", 99, 115], ["The H275Y mutation", "PROBLEM", 0, 18], ["the susceptibility (IC50", "PROBLEM", 27, 51], ["the half maximal inhibitory concentration", "TREATMENT", 53, 94], ["influenza", "PROBLEM", 99, 108], ["oseltamivir", "TREATMENT", 119, 130], ["zanamivir", "TREATMENT", 165, 174]]], ["Peramivir binds to sialic acid residues in a similar manner to oseltamivir and is also affected by the H275Y mutation [30].", [["Peramivir", "CHEMICAL", 0, 9], ["sialic acid", "CHEMICAL", 19, 30], ["oseltamivir", "CHEMICAL", 63, 74], ["Peramivir", "CHEMICAL", 0, 9], ["sialic acid", "CHEMICAL", 19, 30], ["oseltamivir", "CHEMICAL", 63, 74], ["Peramivir", "SIMPLE_CHEMICAL", 0, 9], ["sialic acid", "SIMPLE_CHEMICAL", 19, 30], ["oseltamivir", "SIMPLE_CHEMICAL", 63, 74], ["Peramivir binds", "TREATMENT", 0, 15], ["sialic acid residues", "TREATMENT", 19, 39], ["oseltamivir", "TREATMENT", 63, 74], ["sialic acid", "OBSERVATION", 19, 30]]], ["This mutation has been shown to persist even after cessation of treatment, and strains harbouring this mutation are capable of causing outbreaks and significant morbidity and mortality in a similar fashion to their wild-type counterparts [14, 27].", [["This mutation", "PROBLEM", 0, 13], ["treatment", "TREATMENT", 64, 73], ["strains harbouring this mutation", "PROBLEM", 79, 111], ["outbreaks", "PROBLEM", 135, 144], ["significant morbidity", "PROBLEM", 149, 170], ["significant", "OBSERVATION_MODIFIER", 149, 160], ["morbidity", "OBSERVATION", 161, 170]]], ["Children and severely immunocompromised patients are at higher risk of developing resistance most likely due to higher viral loads and prolonged viral shedding [31].Neuraminidase inhibitorsDue to certain difference in the neuraminidase enzyme structure, neuraminidase resistance is less likely to occur in influenza A H3N2 and influenza B compared with A H1N1 pdm09 without causing significant loss of neuraminidase enzymatic function and reduced viral fitness [32, 33].", [["influenza A H3N2", "DISEASE", 306, 322], ["influenza B", "DISEASE", 327, 338], ["Children", "ORGANISM", 0, 8], ["patients", "ORGANISM", 40, 48], ["Neuraminidase", "GENE_OR_GENE_PRODUCT", 165, 178], ["neuraminidase enzyme", "GENE_OR_GENE_PRODUCT", 222, 242], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 254, 267], ["influenza A H3N2", "ORGANISM", 306, 322], ["influenza B", "ORGANISM", 327, 338], ["A H1N1 pdm09", "ORGANISM", 353, 365], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 402, 415], ["neuraminidase enzyme", "PROTEIN", 222, 242], ["neuraminidase", "PROTEIN", 254, 267], ["neuraminidase", "PROTEIN", 402, 415], ["Children", "SPECIES", 0, 8], ["patients", "SPECIES", 40, 48], ["influenza A H3N2", "SPECIES", 306, 322], ["A H1N1 pdm09", "SPECIES", 353, 365], ["influenza A H3N2", "SPECIES", 306, 322], ["A H1N1 pdm09", "SPECIES", 353, 365], ["severely immunocompromised", "PROBLEM", 13, 39], ["developing resistance", "PROBLEM", 71, 92], ["higher viral loads", "PROBLEM", 112, 130], ["prolonged viral shedding", "PROBLEM", 135, 159], ["Neuraminidase inhibitors", "TREATMENT", 165, 189], ["the neuraminidase enzyme structure", "PROBLEM", 218, 252], ["neuraminidase resistance", "PROBLEM", 254, 278], ["influenza", "PROBLEM", 306, 315], ["A H3N2", "PROBLEM", 316, 322], ["influenza B", "PROBLEM", 327, 338], ["A H1N1 pdm09", "PROBLEM", 353, 365], ["significant loss of neuraminidase enzymatic function", "PROBLEM", 382, 434], ["reduced viral fitness", "PROBLEM", 439, 460], ["severely", "OBSERVATION_MODIFIER", 13, 21], ["immunocompromised", "OBSERVATION", 22, 39], ["resistance", "OBSERVATION", 82, 92], ["viral loads", "OBSERVATION", 119, 130], ["neuraminidase resistance", "OBSERVATION", 254, 278], ["less likely", "UNCERTAINTY", 282, 293]]], ["In vitro and in vivo studies have demonstrated that influenza A H3N2 and influenza B neuraminidase inhibitor resistant strains have a lower replicative capacity and less ability to transmit.", [["influenza A H3N2", "ORGANISM", 52, 68], ["influenza B neuraminidase", "ORGANISM", 73, 98], ["influenza A H3N2", "SPECIES", 52, 68], ["influenza B neuraminidase", "SPECIES", 73, 98], ["A H3N2", "SPECIES", 62, 68], ["vivo studies", "TEST", 16, 28], ["influenza", "PROBLEM", 52, 61], ["A H3N2", "TREATMENT", 62, 68], ["influenza B neuraminidase inhibitor", "TREATMENT", 73, 108], ["resistant strains", "PROBLEM", 109, 126], ["a lower replicative capacity", "PROBLEM", 132, 160]]], ["In many of the case reports of influenza A H3N2 and B resistant strains, resistance only occurs after prolonged treatment (> 10 days but over 1 month in many) and these resistant variants often disappear once treatment is ceased [34, 35].", [["influenza A H3N2 and B", "DISEASE", 31, 53], ["influenza A H3N2", "ORGANISM", 31, 47], ["B resistant strains", "ORGANISM", 52, 71], ["influenza A H3N2", "SPECIES", 31, 47], ["influenza A H3N2", "SPECIES", 31, 47], ["influenza", "PROBLEM", 31, 40], ["A H3N2", "PROBLEM", 41, 47], ["B resistant strains", "PROBLEM", 52, 71], ["prolonged treatment", "TREATMENT", 102, 121], ["these resistant variants", "PROBLEM", 163, 187]]], ["Public Health England (PHE) publishes the most frequently observed influenza A and B mutations and their neuraminidase inhibitor resistance profiles in their \u2018Surveillance and Laboratory Testing of Influenza Neuraminidase Inhibitor Resistance\u2019 reports [36].", [["PHE", "CHEMICAL", 23, 26], ["Influenza", "DISEASE", 198, 207], ["B", "GENE_OR_GENE_PRODUCT", 83, 84], ["influenza", "PROBLEM", 67, 76], ["B mutations", "TREATMENT", 83, 94], ["their neuraminidase inhibitor", "TREATMENT", 99, 128], ["Laboratory Testing", "TEST", 176, 194], ["Influenza Neuraminidase Inhibitor", "TREATMENT", 198, 231]]], ["Table 1 summarises the Centers for Disease Control and Prevention (CDC) and PHE resistance data for the USA and UK, respectively.Neuraminidase inhibitorsThe Influenza Resistance Information Study (IRIS) was a multicentre global observational study of neuraminidase inhibitor resistance and clinical outcomes in immunocompetent patients conducted from 2008 to 2013 [37].", [["PHE", "CHEMICAL", 76, 79], ["Influenza", "DISEASE", 157, 166], ["Neuraminidase", "GENE_OR_GENE_PRODUCT", 129, 142], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 251, 264], ["patients", "ORGANISM", 327, 335], ["patients", "SPECIES", 327, 335], ["Disease Control", "TREATMENT", 35, 50], ["PHE resistance data", "TEST", 76, 95], ["Neuraminidase inhibitors", "TREATMENT", 129, 153], ["neuraminidase inhibitor resistance", "TREATMENT", 251, 285]]], ["This study included patients over 1 year of age presenting within 24 hours of an influenza-like illness and/or had a positive rapid influenza test.", [["influenza-like illness", "DISEASE", 81, 103], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["This study", "TEST", 0, 10], ["an influenza-like illness", "PROBLEM", 78, 103], ["a positive rapid influenza test", "PROBLEM", 115, 146], ["influenza", "OBSERVATION", 81, 90]]], ["Nose throat swabs were collected on days 1, 3, 6 and 10 for influenza typing/subtyping, sequencing and neuraminidase inhibitor phenotypic susceptibility testing.", [["Nose throat swabs", "ANATOMY", 0, 17], ["Nose throat swabs", "ORGANISM_SUBSTANCE", 0, 17], ["Nose throat swabs", "TEST", 0, 17], ["influenza typing", "TEST", 60, 76], ["sequencing", "TEST", 88, 98], ["neuraminidase inhibitor", "TREATMENT", 103, 126], ["phenotypic susceptibility testing", "TEST", 127, 160], ["throat", "ANATOMY", 5, 11]]], ["There were 3230 influenza A and B reverse-transcription polymerase chain reaction (RT-PCR) positive patients in the study.", [["B reverse-transcription polymerase chain", "GENE_OR_GENE_PRODUCT", 32, 72], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["influenza", "PROBLEM", 16, 25], ["RT-PCR", "TEST", 83, 89], ["the study", "TEST", 112, 121]]], ["Except for 30 patients with pre-treatment (i.e. transmitted) resistant influenza A H1N1 strains, no resistance was detected in day 1 samples.", [["samples", "ANATOMY", 133, 140], ["influenza", "DISEASE", 71, 80], ["patients", "ORGANISM", 14, 22], ["influenza A H1N1", "ORGANISM", 71, 87], ["patients", "SPECIES", 14, 22], ["influenza A H1N1", "SPECIES", 71, 87], ["A H1N1", "SPECIES", 81, 87], ["pre-treatment", "TREATMENT", 28, 41], ["transmitted) resistant influenza A H1N1 strains", "PROBLEM", 48, 95], ["resistance", "PROBLEM", 100, 110], ["no", "UNCERTAINTY", 97, 99]]], ["Emergence of oseltamivir resistance after day 1 was detected in 43/1207 (3.56%) of oseltamivir-treated influenza A positive patients; a higher frequency was seen in 1\u20135 year old (11.8%) compared with those over 5 years (1.4%).", [["oseltamivir", "CHEMICAL", 13, 24], ["oseltamivir", "CHEMICAL", 83, 94], ["influenza A positive", "DISEASE", 103, 123], ["oseltamivir", "CHEMICAL", 13, 24], ["oseltamivir", "CHEMICAL", 83, 94], ["oseltamivir", "SIMPLE_CHEMICAL", 83, 94], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["oseltamivir resistance", "TREATMENT", 13, 35], ["oseltamivir", "TREATMENT", 83, 94], ["influenza", "PROBLEM", 103, 112], ["oseltamivir resistance", "OBSERVATION", 13, 35]]], ["All resistant H1N1 viruses had the H275Y mutation and all resistant H3N2 viruses had the R292K mutation (conferring reduced susceptibility to both oseltamivir and zanamivir).", [["oseltamivir", "CHEMICAL", 147, 158], ["zanamivir", "CHEMICAL", 163, 172], ["oseltamivir", "CHEMICAL", 147, 158], ["zanamivir", "CHEMICAL", 163, 172], ["H1N1 viruses", "ORGANISM", 14, 26], ["H275Y", "GENE_OR_GENE_PRODUCT", 35, 40], ["H3N2 viruses", "ORGANISM", 68, 80], ["R292K", "GENE_OR_GENE_PRODUCT", 89, 94], ["oseltamivir", "SIMPLE_CHEMICAL", 147, 158], ["zanamivir", "SIMPLE_CHEMICAL", 163, 172], ["H1N1 viruses", "SPECIES", 14, 26], ["All resistant H1N1 viruses", "PROBLEM", 0, 26], ["the H275Y mutation", "PROBLEM", 31, 49], ["all resistant H3N2 viruses", "PROBLEM", 54, 80], ["the R292K mutation", "PROBLEM", 85, 103], ["oseltamivir", "TREATMENT", 147, 158], ["zanamivir", "TREATMENT", 163, 172], ["resistant", "OBSERVATION_MODIFIER", 4, 13], ["H1N1", "OBSERVATION", 14, 18]]], ["Virus clearance was a median of 8.1 days for treated patients with oseltamivir-resistant virus vs 9.9 days for untreated patients vs 10.9 days for treated patients with oseltamivir-resistant virus.", [["oseltamivir", "CHEMICAL", 67, 78], ["oseltamivir", "CHEMICAL", 169, 180], ["oseltamivir", "CHEMICAL", 67, 78], ["oseltamivir", "CHEMICAL", 169, 180], ["Virus", "ORGANISM", 0, 5], ["patients", "ORGANISM", 53, 61], ["oseltamivir", "SIMPLE_CHEMICAL", 67, 78], ["patients", "ORGANISM", 121, 129], ["patients", "ORGANISM", 155, 163], ["oseltamivir-resistant virus", "ORGANISM", 169, 196], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 121, 129], ["patients", "SPECIES", 155, 163], ["Virus clearance", "TEST", 0, 15], ["oseltamivir", "TREATMENT", 67, 78], ["resistant virus", "PROBLEM", 79, 94], ["oseltamivir", "TREATMENT", 169, 180], ["resistant virus", "PROBLEM", 181, 196]]], ["Time to alleviation of symptoms was 1 day shorter in treated patients as compared with untreated patients.", [["patients", "ORGANISM", 61, 69], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 97, 105], ["symptoms", "PROBLEM", 23, 31]]], ["Interestingly, the oseltamivir-resistant treated group exhibited the shortest duration of symptoms (symptoms resolved by day 6 or earlier).Neuraminidase inhibitorsDual resistance to oseltamivir and zanamivir is rare.", [["oseltamivir", "CHEMICAL", 19, 30], ["oseltamivir", "CHEMICAL", 182, 193], ["zanamivir", "CHEMICAL", 198, 207], ["oseltamivir", "CHEMICAL", 19, 30], ["oseltamivir", "CHEMICAL", 182, 193], ["zanamivir", "CHEMICAL", 198, 207], ["oseltamivir", "SIMPLE_CHEMICAL", 19, 30], ["Neuraminidase", "GENE_OR_GENE_PRODUCT", 139, 152], ["oseltamivir", "SIMPLE_CHEMICAL", 182, 193], ["zanamivir", "SIMPLE_CHEMICAL", 198, 207], ["the oseltamivir", "TREATMENT", 15, 30], ["symptoms", "PROBLEM", 90, 98], ["symptoms", "PROBLEM", 100, 108], ["Neuraminidase inhibitors", "TREATMENT", 139, 163], ["oseltamivir", "TREATMENT", 182, 193], ["zanamivir", "TREATMENT", 198, 207], ["resistance", "OBSERVATION", 168, 178], ["oseltamivir", "OBSERVATION", 182, 193]]], ["A literature review by Abed et al. identified 14 published cases of human influenza A and B infections with mutations conferring reduced susceptibility to both oseltamivir and zanamivir [38].", [["influenza A and B infections", "DISEASE", 74, 102], ["oseltamivir", "CHEMICAL", 160, 171], ["zanamivir", "CHEMICAL", 176, 185], ["oseltamivir", "CHEMICAL", 160, 171], ["zanamivir", "CHEMICAL", 176, 185], ["human", "ORGANISM", 68, 73], ["influenza A", "ORGANISM", 74, 85], ["B", "CANCER", 90, 91], ["oseltamivir", "SIMPLE_CHEMICAL", 160, 171], ["zanamivir", "SIMPLE_CHEMICAL", 176, 185], ["human", "SPECIES", 68, 73], ["human influenza A", "SPECIES", 68, 85], ["human influenza A", "PROBLEM", 68, 85], ["B infections", "PROBLEM", 90, 102], ["mutations", "PROBLEM", 108, 117], ["reduced susceptibility", "PROBLEM", 129, 151], ["oseltamivir", "TREATMENT", 160, 171], ["zanamivir", "TREATMENT", 176, 185]]], ["Seven had influenza A H1N1 pdm09, 4 had influenza A H3N2, 1 had avian influenza A H7N9 and 2 had influenza B. The age range was 8 months to 88 years and 12 out of the 14 patients were immunocompromised.", [["influenza A H1N1 pdm09", "DISEASE", 10, 32], ["influenza A H3N2", "DISEASE", 40, 56], ["influenza A H7N9", "DISEASE", 70, 86], ["influenza B.", "DISEASE", 97, 109], ["influenza A H1N1 pdm09", "ORGANISM", 10, 32], ["influenza A H3N2", "ORGANISM", 40, 56], ["avian", "ORGANISM", 64, 69], ["influenza A H7N9", "ORGANISM", 70, 86], ["patients", "ORGANISM", 170, 178], ["influenza", "SPECIES", 10, 19], ["A H1N1 pdm09", "SPECIES", 20, 32], ["influenza A H3N2", "SPECIES", 40, 56], ["avian influenza A H7N9", "SPECIES", 64, 86], ["patients", "SPECIES", 170, 178], ["influenza A H1N1 pdm09", "SPECIES", 10, 32], ["H7N9", "SPECIES", 82, 86], ["influenza A H1N1 pdm09", "PROBLEM", 10, 32], ["influenza A H3N2", "PROBLEM", 40, 56], ["avian influenza A H7N9", "PROBLEM", 64, 86], ["influenza B.", "PROBLEM", 97, 109], ["immunocompromised", "PROBLEM", 184, 201], ["immunocompromised", "OBSERVATION", 184, 201]]], ["The other two patients had underlying chronic lung disease.", [["lung", "ANATOMY", 46, 50], ["chronic lung disease", "DISEASE", 38, 58], ["patients", "ORGANISM", 14, 22], ["lung", "ORGAN", 46, 50], ["patients", "SPECIES", 14, 22], ["underlying chronic lung disease", "PROBLEM", 27, 58], ["chronic", "OBSERVATION_MODIFIER", 38, 45], ["lung", "ANATOMY", 46, 50], ["disease", "OBSERVATION", 51, 58]]], ["Thirteen out of 14 patients had received neuraminidase inhibitor therapy before emergence resistance mutations (5 oseltamivir alone, 2 oseltamivir then zanamivir, 2 zanamivir alone, 3 zanamivir and oseltamivir simultaneously, 1 oseltamivir then peramivir).", [["neuraminidase inhibitor", "CHEMICAL", 41, 64], ["oseltamivir", "CHEMICAL", 114, 125], ["oseltamivir", "CHEMICAL", 135, 146], ["zanamivir", "CHEMICAL", 152, 161], ["zanamivir", "CHEMICAL", 165, 174], ["zanamivir", "CHEMICAL", 184, 193], ["oseltamivir", "CHEMICAL", 198, 209], ["oseltamivir", "CHEMICAL", 228, 239], ["peramivir", "CHEMICAL", 245, 254], ["oseltamivir", "CHEMICAL", 114, 125], ["oseltamivir", "CHEMICAL", 135, 146], ["zanamivir", "CHEMICAL", 152, 161], ["zanamivir", "CHEMICAL", 165, 174], ["zanamivir", "CHEMICAL", 184, 193], ["oseltamivir", "CHEMICAL", 198, 209], ["oseltamivir", "CHEMICAL", 228, 239], ["peramivir", "CHEMICAL", 245, 254], ["patients", "ORGANISM", 19, 27], ["zanamivir", "SIMPLE_CHEMICAL", 152, 161], ["zanamivir", "SIMPLE_CHEMICAL", 165, 174], ["zanamivir", "SIMPLE_CHEMICAL", 184, 193], ["oseltamivir", "SIMPLE_CHEMICAL", 198, 209], ["oseltamivir", "SIMPLE_CHEMICAL", 228, 239], ["peramivir", "SIMPLE_CHEMICAL", 245, 254], ["patients", "SPECIES", 19, 27], ["neuraminidase inhibitor therapy", "TREATMENT", 41, 72], ["emergence resistance mutations", "TREATMENT", 80, 110], ["5 oseltamivir alone", "TREATMENT", 112, 131], ["oseltamivir", "TREATMENT", 135, 146], ["zanamivir", "TREATMENT", 152, 161], ["2 zanamivir alone", "TREATMENT", 163, 180], ["3 zanamivir", "TREATMENT", 182, 193], ["oseltamivir", "TREATMENT", 198, 209], ["1 oseltamivir", "TREATMENT", 226, 239], ["peramivir", "TREATMENT", 245, 254]]], ["There was a mean of 12.76 days (range 0\u201372 days) treatment before detection of the first mutation.", [["treatment", "TREATMENT", 49, 58], ["the first mutation", "PROBLEM", 79, 97]]], ["Mortality was high at 71% (10/14 patients).", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["Mortality", "TEST", 0, 9], ["high", "OBSERVATION_MODIFIER", 14, 18]]], ["Of the 4 survivors, there was an immunocompetent asthmatic child with H1N1 pdm09 who received no treatment, 1 immunocompromised adult with H1N1 pdm09 who received oseltamivir for 14 days then inhaled zanamivir for 40 days, 1 immunocompromised adult with H3N2 who had 5 days of oseltamivir and 1 immunocompromised child with H3N2 who received oseltamivir for 3 months and then inhaled zanamivir for 72 days.Neuraminidase inhibitorsIn a recently published UK series of three cases of oseltamivir-resistant influenza A H1N1 pdm09 that occurred in England in immunocompetent patients in the 2018\u20132019 influenza season, two of the patients (a 7-week old previously well boy and a 39-year old asthmatic woman) made a good recovery with 5 days of oseltamivir despite whole genome sequencing revealing H275Y mutations in 44% and 100% of the virus population, respectively [39].", [["oseltamivir", "CHEMICAL", 163, 174], ["zanamivir", "CHEMICAL", 200, 209], ["H3N2", "DISEASE", 254, 258], ["oseltamivir", "CHEMICAL", 277, 288], ["H3N2", "DISEASE", 324, 328], ["oseltamivir", "CHEMICAL", 342, 353], ["zanamivir", "CHEMICAL", 384, 393], ["oseltamivir", "CHEMICAL", 482, 493], ["influenza A H1N1 pdm09", "DISEASE", 504, 526], ["influenza", "DISEASE", 597, 606], ["oseltamivir", "CHEMICAL", 740, 751], ["oseltamivir", "CHEMICAL", 163, 174], ["zanamivir", "CHEMICAL", 200, 209], ["oseltamivir", "CHEMICAL", 277, 288], ["oseltamivir", "CHEMICAL", 342, 353], ["zanamivir", "CHEMICAL", 384, 393], ["oseltamivir", "CHEMICAL", 482, 493], ["oseltamivir", "CHEMICAL", 740, 751], ["child", "ORGANISM", 59, 64], ["zanamivir", "SIMPLE_CHEMICAL", 200, 209], ["child", "ORGANISM", 313, 318], ["zanamivir", "SIMPLE_CHEMICAL", 384, 393], ["Neuraminidase", "GENE_OR_GENE_PRODUCT", 406, 419], ["oseltamivir", "ORGANISM", 482, 493], ["influenza A H1N1 pdm09", "ORGANISM", 504, 526], ["patients", "ORGANISM", 571, 579], ["patients", "ORGANISM", 626, 634], ["boy", "ORGANISM", 665, 668], ["woman", "ORGANISM", 697, 702], ["oseltamivir", "SIMPLE_CHEMICAL", 740, 751], ["H275Y", "GENE_OR_GENE_PRODUCT", 794, 799], ["influenza A H1N1", "SPECIES", 504, 520], ["patients", "SPECIES", 571, 579], ["patients", "SPECIES", 626, 634], ["boy", "SPECIES", 665, 668], ["woman", "SPECIES", 697, 702], ["H1N1", "PROBLEM", 70, 74], ["treatment", "TREATMENT", 97, 106], ["H1N1", "PROBLEM", 139, 143], ["oseltamivir", "TREATMENT", 163, 174], ["inhaled zanamivir", "TREATMENT", 192, 209], ["H3N2", "PROBLEM", 254, 258], ["oseltamivir", "TREATMENT", 277, 288], ["H3N2", "PROBLEM", 324, 328], ["oseltamivir", "TREATMENT", 342, 353], ["inhaled zanamivir", "TREATMENT", 376, 393], ["Neuraminidase inhibitors", "TREATMENT", 406, 430], ["oseltamivir", "TREATMENT", 482, 493], ["resistant influenza A H1N1 pdm09", "PROBLEM", 494, 526], ["oseltamivir", "TREATMENT", 740, 751], ["whole genome sequencing", "TEST", 760, 783], ["H275Y mutations", "PROBLEM", 794, 809], ["the virus population", "PROBLEM", 829, 849], ["immunocompetent", "OBSERVATION_MODIFIER", 33, 48], ["asthmatic", "OBSERVATION", 49, 58]]], ["The third case was a 15-month old girl with a developmental condition (Najer syndrome) admitted with a 1-day history of respiratory illness who showed minimal clinical improvement with 15 days of oseltamivir after which she was switched to intravenous zanamivir (as well as receiving antibiotics) and died soon after.", [["respiratory", "ANATOMY", 120, 131], ["intravenous", "ANATOMY", 240, 251], ["Najer syndrome", "DISEASE", 71, 85], ["respiratory illness", "DISEASE", 120, 139], ["oseltamivir", "CHEMICAL", 196, 207], ["zanamivir", "CHEMICAL", 252, 261], ["oseltamivir", "CHEMICAL", 196, 207], ["zanamivir", "CHEMICAL", 252, 261], ["girl", "ORGANISM", 34, 38], ["oseltamivir", "SIMPLE_CHEMICAL", 196, 207], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 240, 251], ["zanamivir", "SIMPLE_CHEMICAL", 252, 261], ["girl", "SPECIES", 34, 38], ["a developmental condition", "PROBLEM", 44, 69], ["Najer syndrome", "PROBLEM", 71, 85], ["respiratory illness", "PROBLEM", 120, 139], ["oseltamivir", "TREATMENT", 196, 207], ["intravenous zanamivir", "TREATMENT", 240, 261], ["antibiotics", "TREATMENT", 284, 295], ["respiratory", "ANATOMY", 120, 131], ["illness", "OBSERVATION", 132, 139], ["minimal", "OBSERVATION_MODIFIER", 151, 158]]], ["PHE sequencing data later revealed H275Y mutations in 35% of the virus population in a day 5 nasopharyngeal aspirate specimen and this rapidly rose to 80% of the virus population harbouring H275Y mutations 1 day later in a day 6 nasopharyngeal aspirate sample.Neuraminidase inhibitorsThe treatment of influenza as recommended by PHE is oseltamivir as first line for immunocompetent children and adults [40].", [["nasopharyngeal aspirate specimen", "ANATOMY", 93, 125], ["nasopharyngeal aspirate sample", "ANATOMY", 229, 259], ["PHE", "CHEMICAL", 0, 3], ["influenza", "DISEASE", 301, 310], ["PHE", "CHEMICAL", 329, 332], ["oseltamivir", "CHEMICAL", 336, 347], ["PHE", "CHEMICAL", 329, 332], ["oseltamivir", "CHEMICAL", 336, 347], ["H275Y", "GENE_OR_GENE_PRODUCT", 35, 40], ["Neuraminidase", "GENE_OR_GENE_PRODUCT", 260, 273], ["influenza", "ORGANISM", 301, 310], ["PHE", "SIMPLE_CHEMICAL", 329, 332], ["oseltamivir", "SIMPLE_CHEMICAL", 336, 347], ["children", "ORGANISM", 382, 390], ["children", "SPECIES", 382, 390], ["PHE sequencing data", "TEST", 0, 19], ["H275Y mutations", "PROBLEM", 35, 50], ["the virus population", "PROBLEM", 61, 81], ["nasopharyngeal aspirate specimen", "TEST", 93, 125], ["nasopharyngeal aspirate sample", "TEST", 229, 259], ["Neuraminidase inhibitors", "TREATMENT", 260, 284], ["influenza", "PROBLEM", 301, 310], ["oseltamivir", "TREATMENT", 336, 347], ["nasopharyngeal", "ANATOMY", 229, 243]]], ["For immunosuppressed patients, neuraminidase inhibitor choice is based on the dominant circulating strain in that particular season; oseltamivir is recommended when the dominant circulating strain is of lower risk for oseltamivir resistance (i.e. influenza A H3N2 or B) and zanamivir is recommended when the dominant strain has a higher risk of oseltamivir resistance (e.g. H1N1 pdm09).", [["oseltamivir", "CHEMICAL", 133, 144], ["oseltamivir", "CHEMICAL", 218, 229], ["influenza A H3N2 or B", "CHEMICAL", 247, 268], ["zanamivir", "CHEMICAL", 274, 283], ["oseltamivir", "CHEMICAL", 345, 356], ["oseltamivir", "CHEMICAL", 133, 144], ["oseltamivir", "CHEMICAL", 218, 229], ["zanamivir", "CHEMICAL", 274, 283], ["oseltamivir", "CHEMICAL", 345, 356], ["patients", "ORGANISM", 21, 29], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 31, 44], ["oseltamivir", "SIMPLE_CHEMICAL", 133, 144], ["oseltamivir", "SIMPLE_CHEMICAL", 218, 229], ["influenza A H3N2", "ORGANISM", 247, 263], ["B", "GENE_OR_GENE_PRODUCT", 267, 268], ["zanamivir", "SIMPLE_CHEMICAL", 274, 283], ["oseltamivir", "SIMPLE_CHEMICAL", 345, 356], ["patients", "SPECIES", 21, 29], ["influenza A H3N2", "SPECIES", 247, 263], ["immunosuppressed patients", "TREATMENT", 4, 29], ["neuraminidase inhibitor choice", "TREATMENT", 31, 61], ["the dominant circulating strain", "PROBLEM", 74, 105], ["oseltamivir", "TREATMENT", 133, 144], ["the dominant circulating strain", "PROBLEM", 165, 196], ["oseltamivir resistance", "PROBLEM", 218, 240], ["influenza", "PROBLEM", 247, 256], ["A H3N2", "TREATMENT", 257, 263], ["zanamivir", "TREATMENT", 274, 283], ["the dominant strain", "PROBLEM", 304, 323], ["oseltamivir resistance", "PROBLEM", 345, 367], ["oseltamivir resistance", "OBSERVATION", 345, 367]]], ["Currently, available PHE date for the 2019\u20132020 influenza season indicates that influenza A H3N2 is the dominant circulating strain [41].", [["PHE", "CHEMICAL", 21, 24], ["influenza", "DISEASE", 48, 57], ["influenza A H3N2", "DISEASE", 80, 96], ["influenza A H3N2", "ORGANISM", 80, 96], ["influenza A H3N2", "SPECIES", 80, 96], ["A H3N2", "SPECIES", 90, 96], ["influenza", "PROBLEM", 48, 57], ["influenza", "PROBLEM", 80, 89], ["the dominant circulating strain", "PROBLEM", 100, 131]]], ["In many laboratories, typing/subtyping results are becoming available early in the treatment course therefore guiding selection of treatment.Neuraminidase inhibitor susceptibility testingNeuraminidase inhibitor susceptibility testing should be considered particularly in young children and immunocompromised patients being treated with a neuraminidase inhibitor for influenza (especially H1N1 pdm09), who are not responding to treatment and/or have persistently high viral loads (low cycle threshold values using RT-PCR) and/or exposed to a suspected or confirmed resistant case.", [["Neuraminidase inhibitor", "CHEMICAL", 187, 210], ["influenza", "DISEASE", 366, 375], ["Neuraminidase inhibitor", "GENE_OR_GENE_PRODUCT", 141, 164], ["Neuraminidase inhibitor", "GENE_OR_GENE_PRODUCT", 187, 210], ["children", "ORGANISM", 277, 285], ["patients", "ORGANISM", 308, 316], ["H1N1 pdm09", "ORGANISM", 388, 398], ["children", "SPECIES", 277, 285], ["patients", "SPECIES", 308, 316], ["typing/subtyping", "TEST", 22, 38], ["treatment", "TREATMENT", 131, 140], ["Neuraminidase inhibitor susceptibility testingNeuraminidase inhibitor", "TREATMENT", 141, 210], ["susceptibility testing", "TEST", 211, 233], ["a neuraminidase inhibitor", "TREATMENT", 336, 361], ["influenza", "PROBLEM", 366, 375], ["treatment", "TREATMENT", 427, 436], ["persistently high viral loads", "PROBLEM", 449, 478], ["low cycle threshold values", "PROBLEM", 480, 506], ["RT-PCR", "TEST", 513, 519]]], ["Given that resistance variants can emerge within only 1\u20132 days of treatment (as well as can be transmitted), resistance testing can be performed at any time prior to, during or after treatment.", [["resistance variants", "PROBLEM", 11, 30], ["treatment", "TREATMENT", 66, 75], ["resistance testing", "TEST", 109, 127], ["treatment", "TREATMENT", 183, 192]]], ["In England, PHE offers both genotypic and phenotypic influenza A and B susceptibility testing which is summarised in Table 2 [36].Neuraminidase inhibitor susceptibility testingRelatively newer techniques also exist such as pyrosequencing, a high-throughput sequencing method that is able to type/subtype, screen for mutations and delineate the relative proportions of the various influenza variants [42, 43].", [["PHE", "CHEMICAL", 12, 15], ["Neuraminidase", "GENE_OR_GENE_PRODUCT", 130, 143], ["phenotypic influenza A", "PROBLEM", 42, 64], ["B susceptibility testing", "TEST", 69, 93], ["Neuraminidase inhibitor", "TREATMENT", 130, 153], ["susceptibility testing", "TEST", 154, 176], ["pyrosequencing", "TEST", 223, 237], ["a high-throughput sequencing method", "PROBLEM", 239, 274], ["mutations", "PROBLEM", 316, 325], ["the various influenza variants", "PROBLEM", 368, 398]]], ["Another molecular technique, digital PCR (using a droplet-based system) has been shown to be highly accurate and precise in the identification and quantification of influenza sequence variants with the ability to detect rare single nucleotide polymorphisms present at levels as low as 0.001% of the virus population [44\u201346].", [["Another molecular technique", "TEST", 0, 27], ["digital PCR", "TEST", 29, 40], ["a droplet-based system", "TREATMENT", 48, 70], ["influenza sequence variants", "PROBLEM", 165, 192], ["rare single nucleotide polymorphisms", "PROBLEM", 220, 256]]], ["From a direct clinical perspective, identification of variants at such low proportions may not be relevant but these techniques may provide further insights into the viral dynamics in the emergence of resistant influenza viruses.Novel influenza therapiesBaloxavir marboxil is a single dose oral agent for the treatment of influenza A and B (no data for it is used of prophylaxis).", [["oral", "ANATOMY", 290, 294], ["influenza viruses", "DISEASE", 211, 228], ["Baloxavir marboxil", "CHEMICAL", 254, 272], ["influenza A and B", "DISEASE", 322, 339], ["Baloxavir marboxil", "CHEMICAL", 254, 272], ["influenza viruses", "ORGANISM", 211, 228], ["Baloxavir marboxil", "SIMPLE_CHEMICAL", 254, 272], ["oral", "ORGANISM_SUBDIVISION", 290, 294], ["variants", "PROBLEM", 54, 62], ["the viral dynamics", "PROBLEM", 162, 180], ["resistant influenza viruses", "PROBLEM", 201, 228], ["Novel influenza therapies", "TREATMENT", 229, 254], ["Baloxavir marboxil", "TREATMENT", 254, 272], ["a single dose oral agent", "TREATMENT", 276, 300], ["the treatment", "TREATMENT", 305, 318], ["influenza", "PROBLEM", 322, 331], ["prophylaxis", "TREATMENT", 367, 378], ["influenza viruses", "OBSERVATION", 211, 228]]], ["It was licensed in Japan and USA in 2018 but is not currently licensed in the UK.", [["UK", "GENE_OR_GENE_PRODUCT", 78, 80]]], ["It suppresses influenza replication by inhibition of cap-dependent endonuclease (an enzyme required for initiation of influenza mRNA synthesis) and therefore, its mechanism of action is different to that of the neuraminidase inhibitors [47].", [["cap-dependent endonuclease", "GENE_OR_GENE_PRODUCT", 53, 79], ["cap-dependent endonuclease", "PROTEIN", 53, 79], ["influenza mRNA", "RNA", 118, 132], ["influenza replication", "TREATMENT", 14, 35], ["cap-dependent endonuclease", "TREATMENT", 53, 79], ["an enzyme", "TEST", 81, 90], ["influenza mRNA synthesis", "TREATMENT", 118, 142], ["the neuraminidase inhibitors", "TREATMENT", 207, 235], ["influenza replication", "OBSERVATION", 14, 35]]], ["There is limited data on resistance but a recent US/Japan randomised controlled study of healthy adults/adolescents with influenza A and B treated with baloxavir marboxil found that 9.7% (36/370) developed a specific mutation (PA/I38X) 3\u20139 days after treatment and that the emergence of these PA/I38X variants was associated with higher viral loads, prolonged detection of virus and a longer duration of symptoms compared with baloxavir marboxil treated individuals who did not develop the PA/I38X mutation [48].Novel influenza therapiesFavipiravir is an oral (and intravenous) antiviral which inhibits RNA-dependent RNA polymerases [49, 50].", [["oral", "ANATOMY", 555, 559], ["intravenous", "ANATOMY", 565, 576], ["influenza A and B", "DISEASE", 121, 138], ["baloxavir marboxil", "CHEMICAL", 152, 170], ["baloxavir marboxil", "CHEMICAL", 427, 445], ["Favipiravir", "CHEMICAL", 537, 548], ["baloxavir marboxil", "CHEMICAL", 152, 170], ["baloxavir marboxil", "CHEMICAL", 427, 445], ["Favipiravir", "CHEMICAL", 537, 548], ["adolescents", "ORGANISM", 104, 115], ["B", "CANCER", 137, 138], ["baloxavir marboxil", "SIMPLE_CHEMICAL", 152, 170], ["PA", "GENE_OR_GENE_PRODUCT", 293, 295], ["I38X", "GENE_OR_GENE_PRODUCT", 296, 300], ["baloxavir marboxil", "SIMPLE_CHEMICAL", 427, 445], ["PA", "GENE_OR_GENE_PRODUCT", 490, 492], ["Favipiravir", "SIMPLE_CHEMICAL", 537, 548], ["oral", "ORGANISM_SUBDIVISION", 555, 559], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 565, 576], ["RNA-dependent RNA polymerases", "PROTEIN", 603, 632], ["adolescents", "SPECIES", 104, 115], ["a recent US", "TEST", 40, 51], ["influenza A", "PROBLEM", 121, 132], ["baloxavir marboxil", "TREATMENT", 152, 170], ["a specific mutation", "PROBLEM", 206, 225], ["treatment", "TREATMENT", 251, 260], ["these PA/I38X variants", "PROBLEM", 287, 309], ["higher viral loads", "PROBLEM", 330, 348], ["virus", "PROBLEM", 373, 378], ["symptoms", "PROBLEM", 404, 412], ["baloxavir marboxil", "TREATMENT", 427, 445], ["Novel influenza therapies", "TREATMENT", 512, 537], ["Favipiravir", "TREATMENT", 537, 548], ["an oral (and intravenous) antiviral", "TREATMENT", 552, 587], ["dependent RNA polymerases", "PROBLEM", 607, 632]]], ["It has been approved for the treatment of influenza A and B in Japan with very strict regulation for clinical use and is intended to be reserved for pandemics causes by novel/re-emerging influenza strains resistant to other antivirals.", [["influenza A and B", "DISEASE", 42, 59], ["pandemics", "DISEASE", 149, 158], ["influenza", "DISEASE", 187, 196], ["influenza A", "PROBLEM", 42, 53], ["pandemics", "PROBLEM", 149, 158], ["influenza strains", "PROBLEM", 187, 204], ["other antivirals", "TREATMENT", 218, 234]]], ["A recent study has demonstrated that a specific K229R mutation in the PB1 subunit of the influenza virus polymerase results in reduced susceptibility to favipiravir in vitro and in cell culture.", [["cell culture", "ANATOMY", 181, 193], ["favipiravir", "CHEMICAL", 153, 164], ["favipiravir", "CHEMICAL", 153, 164], ["K229R", "GENE_OR_GENE_PRODUCT", 48, 53], ["influenza virus", "ORGANISM", 89, 104], ["favipiravir", "SIMPLE_CHEMICAL", 153, 164], ["cell culture", "CELL", 181, 193], ["K229R", "PROTEIN", 48, 53], ["PB1 subunit", "PROTEIN", 70, 81], ["influenza virus polymerase", "PROTEIN", 89, 115], ["influenza virus", "SPECIES", 89, 104], ["influenza virus", "SPECIES", 89, 104], ["A recent study", "TEST", 0, 14], ["a specific K229R mutation", "PROBLEM", 37, 62], ["the influenza virus polymerase", "TEST", 85, 115], ["reduced susceptibility", "PROBLEM", 127, 149], ["favipiravir", "TREATMENT", 153, 164], ["cell culture", "TEST", 181, 193]]], ["Viral fitness, which was demonstrated to be impaired by this mutation, can be restored by a compensatory second (P653L) mutation [51].", [["Viral", "ORGANISM", 0, 5], ["Viral fitness", "PROBLEM", 0, 13], ["this mutation", "PROBLEM", 56, 69]]], ["The effects or these mutations in a clinical setting are yet to be determined.Experimental treatment strategiesHuman clinical trials of dual therapy with oseltamivir plus zanamivir for H1N1 have been investigated in various settings (including in ECMO patients) with varying outcomes and no clear benefit in terms of clinical outcome or prevention of drug resistance [52\u201354].", [["oseltamivir", "CHEMICAL", 154, 165], ["zanamivir", "CHEMICAL", 171, 180], ["H1N1", "DISEASE", 185, 189], ["oseltamivir", "CHEMICAL", 154, 165], ["zanamivir", "CHEMICAL", 171, 180], ["Human", "ORGANISM", 111, 116], ["oseltamivir", "SIMPLE_CHEMICAL", 154, 165], ["zanamivir", "SIMPLE_CHEMICAL", 171, 180], ["patients", "ORGANISM", 252, 260], ["Human", "SPECIES", 111, 116], ["patients", "SPECIES", 252, 260], ["these mutations", "PROBLEM", 15, 30], ["Experimental treatment strategies", "TREATMENT", 78, 111], ["dual therapy", "TREATMENT", 136, 148], ["oseltamivir", "TREATMENT", 154, 165], ["zanamivir", "TREATMENT", 171, 180], ["H1N1", "PROBLEM", 185, 189], ["drug resistance", "PROBLEM", 351, 366]]], ["Studies in mice also failed to show a benefit [55].Experimental treatment strategiesDouble dose oseltamivir did not reduce the risk of emergence of oseltamivir resistance in patients with influenza A H1N1 pdm09 [56].", [["oseltamivir", "CHEMICAL", 96, 107], ["oseltamivir", "CHEMICAL", 148, 159], ["oseltamivir", "CHEMICAL", 96, 107], ["oseltamivir", "CHEMICAL", 148, 159], ["mice", "ORGANISM", 11, 15], ["oseltamivir", "SIMPLE_CHEMICAL", 148, 159], ["patients", "ORGANISM", 174, 182], ["influenza A H1N1", "ORGANISM", 188, 204], ["mice", "SPECIES", 11, 15], ["patients", "SPECIES", 174, 182], ["influenza A H1N1", "SPECIES", 188, 204], ["mice", "SPECIES", 11, 15], ["Experimental treatment strategies", "TREATMENT", 51, 84], ["Double dose oseltamivir", "TREATMENT", 84, 107], ["oseltamivir resistance", "TREATMENT", 148, 170], ["influenza", "PROBLEM", 188, 197], ["oseltamivir resistance", "OBSERVATION", 148, 170]]], ["This study was a small (n = 52), randomised trial of patients treated in community.", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["This study", "TEST", 0, 10], ["small", "OBSERVATION_MODIFIER", 17, 22]]], ["One patient in the single dose group and one in the double dose group developed oseltamivir resistance.", [["oseltamivir", "CHEMICAL", 80, 91], ["oseltamivir", "CHEMICAL", 80, 91], ["patient", "ORGANISM", 4, 11], ["oseltamivir", "SIMPLE_CHEMICAL", 80, 91], ["patient", "SPECIES", 4, 11], ["oseltamivir resistance", "TREATMENT", 80, 102], ["oseltamivir resistance", "OBSERVATION", 80, 102]]], ["There was no mention of any immunocompromised patients in the study.Experimental treatment strategiesA triple-combination of amantadine, oseltamivir and ribavirin (TCAD regimen) was shown in vitro and in the mouse model to have synergistic activity against sensitive and resistant influenza viruses (with greater synergy than any double antiviral regimen) [57].", [["amantadine", "CHEMICAL", 125, 135], ["oseltamivir", "CHEMICAL", 137, 148], ["ribavirin", "CHEMICAL", 153, 162], ["TCAD regimen", "CHEMICAL", 164, 176], ["influenza viruses", "DISEASE", 281, 298], ["amantadine", "CHEMICAL", 125, 135], ["oseltamivir", "CHEMICAL", 137, 148], ["ribavirin", "CHEMICAL", 153, 162], ["TCAD", "CHEMICAL", 164, 168], ["patients", "ORGANISM", 46, 54], ["amantadine", "SIMPLE_CHEMICAL", 125, 135], ["oseltamivir", "SIMPLE_CHEMICAL", 137, 148], ["ribavirin", "SIMPLE_CHEMICAL", 153, 162], ["TCAD", "SIMPLE_CHEMICAL", 164, 168], ["mouse", "ORGANISM", 208, 213], ["influenza viruses", "ORGANISM", 281, 298], ["patients", "SPECIES", 46, 54], ["mouse", "SPECIES", 208, 213], ["mouse", "SPECIES", 208, 213], ["the study", "TEST", 58, 67], ["Experimental treatment strategies", "TREATMENT", 68, 101], ["A triple", "TREATMENT", 101, 109], ["amantadine", "TREATMENT", 125, 135], ["oseltamivir", "TREATMENT", 137, 148], ["ribavirin (TCAD regimen", "TREATMENT", 153, 176], ["synergistic activity", "PROBLEM", 228, 248], ["resistant influenza viruses", "PROBLEM", 271, 298], ["any double antiviral regimen", "TREATMENT", 326, 354], ["no mention of", "UNCERTAINTY", 10, 23], ["immunocompromised", "OBSERVATION", 28, 45]]], ["There was a phase I pilot study of TCAD in 2013 to assess pharmacokinetics and safety in 6 immunocompromised patients with influenza A (H1N1 & H3N2).", [["TCAD", "DISEASE", 35, 39], ["influenza A (H1N1 & H3N2", "DISEASE", 123, 147], ["patients", "ORGANISM", 109, 117], ["influenza A", "ORGANISM", 123, 134], ["H1N1 & H3N2", "ORGANISM", 136, 147], ["patients", "SPECIES", 109, 117], ["influenza A", "PROBLEM", 123, 134]]], ["Five out of 6 tolerated and completed the 10-day course of treatment (1 patient had worsening respiratory failure and TCAD was stopped) [58].", [["respiratory", "ANATOMY", 94, 105], ["respiratory failure", "DISEASE", 94, 113], ["TCAD", "DISEASE", 118, 122], ["patient", "ORGANISM", 72, 79], ["patient", "SPECIES", 72, 79], ["treatment", "TREATMENT", 59, 68], ["worsening respiratory failure", "PROBLEM", 84, 113], ["TCAD", "TREATMENT", 118, 122], ["respiratory failure", "OBSERVATION", 94, 113]]], ["A clinical response and a corresponding viral load reduction in the 5 patients that completed treatment.", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["a corresponding viral load reduction", "TREATMENT", 24, 60], ["treatment", "TREATMENT", 94, 103], ["viral load", "OBSERVATION", 40, 50]]], ["No drug-drug interactions were seen and no haematological toxicity was seen with ribavirin.", [["toxicity", "DISEASE", 58, 66], ["ribavirin", "CHEMICAL", 81, 90], ["ribavirin", "CHEMICAL", 81, 90], ["ribavirin", "SIMPLE_CHEMICAL", 81, 90], ["haematological toxicity", "PROBLEM", 43, 66], ["ribavirin", "TREATMENT", 81, 90]]], ["No new resistance mutations emerged on treatment.", [["new resistance mutations", "PROBLEM", 3, 27], ["treatment", "TREATMENT", 39, 48], ["new", "OBSERVATION_MODIFIER", 3, 6], ["resistance mutations", "OBSERVATION", 7, 27]]], ["A study of TCAD vs oseltamivir in critically ill mechanically-ventilated patients with pandemic H1N1 showed that TCAD was well tolerated but did not improve outcomes compared with oseltamivir alone [59].Experimental treatment strategiesAn in vitro study in 2016 of a zanamivir-oseltamivir hybrid inhibitor (MS-257) showed effectiveness against neuraminidase inhibitor-resistant influenza strains but there have been no further published studies to date [60].ConclusionsOseltamivir resistance is rare and zanamivir resistance is extremely rare.", [["TCAD", "CHEMICAL", 11, 15], ["oseltamivir", "CHEMICAL", 19, 30], ["critically ill", "DISEASE", 34, 48], ["H1N1", "DISEASE", 96, 100], ["TCAD", "CHEMICAL", 113, 117], ["oseltamivir", "CHEMICAL", 180, 191], ["zanamivir", "CHEMICAL", 267, 276], ["oseltamivir", "CHEMICAL", 277, 288], ["MS-257", "CHEMICAL", 307, 313], ["influenza", "DISEASE", 378, 387], ["Oseltamivir", "CHEMICAL", 469, 480], ["zanamivir", "CHEMICAL", 504, 513], ["oseltamivir", "CHEMICAL", 19, 30], ["TCAD", "CHEMICAL", 113, 117], ["oseltamivir", "CHEMICAL", 180, 191], ["zanamivir", "CHEMICAL", 267, 276], ["oseltamivir", "CHEMICAL", 277, 288], ["MS-257", "CHEMICAL", 307, 313], ["Oseltamivir", "CHEMICAL", 469, 480], ["zanamivir", "CHEMICAL", 504, 513], ["TCAD", "SIMPLE_CHEMICAL", 11, 15], ["oseltamivir", "SIMPLE_CHEMICAL", 19, 30], ["patients", "ORGANISM", 73, 81], ["TCAD", "SIMPLE_CHEMICAL", 113, 117], ["oseltamivir", "SIMPLE_CHEMICAL", 180, 191], ["zanamivir", "SIMPLE_CHEMICAL", 267, 276], ["MS-257", "SIMPLE_CHEMICAL", 307, 313], ["neuraminidase inhibitor", "SIMPLE_CHEMICAL", 344, 367], ["Oseltamivir", "SIMPLE_CHEMICAL", 469, 480], ["zanamivir", "SIMPLE_CHEMICAL", 504, 513], ["patients", "SPECIES", 73, 81], ["A study", "TEST", 0, 7], ["TCAD", "TEST", 11, 15], ["oseltamivir", "TREATMENT", 19, 30], ["pandemic H1N1", "PROBLEM", 87, 100], ["oseltamivir", "TREATMENT", 180, 191], ["Experimental treatment strategies", "TREATMENT", 203, 236], ["An in vitro study", "TEST", 236, 253], ["a zanamivir-oseltamivir hybrid inhibitor", "TREATMENT", 265, 305], ["MS", "TEST", 307, 309], ["neuraminidase inhibitor", "PROBLEM", 344, 367], ["resistant influenza strains", "PROBLEM", 368, 395], ["Oseltamivir resistance", "TEST", 469, 491], ["zanamivir resistance", "PROBLEM", 504, 524], ["Oseltamivir resistance", "OBSERVATION", 469, 491], ["zanamivir resistance", "OBSERVATION", 504, 524]]], ["The presence of resistant virus does not necessarily mean a more severe infection and/or worse outcome, particularly in immunocompetent adults.", [["infection", "DISEASE", 72, 81], ["adults", "ORGANISM", 136, 142], ["resistant virus", "PROBLEM", 16, 31], ["a more severe infection", "PROBLEM", 58, 81], ["resistant", "OBSERVATION_MODIFIER", 16, 25], ["virus", "OBSERVATION", 26, 31], ["severe", "OBSERVATION_MODIFIER", 65, 71], ["infection", "OBSERVATION", 72, 81]]], ["In some instances, neuraminidase inhibitor resistant virus may actually be less fit (especially with H3N2 and influenza B).", [["influenza B", "DISEASE", 110, 121], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 19, 32], ["influenza B", "ORGANISM", 110, 121], ["neuraminidase inhibitor resistant virus", "PROBLEM", 19, 58], ["H3N2", "PROBLEM", 101, 105], ["influenza B", "TREATMENT", 110, 121]]], ["There is an increased risk of resistance in the immunocompromised (but resistance does occur in the immunocompetent) and young children (< 5 years); this is primarily with influenza AH1N1 pdm09 but can occur less commonly with influenza A H3N2 and B.ConclusionsNeuraminidase inhibitor susceptibility testing should be considered primarily in H1N1 infected immunocompromised patients and young children failing to respond to treatment, and clinicians should consider zanamivir in the intravenous form for patients that are critically ill/developing severe complications.", [["intravenous", "ANATOMY", 483, 494], ["H1N1 infected immunocompromised", "DISEASE", 342, 373], ["zanamivir", "CHEMICAL", 466, 475], ["critically ill", "DISEASE", 522, 536], ["zanamivir", "CHEMICAL", 466, 475], ["children", "ORGANISM", 127, 135], ["influenza AH1N1 pdm09", "ORGANISM", 172, 193], ["influenza A H3N2", "ORGANISM", 227, 243], ["B.ConclusionsNeuraminidase inhibitor", "GENE_OR_GENE_PRODUCT", 248, 284], ["patients", "ORGANISM", 374, 382], ["children", "ORGANISM", 393, 401], ["zanamivir", "SIMPLE_CHEMICAL", 466, 475], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 483, 494], ["patients", "ORGANISM", 504, 512], ["children", "SPECIES", 127, 135], ["influenza A H3N2", "SPECIES", 227, 243], ["patients", "SPECIES", 374, 382], ["children", "SPECIES", 393, 401], ["patients", "SPECIES", 504, 512], ["AH1N1", "SPECIES", 182, 187], ["the immunocompromised", "PROBLEM", 44, 65], ["influenza AH1N1 pdm09", "PROBLEM", 172, 193], ["influenza", "PROBLEM", 227, 236], ["A H3N2", "TREATMENT", 237, 243], ["Neuraminidase inhibitor susceptibility testing", "TEST", 261, 307], ["treatment", "TREATMENT", 424, 433], ["zanamivir", "TREATMENT", 466, 475], ["critically ill", "PROBLEM", 522, 536], ["severe complications", "PROBLEM", 548, 568], ["increased", "OBSERVATION_MODIFIER", 12, 21], ["risk of resistance", "OBSERVATION", 22, 40], ["immunocompromised", "OBSERVATION", 48, 65], ["severe", "OBSERVATION_MODIFIER", 548, 554], ["complications", "OBSERVATION", 555, 568]]], ["There should potentially be a higher threshold for neuraminidase inhibitor susceptibility testing in influenza H3N2 or B infected patients.", [["influenza H3N2 or B infected", "DISEASE", 101, 129], ["neuraminidase inhibitor", "GENE_OR_GENE_PRODUCT", 51, 74], ["influenza H3N2", "ORGANISM", 101, 115], ["B infected", "ORGANISM", 119, 129], ["patients", "ORGANISM", 130, 138], ["influenza H3N2", "SPECIES", 101, 115], ["patients", "SPECIES", 130, 138], ["influenza H3N2", "SPECIES", 101, 115], ["neuraminidase inhibitor susceptibility testing", "TREATMENT", 51, 97], ["influenza", "PROBLEM", 101, 110], ["H3N2", "PROBLEM", 111, 115]]], ["This should generally be reserved for those that have had extended treatment (at least 10 days) and not responded/deteriorated with persistent low Ct values and no other identifiable cause.ConclusionsFinally, there is no clearly proven benefit from combination (or double dose) antiviral therapy for influenza in terms of clinical outcome or emergence of resistance.", [["influenza", "DISEASE", 300, 309], ["persistent low Ct values", "PROBLEM", 132, 156], ["double dose)", "TREATMENT", 265, 277], ["antiviral therapy", "TREATMENT", 278, 295], ["influenza", "PROBLEM", 300, 309], ["no other identifiable", "UNCERTAINTY", 161, 182], ["no clearly", "UNCERTAINTY", 218, 228]]]], "PMC7119659": [["IntroductionAvian reovirus (ARV) causing arthritis, chronic respiratory diseases, and malabsorption syndrome leads to considerable economic losses (Kibenege and Wilcox, 1983).", [["respiratory", "ANATOMY", 60, 71], ["arthritis", "DISEASE", 41, 50], ["chronic respiratory diseases", "DISEASE", 52, 80], ["malabsorption syndrome", "DISEASE", 86, 108], ["IntroductionAvian reovirus", "ORGANISM", 0, 26], ["IntroductionAvian reovirus", "PROBLEM", 0, 26], ["arthritis", "PROBLEM", 41, 50], ["chronic respiratory diseases", "PROBLEM", 52, 80], ["malabsorption syndrome", "PROBLEM", 86, 108], ["considerable economic losses", "PROBLEM", 118, 146], ["arthritis", "OBSERVATION", 41, 50], ["chronic", "OBSERVATION_MODIFIER", 52, 59], ["respiratory diseases", "OBSERVATION", 60, 80], ["malabsorption syndrome", "OBSERVATION", 86, 108], ["considerable", "OBSERVATION_MODIFIER", 118, 130], ["economic losses", "OBSERVATION", 131, 146]]], ["ARV-encoded proteins, including at least 10 structural proteins and 4 non-structural proteins have been demonstrated (Varela and Benavente, 1994, Bodelon et al., 2001).", [["ARV-encoded proteins", "PROTEIN", 0, 20], ["structural proteins", "PROTEIN", 44, 63], ["non-structural proteins", "PROTEIN", 70, 93], ["ARV", "TEST", 0, 3], ["4 non-structural proteins", "PROBLEM", 68, 93]]], ["In the \u03c3-class proteins of ARV, protein \u03c3C, is a minor outer-capsid protein of ARV that is encoded by the largest open reading frame of the S1 segment (Varela and Benavente, 1994, Bodelon et al., 2001).", [["\u03c3C", "GENE_OR_GENE_PRODUCT", 40, 42], ["\u03c3-class proteins", "PROTEIN", 7, 23], ["ARV", "PROTEIN", 27, 30], ["protein \u03c3C", "PROTEIN", 32, 42], ["minor outer-capsid protein", "PROTEIN", 49, 75], ["ARV", "PROTEIN", 79, 82], ["open reading frame", "DNA", 114, 132], ["S1 segment", "DNA", 140, 150], ["ARV", "TEST", 27, 30], ["protein \u03c3C", "TEST", 32, 42], ["a minor outer-capsid protein of ARV", "PROBLEM", 47, 82], ["capsid protein of ARV", "OBSERVATION", 61, 82], ["largest", "OBSERVATION_MODIFIER", 106, 113], ["S1", "ANATOMY", 140, 142], ["segment", "ANATOMY_MODIFIER", 143, 150]]], ["It is not only an attachment protein (Martinez-Costas et al., 1997) but also an apoptosis inducer (Shih et al., 2004).", [["not only", "UNCERTAINTY", 6, 14], ["apoptosis", "OBSERVATION", 80, 89]]], ["Some studies have suggested that \u03c3C is the target for type-specific neutralizing antibodies while \u03c3B is target for group-specific antibodies (Wickramasinghe et al., 1993).", [["\u03c3C", "CHEMICAL", 33, 35], ["\u03c3C", "GENE_OR_GENE_PRODUCT", 33, 35], ["\u03c3B", "GENE_OR_GENE_PRODUCT", 98, 100], ["\u03c3C", "PROTEIN", 33, 35], ["type-specific neutralizing antibodies", "PROTEIN", 54, 91], ["\u03c3B", "PROTEIN", 98, 100], ["Some studies", "TEST", 0, 12], ["type-specific neutralizing antibodies", "TEST", 54, 91]]], ["Protein P10 is a viroporin (Bodelon et al., 2002) responsible for ARV-induced cell fusion (Bodelon et al., 2001).", [["cell", "ANATOMY", 78, 82], ["P10", "GENE_OR_GENE_PRODUCT", 8, 11], ["viroporin", "GENE_OR_GENE_PRODUCT", 17, 26], ["cell", "CELL", 78, 82], ["Protein P10", "TEST", 0, 11], ["ARV-induced cell fusion", "TREATMENT", 66, 89], ["cell fusion", "OBSERVATION", 78, 89]]], ["A recent report suggests that P17 retards cell growth by activation of P53 pathway (Liu et al., 2005).", [["cell", "ANATOMY", 42, 46], ["P17", "GENE_OR_GENE_PRODUCT", 30, 33], ["cell", "CELL", 42, 46], ["P53", "GENE_OR_GENE_PRODUCT", 71, 74], ["P17", "PROTEIN", 30, 33], ["P53", "PROTEIN", 71, 74], ["P17 retards cell growth", "PROBLEM", 30, 53]]], ["ARV \u03c3A, encoded by the genome segment S2 (Yin et al., 2000), has been identified as a double-stranded RNA (dsRNA) binding protein (Yin et al., 2000) and is an inhibitor of the double-stranded RNA-dependent protein kinas (Gonzalez-Lopez et al., 2003).", [["ARV \u03c3A", "GENE_OR_GENE_PRODUCT", 0, 6], ["ARV \u03c3A", "PROTEIN", 0, 6], ["genome segment S2", "DNA", 23, 40], ["double-stranded RNA (dsRNA) binding protein", "PROTEIN", 86, 129], ["double-stranded RNA-dependent protein kinas", "PROTEIN", 176, 219], ["a double-stranded RNA (dsRNA", "TREATMENT", 84, 112], ["segment", "ANATOMY_MODIFIER", 30, 37], ["S2", "ANATOMY", 38, 40]]], ["Another ARV protein, \u03c3NS, encoded by the genome segment S4 (Chiu and Lee, 1997), has been reported for its single-stranded RNA (ssRNA) binding activity (Yin and Lee, 1998).IntroductionThe ubiquitin-proteasome pathway, a major intracellular protein degradation pathway in eukaryotic cells (Myung et al., 2001), plays an important role in a wide variety of cellular functions, including signal transduction, antigen processing, cell cycle regulation, transcription regulation, DNA repair, and apoptosis (Ciechanover, 1994, Glickman and Ciechanover, 2002).", [["intracellular", "ANATOMY", 226, 239], ["cells", "ANATOMY", 282, 287], ["cellular", "ANATOMY", 355, 363], ["cell", "ANATOMY", 426, 430], ["\u03c3NS", "GENE_OR_GENE_PRODUCT", 21, 24], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 226, 239], ["cells", "CELL", 282, 287], ["cellular", "CELL", 355, 363], ["antigen", "GENE_OR_GENE_PRODUCT", 406, 413], ["cell", "CELL", 426, 430], ["DNA", "CELLULAR_COMPONENT", 475, 478], ["ARV protein", "PROTEIN", 8, 19], ["\u03c3NS", "PROTEIN", 21, 24], ["genome segment S4", "DNA", 41, 58], ["eukaryotic cells", "CELL_TYPE", 271, 287], ["Another ARV protein", "TEST", 0, 19], ["NS", "TEST", 22, 24], ["its single-stranded RNA (ssRNA) binding activity", "PROBLEM", 103, 151], ["The ubiquitin-proteasome pathway", "TREATMENT", 184, 216], ["a major intracellular protein degradation pathway", "PROBLEM", 218, 267], ["signal transduction", "TREATMENT", 385, 404], ["antigen processing", "TREATMENT", 406, 424], ["cell cycle regulation", "TREATMENT", 426, 447], ["transcription regulation", "TREATMENT", 449, 473], ["DNA repair", "TREATMENT", 475, 485], ["segment", "ANATOMY_MODIFIER", 48, 55], ["S4", "ANATOMY_MODIFIER", 56, 58], ["stranded RNA", "OBSERVATION_MODIFIER", 114, 126], ["eukaryotic cells", "OBSERVATION", 271, 287], ["cellular functions", "OBSERVATION", 355, 373], ["DNA repair", "OBSERVATION", 475, 485]]], ["In the present study, attempts were made to explore the role of proteasome inhibition in ARV infectivity and the mechanisms involved in the proteasome inhibitor suppression of ARV replication and apoptosis induction in cultured cells.IntroductionIt was shown previously that ARV \u03c3C is an apoptosis inducer that causes apoptosis by linking Src kinase to p53-mitochondrial pathway in cultured cells (Shih et al., 2004, Lin et al., 2006).", [["cells", "ANATOMY", 228, 233], ["mitochondrial", "ANATOMY", 357, 370], ["cells", "ANATOMY", 391, 396], ["cells", "CELL", 228, 233], ["ARV \u03c3C", "GENE_OR_GENE_PRODUCT", 275, 281], ["Src", "GENE_OR_GENE_PRODUCT", 339, 342], ["p53", "GENE_OR_GENE_PRODUCT", 353, 356], ["mitochondrial", "CELLULAR_COMPONENT", 357, 370], ["cells", "CELL", 391, 396], ["proteasome", "PROTEIN", 64, 74], ["proteasome", "PROTEIN", 140, 150], ["cultured cells", "CELL_LINE", 219, 233], ["Src kinase", "PROTEIN", 339, 349], ["p53", "PROTEIN", 353, 356], ["cultured cells", "CELL_LINE", 382, 396], ["the present study", "TEST", 3, 20], ["proteasome inhibition", "TREATMENT", 64, 85], ["ARV infectivity", "TREATMENT", 89, 104], ["the proteasome inhibitor suppression", "TREATMENT", 136, 172], ["ARV replication", "TREATMENT", 176, 191], ["apoptosis induction", "TREATMENT", 196, 215], ["an apoptosis inducer", "PROBLEM", 285, 305], ["apoptosis", "PROBLEM", 318, 327], ["Src kinase", "TEST", 339, 349], ["p53", "TEST", 353, 356], ["apoptosis", "OBSERVATION", 288, 297]]], ["Using the proteasome inhibitor MG132 to inhibit the cellular proteasome pathway, it was found that MG132 could reduce ARV-induced apoptosis, cytopathic effect (CPE), virus titer, and protein expression.", [["cellular", "ANATOMY", 52, 60], ["MG132", "CHEMICAL", 31, 36], ["MG132", "CHEMICAL", 99, 104], ["MG132", "CHEMICAL", 31, 36], ["MG132", "CHEMICAL", 99, 104], ["MG132", "SIMPLE_CHEMICAL", 31, 36], ["cellular", "CELL", 52, 60], ["MG132", "SIMPLE_CHEMICAL", 99, 104], ["the proteasome inhibitor MG132", "TREATMENT", 6, 36], ["MG132", "PROBLEM", 99, 104], ["ARV", "TEST", 118, 121], ["induced apoptosis", "PROBLEM", 122, 139], ["cytopathic effect (CPE", "PROBLEM", 141, 163], ["virus titer", "TEST", 166, 177], ["cytopathic", "OBSERVATION_MODIFIER", 141, 151]]], ["Inhibition of the ubiquitin-proteasome pathway did not affect viral entry and host cell translation.", [["cell", "ANATOMY", 83, 87], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 18, 27], ["cell", "CELL", 83, 87], ["proteasome", "PROTEIN", 28, 38], ["the ubiquitin-proteasome pathway", "TREATMENT", 14, 46], ["host cell translation", "OBSERVATION", 78, 99]]], ["To our knowledge, this is the first finding demonstrating that ARV replication and ARV-induced apoptosis could be suppressed by MG132.Antibodies ::: Materials and methodsTwo monoclonal antibodies against ARV \u03c3A and \u03c3NS were kindly provided by Dr. Long H. Lee (Hou et al., 2001, Pai et al., 2003, Huang et al., 2005).", [["MG132", "CHEMICAL", 128, 133], ["MG132", "CHEMICAL", 128, 133], ["MG132", "SIMPLE_CHEMICAL", 128, 133], ["monoclonal antibodies", "PROTEIN", 174, 195], ["ARV replication", "TREATMENT", 63, 78], ["ARV-induced apoptosis", "TREATMENT", 83, 104], ["MG132", "PROBLEM", 128, 133], ["Two monoclonal antibodies", "TREATMENT", 170, 195], ["A and \u03c3NS", "TREATMENT", 209, 218]]], ["The monoclonal antibody against ARV \u03c3C was a laboratory stock (Hsu et al., 2006).", [["monoclonal antibody", "PROTEIN", 4, 23], ["ARV \u03c3C", "PROTEIN", 32, 38], ["The monoclonal antibody", "TEST", 0, 23]]], ["The monoclonal antibody, which detects ser15-phosphorylated p53 was purchased from R&D systems Inc. (Minneapolis, MN, USA).", [["ser15", "GENE_OR_GENE_PRODUCT", 39, 44], ["p53", "GENE_OR_GENE_PRODUCT", 60, 63], ["monoclonal antibody", "PROTEIN", 4, 23], ["ser15", "PROTEIN", 39, 44], ["phosphorylated p53", "PROTEIN", 45, 63], ["The monoclonal antibody", "TEST", 0, 23], ["monoclonal antibody", "OBSERVATION", 4, 23]]], ["The polyclonal antibodies against GFP and actin were from Invitrogen (Carlsbad, CA, USA) and Chemicon (Temecula, CA, USA), respectively.Cell viability assay ::: Materials and methodsA modified 3,4-(5-dimethylthiazol-2-yl)-5-(3-carboxyme-thoxy phenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt (MTT) assay, which measures mitochondrial function, was used to determine cell viability according to the manufacturer's instruction (Promega, Madison, WI, USA).", [["Cell", "ANATOMY", 136, 140], ["mitochondrial", "ANATOMY", 317, 330], ["cell", "ANATOMY", 363, 367], ["3,4-(5-dimethylthiazol-2-yl)-5-(3-carboxyme-thoxy phenyl)-2-(4-sulfophenyl)-2H-tetrazolium", "CHEMICAL", 193, 283], ["3,4-(5-dimethylthiazol-2-yl)-5-(3-carboxyme-thoxy phenyl)-2-(4-sulfophenyl)-2H-tetrazolium", "CHEMICAL", 193, 283], ["MTT", "CHEMICAL", 290, 293], ["GFP", "GENE_OR_GENE_PRODUCT", 34, 37], ["actin", "GENE_OR_GENE_PRODUCT", 42, 47], ["Cell", "CELL", 136, 140], ["3,4-(5-dimethylthiazol-2-yl)-5-(3-carboxyme-thoxy phenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt", "SIMPLE_CHEMICAL", 193, 288], ["MTT", "SIMPLE_CHEMICAL", 290, 293], ["mitochondrial", "CELLULAR_COMPONENT", 317, 330], ["cell", "CELL", 363, 367], ["polyclonal antibodies", "PROTEIN", 4, 25], ["GFP", "PROTEIN", 34, 37], ["actin", "PROTEIN", 42, 47], ["The polyclonal antibodies", "TEST", 0, 25], ["GFP", "TEST", 34, 37], ["Invitrogen", "TEST", 58, 68], ["Carlsbad", "TEST", 70, 78], ["CA", "TEST", 80, 82], ["Chemicon", "TEST", 93, 101], ["Materials", "TEST", 161, 170], ["methodsA", "TEST", 175, 183], ["dimethylthiazol", "TREATMENT", 200, 215], ["carboxyme-thoxy phenyl)", "TREATMENT", 227, 250], ["tetrazolium salt (MTT) assay", "TREATMENT", 272, 300]]], ["BHK-21 cells were pretreated with various concentrations of MG132 and then infected with ARV s1133 (MOI = 5) for 1 h.", [["BHK-21 cells", "ANATOMY", 0, 12], ["MG132", "CHEMICAL", 60, 65], ["ARV s1133", "CHEMICAL", 89, 98], ["MG132", "CHEMICAL", 60, 65], ["BHK-21 cells", "CELL", 0, 12], ["MG132", "SIMPLE_CHEMICAL", 60, 65], ["BHK-21 cells", "CELL_LINE", 0, 12], ["BHK", "TEST", 0, 3], ["various concentrations of MG132", "TREATMENT", 34, 65], ["ARV s", "TEST", 89, 94], ["MOI", "TEST", 100, 103], ["21 cells", "OBSERVATION_MODIFIER", 4, 12]]], ["Cell viability was assessed by MTT assay at 18 h post-infection (h.p.i.).Virus titer ::: Materials and methodsARV s1133 propagated in BHK-21 cells was described previously (Liu et al., 2003, Liu et al., 2004).", [["Cell", "ANATOMY", 0, 4], ["BHK-21 cells", "ANATOMY", 134, 146], ["MTT", "CHEMICAL", 31, 34], ["Cell", "CELL", 0, 4], ["Virus", "ORGANISM", 73, 78], ["BHK-21 cells", "CELL", 134, 146], ["BHK-21 cells", "CELL_LINE", 134, 146], ["Cell viability", "TEST", 0, 14], ["MTT assay", "TEST", 31, 40], ["methodsARV s", "TEST", 103, 115]]], ["To study the effect of MG132 on ARV replication and virus internalization, BHK-21 cells were infected with ARV at various MOIs or treated with various concentrations of MG132.", [["BHK-21 cells", "ANATOMY", 75, 87], ["MG132", "CHEMICAL", 23, 28], ["MG132", "CHEMICAL", 169, 174], ["MG132", "CHEMICAL", 23, 28], ["MG132", "CHEMICAL", 169, 174], ["MG132", "SIMPLE_CHEMICAL", 23, 28], ["BHK-21 cells", "CELL", 75, 87], ["MG132", "SIMPLE_CHEMICAL", 169, 174], ["BHK-21 cells", "CELL_LINE", 75, 87], ["BHK-21", "SPECIES", 75, 81], ["MG132", "TREATMENT", 23, 28], ["ARV replication", "TREATMENT", 32, 47], ["virus internalization", "TREATMENT", 52, 73], ["BHK", "TEST", 75, 78], ["ARV", "TREATMENT", 107, 110], ["various concentrations of MG132", "TREATMENT", 143, 174]]], ["Virus titers were determined at 18 h.p.i. by a plaque assay and Western blot for confirmation of expression of \u03c3A, \u03c3NS, and \u03c3C proteins.", [["plaque", "ANATOMY", 47, 53], ["Virus", "ORGANISM", 0, 5], ["\u03c3A", "GENE_OR_GENE_PRODUCT", 111, 113], ["\u03c3NS", "GENE_OR_GENE_PRODUCT", 115, 118], ["\u03c3C", "GENE_OR_GENE_PRODUCT", 124, 126], ["\u03c3A", "PROTEIN", 111, 113], ["\u03c3NS", "PROTEIN", 115, 118], ["\u03c3C proteins", "PROTEIN", 124, 135], ["Virus titers", "TEST", 0, 12], ["a plaque assay", "TEST", 45, 59], ["NS", "TREATMENT", 116, 118], ["\u03c3C proteins", "PROBLEM", 124, 135]]], ["Representative morphological changes of BHK-21 cells treated with MG132 or DMSO were observed by a phase-contrast microscopy at 18 h.p.i.Virus titer ::: Materials and methodsTo explore the effect of proteasome inactivation during the course of ARV infection, BHK-21 cells were treated with MG132 at different times.", [["BHK-21 cells", "ANATOMY", 40, 52], ["BHK-21 cells", "ANATOMY", 259, 271], ["MG132", "CHEMICAL", 66, 71], ["DMSO", "CHEMICAL", 75, 79], ["infection", "DISEASE", 248, 257], ["MG132", "CHEMICAL", 290, 295], ["MG132", "CHEMICAL", 66, 71], ["DMSO", "CHEMICAL", 75, 79], ["MG132", "CHEMICAL", 290, 295], ["BHK-21 cells", "CELL", 40, 52], ["MG132", "SIMPLE_CHEMICAL", 66, 71], ["DMSO", "SIMPLE_CHEMICAL", 75, 79], ["Virus", "ORGANISM", 137, 142], ["BHK-21 cells", "CELL", 259, 271], ["MG132", "SIMPLE_CHEMICAL", 290, 295], ["BHK-21 cells", "CELL_LINE", 40, 52], ["proteasome", "PROTEIN", 199, 209], ["BHK-21 cells", "CELL_LINE", 259, 271], ["BHK-21", "SPECIES", 259, 265], ["Representative morphological changes of BHK", "PROBLEM", 0, 43], ["MG132", "TREATMENT", 66, 71], ["DMSO", "TREATMENT", 75, 79], ["a phase-contrast microscopy", "TEST", 97, 124], ["proteasome inactivation", "TREATMENT", 199, 222], ["ARV infection", "PROBLEM", 244, 257], ["BHK", "TEST", 259, 262], ["MG132", "TREATMENT", 290, 295], ["21 cells", "OBSERVATION_MODIFIER", 44, 52], ["proteasome inactivation", "OBSERVATION", 199, 222], ["infection", "OBSERVATION", 248, 257]]], ["The cells were washed to remove the drug and further incubated until 18 h.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["the drug", "TREATMENT", 32, 40]]], ["Whole cell lysates were collected at the indicted time points and a plaque assay was done for each lysate to determine the virus yield during preceding 6-h period.Plasmid construction and reverse transcription and polymerase chain reaction (RT-PCR) ::: Materials and methodsThe GFP gene was derived from the commercial vector pI\u03baB-GFP (Invitrogen).", [["Whole cell lysates", "ANATOMY", 0, 18], ["plaque", "ANATOMY", 68, 74], ["lysate", "ANATOMY", 99, 105], ["cell lysates", "CELL", 6, 18], ["GFP", "GENE_OR_GENE_PRODUCT", 278, 281], ["pI\u03baB-GFP", "GENE_OR_GENE_PRODUCT", 326, 334], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 336, 346], ["GFP gene", "DNA", 278, 286], ["commercial vector pI\u03baB", "DNA", 308, 330], ["GFP", "PROTEIN", 331, 334], ["Whole cell lysates", "TEST", 0, 18], ["a plaque assay", "TEST", 66, 80], ["each lysate", "TREATMENT", 94, 105], ["Plasmid construction", "TREATMENT", 163, 183], ["reverse transcription", "TREATMENT", 188, 209], ["polymerase chain reaction", "PROBLEM", 214, 239], ["The GFP gene", "TEST", 274, 286], ["plaque", "OBSERVATION", 68, 74]]], ["Following respective treatments with Bam HI, Klenow, and Not I, the GFP fragment separated from pI\u03baB-GFP was cloned into pcDNA3.1 (\u2212) vector.", [["Bam HI", "GENE_OR_GENE_PRODUCT", 37, 43], ["Klenow", "GENE_OR_GENE_PRODUCT", 45, 51], ["Not I", "GENE_OR_GENE_PRODUCT", 57, 62], ["GFP", "GENE_OR_GENE_PRODUCT", 68, 71], ["pI\u03baB-GFP", "GENE_OR_GENE_PRODUCT", 96, 104], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 121, 129], ["Bam HI, Klenow, and Not I", "DNA", 37, 62], ["GFP fragment", "DNA", 68, 80], ["pI\u03baB", "DNA", 96, 100], ["GFP", "DNA", 101, 104], ["pcDNA3.1 (\u2212) vector", "DNA", 121, 140], ["respective treatments", "TREATMENT", 10, 31], ["Bam HI, Klenow", "TREATMENT", 37, 51], ["the GFP fragment", "PROBLEM", 64, 80]]], ["The construct was named pcDNA-GFP.", [["pcDNA", "GENE_OR_GENE_PRODUCT", 24, 29], ["GFP", "GENE_OR_GENE_PRODUCT", 30, 33], ["pcDNA", "PROTEIN", 24, 29], ["GFP", "PROTEIN", 30, 33]]], ["In addition, the construction of pcDNA-\u03c3C has been described previously (Shih et al., 2004).Plasmid construction and reverse transcription and polymerase chain reaction (RT-PCR) ::: Materials and methodsTo investigate the effect of MG132 on ARV production was through the reduction of ARV RNA levels, RNA extracted from BHK-21 cells 18 h.p.i. in the presence or absence of MG132 was amplified by RT-PCR.", [["BHK-21 cells", "ANATOMY", 320, 332], ["MG132", "CHEMICAL", 232, 237], ["MG132", "CHEMICAL", 373, 378], ["MG132", "CHEMICAL", 232, 237], ["MG132", "CHEMICAL", 373, 378], ["pcDNA-\u03c3C", "GENE_OR_GENE_PRODUCT", 33, 41], ["MG132", "SIMPLE_CHEMICAL", 232, 237], ["BHK-21 cells", "CELL", 320, 332], ["MG132", "SIMPLE_CHEMICAL", 373, 378], ["pcDNA-\u03c3C", "PROTEIN", 33, 41], ["ARV RNA", "RNA", 285, 292], ["BHK-21 cells", "CELL_LINE", 320, 332], ["Plasmid construction", "TREATMENT", 92, 112], ["reverse transcription", "TREATMENT", 117, 138], ["polymerase chain reaction", "PROBLEM", 143, 168], ["MG132", "TREATMENT", 232, 237], ["ARV production", "TREATMENT", 241, 255], ["ARV RNA levels", "TEST", 285, 299], ["RNA", "TEST", 301, 304], ["BHK", "TEST", 320, 323], ["MG132", "TREATMENT", 373, 378], ["PCR", "TEST", 399, 402]]], ["The primers for amplification of \u03c3A and GAPDH were as follows: \u03c3A forward primer, 5\u2032-GGCTTCTACTTCTCCTCGAAG ACTC-3\u2032 (identical to nucleotides 700\u2013724) and \u03c3A reverse primer, 5\u2032-AGAAGTCATTA GCCTCCTGCGT TA-3\u2032 (complementary to nucleotides 1597\u20131625); GAPDH forward primer, 5\u2032-CATTGACCTCAACTACATGG-3\u2032, GAPDH reverse primer, 5\u2032-TTGCCCA CAGCCTTGGCAGC-3\u2032.", [["nucleotides", "CHEMICAL", 129, 140], ["nucleotides", "CHEMICAL", 224, 235], ["\u03c3A", "GENE_OR_GENE_PRODUCT", 33, 35], ["GAPDH", "GENE_OR_GENE_PRODUCT", 40, 45], ["GAPDH", "GENE_OR_GENE_PRODUCT", 248, 253], ["GAPDH", "GENE_OR_GENE_PRODUCT", 298, 303], ["\u03c3A", "RNA", 33, 35], ["nucleotides 700\u2013724", "DNA", 129, 148], ["3\u2032", "DNA", 203, 205], ["complementary to nucleotides 1597\u20131625", "DNA", 207, 245], ["GAPDH forward primer", "DNA", 248, 268], ["GAPDH reverse primer", "DNA", 298, 318], ["A forward primer", "TEST", 64, 80], ["ACTC", "TEST", 107, 111], ["nucleotides", "TEST", 129, 140], ["TA", "TEST", 200, 202], ["nucleotides", "TEST", 224, 235], ["GAPDH forward primer", "TEST", 248, 268], ["CATTGACCTCAACTACATGG", "TEST", 273, 293], ["CAGCCTTGGCAGC", "TEST", 331, 344]]], ["Reverse transcription was carried out at 50 \u00b0C for 30 min.", [["Reverse transcription", "TREATMENT", 0, 21]]], ["PCR reactions were subjected to 35 cycles consisting of denaturation for 1 min at 94 \u00b0C, annealing for 1 min at 55 \u00b0C and, extension for 90 s at 72 \u00b0C, and one final extension cycle at 72 \u00b0C for 7 min.Western blot and immunofluorescent assay (IFA) ::: Materials and methodsCells in 60 mm dishes were infected with ARV at 5 MOI or transfected with 5 \u03bcg of plasmid DNA using superfect reagent (Qiagen, Valencia, USA).", [["Cells", "ANATOMY", 273, 278], ["plasmid", "ANATOMY", 355, 362], ["Cells", "CELL", 273, 278], ["DNA", "CELLULAR_COMPONENT", 363, 366], ["plasmid DNA", "DNA", 355, 366], ["PCR reactions", "PROBLEM", 0, 13], ["immunofluorescent assay", "TEST", 218, 241], ["Cells", "TEST", 273, 278], ["ARV", "TREATMENT", 314, 317], ["plasmid DNA", "TREATMENT", 355, 366], ["superfect reagent", "TREATMENT", 373, 390], ["60 mm", "OBSERVATION_MODIFIER", 282, 287]]], ["After incubation for 1 h, the medium was removed and cells were grown for an additional 18 h.", [["cells", "ANATOMY", 53, 58], ["cells", "CELL", 53, 58], ["cells", "PROBLEM", 53, 58]]], ["Cells were harvested, washed, and lysed in 0.5 ml RIPA lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Nonidet p-40, 1 mM PMSF).", [["Cells", "ANATOMY", 0, 5], ["NaCl", "CHEMICAL", 96, 100], ["Nonidet p-40", "CHEMICAL", 105, 117], ["Tris", "CHEMICAL", 75, 79], ["NaCl", "CHEMICAL", 96, 100], ["Nonidet p-40", "CHEMICAL", 105, 117], ["PMSF", "CHEMICAL", 124, 128], ["Cells", "CELL", 0, 5], ["Nonidet p-40", "SIMPLE_CHEMICAL", 105, 117], ["PMSF", "SIMPLE_CHEMICAL", 124, 128], ["RIPA lysis buffer", "TREATMENT", 50, 67], ["Tris", "TEST", 75, 79], ["pH", "TEST", 81, 83], ["NaCl", "TEST", 96, 100]]], ["Both the supernatant and pellet were collected, mixed with Laemmli sample buffer and boiled for 5 min.", [["supernatant", "ANATOMY", 9, 20], ["pellet", "ANATOMY", 25, 31], ["Laemmli sample buffer", "TREATMENT", 59, 80], ["supernatant", "OBSERVATION_MODIFIER", 9, 20]]], ["After resolving the samples on a 12% SDS-PAGE, the proteins were transferred to PVDF membranes.", [["samples", "ANATOMY", 20, 27], ["PVDF membranes", "ANATOMY", 80, 94], ["SDS", "CHEMICAL", 37, 40], ["PVDF", "CHEMICAL", 80, 84], ["membranes", "CELLULAR_COMPONENT", 85, 94], ["a 12% SDS", "TREATMENT", 31, 40]]], ["The GFP and ARV \u03c3C, \u03c3A, and \u03c3NS proteins were detected using their respective antibodies described above.", [["GFP", "GENE_OR_GENE_PRODUCT", 4, 7], ["ARV \u03c3C", "GENE_OR_GENE_PRODUCT", 12, 18], ["\u03c3A", "GENE_OR_GENE_PRODUCT", 20, 22], ["\u03c3NS proteins", "GENE_OR_GENE_PRODUCT", 28, 40], ["GFP", "PROTEIN", 4, 7], ["ARV \u03c3C", "PROTEIN", 12, 18], ["\u03c3A", "PROTEIN", 20, 22], ["\u03c3NS proteins", "PROTEIN", 28, 40], ["antibodies", "PROTEIN", 78, 88], ["The GFP", "TEST", 0, 7], ["ARV \u03c3C", "TEST", 12, 18], ["\u03c3NS proteins", "TEST", 28, 40]]], ["The signal was detected by ECL reagent (Amersham Pharmacia Biotech, Hong Kong) and visualized by autoradiography.Western blot and immunofluorescent assay (IFA) ::: Materials and methodsFor IFA assay, ARV s1133-infected BHK-21 cells were fixed in a mixture of 50% acetone and 50% methanol for 10 min, and then incubated with an anti-\u03c3C monoclonal antibody (Hsu et al., 2006).", [["BHK-21 cells", "ANATOMY", 219, 231], ["acetone", "CHEMICAL", 263, 270], ["methanol", "CHEMICAL", 279, 287], ["acetone", "CHEMICAL", 263, 270], ["methanol", "CHEMICAL", 279, 287], ["ARV s1133", "ORGANISM", 200, 209], ["BHK-21 cells", "CELL", 219, 231], ["acetone", "SIMPLE_CHEMICAL", 263, 270], ["methanol", "SIMPLE_CHEMICAL", 279, 287], ["ARV s1133-infected BHK-21 cells", "CELL_LINE", 200, 231], ["anti-\u03c3C monoclonal antibody", "PROTEIN", 327, 354], ["BHK-21", "SPECIES", 219, 225], ["immunofluorescent assay", "TEST", 130, 153], ["methods", "TEST", 178, 185], ["IFA assay", "TEST", 189, 198], ["ARV", "TEST", 200, 203], ["infected BHK", "PROBLEM", 210, 222], ["an anti-\u03c3C monoclonal antibody", "TREATMENT", 324, 354]]], ["The bound antibody was visualized by immunostaining with FITC-conjugated second antibody raised against mouse IgG.Detection of the ser46-phosphorylated p53, active caspase 3, and DNA ladder in ARV-infected BHK-21 cells ::: Materials and methodsTo study whether ARV-induced apoptosis could be blocked in BHK-21 cells by MG132, Western blot detection of the level of ser46-phosphorylated p53, active caspase 3 staining, and DNA fragmentation analysis were carried out.", [["BHK-21 cells", "ANATOMY", 206, 218], ["BHK-21 cells", "ANATOMY", 303, 315], ["MG132", "CHEMICAL", 319, 324], ["FITC", "CHEMICAL", 57, 61], ["MG132", "CHEMICAL", 319, 324], ["FITC", "SIMPLE_CHEMICAL", 57, 61], ["mouse", "ORGANISM", 104, 109], ["IgG", "GENE_OR_GENE_PRODUCT", 110, 113], ["ser46", "GENE_OR_GENE_PRODUCT", 131, 136], ["p53", "GENE_OR_GENE_PRODUCT", 152, 155], ["caspase 3", "GENE_OR_GENE_PRODUCT", 164, 173], ["DNA", "CELLULAR_COMPONENT", 179, 182], ["BHK-21 cells", "CELL", 206, 218], ["BHK-21 cells", "CELL", 303, 315], ["MG132", "SIMPLE_CHEMICAL", 319, 324], ["ser46", "GENE_OR_GENE_PRODUCT", 365, 370], ["p53", "GENE_OR_GENE_PRODUCT", 386, 389], ["caspase 3", "GENE_OR_GENE_PRODUCT", 398, 407], ["DNA", "CELLULAR_COMPONENT", 422, 425], ["FITC-conjugated second antibody", "PROTEIN", 57, 88], ["mouse IgG", "PROTEIN", 104, 113], ["ser46", "PROTEIN", 131, 136], ["phosphorylated p53", "PROTEIN", 137, 155], ["caspase 3", "PROTEIN", 164, 173], ["ARV-infected BHK-21 cells", "CELL_LINE", 193, 218], ["BHK-21 cells", "CELL_LINE", 303, 315], ["ser46", "PROTEIN", 365, 370], ["phosphorylated p53", "PROTEIN", 371, 389], ["caspase 3", "PROTEIN", 398, 407], ["mouse", "SPECIES", 104, 109], ["mouse", "SPECIES", 104, 109], ["BHK-21", "SPECIES", 303, 309], ["The bound antibody", "TEST", 0, 18], ["immunostaining", "TEST", 37, 51], ["FITC", "TEST", 57, 61], ["conjugated second antibody", "TEST", 62, 88], ["mouse IgG", "PROBLEM", 104, 113], ["Detection", "TEST", 114, 123], ["active caspase", "TREATMENT", 157, 171], ["DNA ladder", "TEST", 179, 189], ["ARV", "TEST", 193, 196], ["ARV", "TEST", 261, 264], ["apoptosis", "PROBLEM", 273, 282], ["BHK", "TEST", 303, 306], ["blot detection", "TEST", 334, 348], ["the level", "TEST", 352, 361], ["active caspase 3 staining", "TEST", 391, 416], ["DNA fragmentation analysis", "TEST", 422, 448]]], ["BHK-21 cells were either pre-incubated 30 min before infection or 2 h.p.i. with MG132.", [["BHK-21 cells", "ANATOMY", 0, 12], ["infection", "DISEASE", 53, 62], ["MG132", "CHEMICAL", 80, 85], ["MG132", "CHEMICAL", 80, 85], ["BHK-21 cells", "CELL", 0, 12], ["MG132", "SIMPLE_CHEMICAL", 80, 85], ["BHK-21 cells", "CELL_LINE", 0, 12], ["BHK", "TEST", 0, 3], ["infection", "PROBLEM", 53, 62], ["MG132", "TREATMENT", 80, 85], ["21 cells", "OBSERVATION_MODIFIER", 4, 12]]], ["Cell lysates were collected and assayed from infected cells 18 h after treatment.", [["Cell lysates", "ANATOMY", 0, 12], ["cells", "ANATOMY", 54, 59], ["Cell lysates", "ORGANISM_SUBSTANCE", 0, 12], ["cells", "CELL", 54, 59], ["infected cells", "CELL_TYPE", 45, 59], ["Cell lysates", "TEST", 0, 12], ["treatment", "TREATMENT", 71, 80]]], ["Active caspase 3 in living cells was examined as described previously (Chulu et al., 2007).Protease inhibitor MG132 reduces viral progeny release and ARV-induced CPE ::: ResultsIt was found that different doses of MG132 caused only slight cytotoxicity to BHK-21 cells (data not shown).", [["cells", "ANATOMY", 27, 32], ["BHK-21 cells", "ANATOMY", 255, 267], ["MG132", "CHEMICAL", 110, 115], ["MG132", "CHEMICAL", 214, 219], ["MG132", "CHEMICAL", 110, 115], ["MG132", "CHEMICAL", 214, 219], ["caspase 3", "GENE_OR_GENE_PRODUCT", 7, 16], ["cells", "CELL", 27, 32], ["Protease", "GENE_OR_GENE_PRODUCT", 91, 99], ["MG132", "SIMPLE_CHEMICAL", 110, 115], ["MG132", "SIMPLE_CHEMICAL", 214, 219], ["BHK-21 cells", "CELL", 255, 267], ["caspase 3", "PROTEIN", 7, 16], ["BHK-21 cells", "CELL_LINE", 255, 267], ["Active caspase", "TREATMENT", 0, 14], ["Protease inhibitor MG132", "TREATMENT", 91, 115], ["viral progeny release", "TREATMENT", 124, 145], ["MG132", "TREATMENT", 214, 219], ["slight cytotoxicity", "PROBLEM", 232, 251], ["BHK", "TEST", 255, 258], ["caspase", "OBSERVATION", 7, 14], ["slight", "OBSERVATION_MODIFIER", 232, 238], ["cytotoxicity", "OBSERVATION", 239, 251]]], ["ARV replication in untreated cells resulted in the generation of a viral titer of 107.5PFU/ml after 18 h.p.i., wherease proteasome inhibition reduced the viral titer in a dose-dependent manner (Fig. 1A).", [["cells", "ANATOMY", 29, 34], ["cells", "CELL", 29, 34], ["untreated cells", "CELL_TYPE", 19, 34], ["proteasome", "PROTEIN", 120, 130], ["ARV replication in untreated cells", "TREATMENT", 0, 34], ["a viral titer", "TEST", 65, 78], ["wherease proteasome inhibition", "TREATMENT", 111, 141], ["the viral titer", "PROBLEM", 150, 165], ["untreated cells", "OBSERVATION", 19, 34], ["viral titer", "OBSERVATION", 154, 165]]], ["The results indicated that the proteasome inhibitor significantly blocked ARV production, suggesting that the proteasome may play an important role in ARV replication.", [["proteasome", "PROTEIN", 110, 120], ["the proteasome inhibitor", "TREATMENT", 27, 51], ["the proteasome", "TREATMENT", 106, 120], ["ARV replication", "TREATMENT", 151, 166]]], ["In this study, viral titers in the whole cell lysates harvested at 18 h.p.i. were reduced dramatically by MG132 (Fig. 1A), suggesting that the effect is due to the reduction in virus growth rather than to a delay in virus release.", [["cell lysates", "ANATOMY", 41, 53], ["MG132", "CHEMICAL", 106, 111], ["MG132", "CHEMICAL", 106, 111], ["cell lysates", "CELL", 41, 53], ["MG132", "SIMPLE_CHEMICAL", 106, 111], ["this study", "TEST", 3, 13], ["viral titers", "TEST", 15, 27], ["the whole cell lysates", "TREATMENT", 31, 53], ["the reduction in virus growth", "PROBLEM", 160, 189], ["a delay in virus release", "PROBLEM", 205, 229], ["virus", "OBSERVATION", 177, 182]]], ["Different amounts of input virus change the absolute amount of progeny virus but do not affect significantly the percentage of reduction in viral titers, suggesting that the antiviral properties of MG132 are independent of the multiplicity of infection (Fig. 1B).", [["MG132", "CHEMICAL", 198, 203], ["infection", "DISEASE", 243, 252], ["MG132", "CHEMICAL", 198, 203], ["MG132", "SIMPLE_CHEMICAL", 198, 203], ["input virus", "PROBLEM", 21, 32], ["progeny virus", "PROBLEM", 63, 76], ["reduction in viral titers", "PROBLEM", 127, 152], ["the antiviral properties of MG132", "TREATMENT", 170, 203], ["infection", "PROBLEM", 243, 252], ["amounts", "OBSERVATION_MODIFIER", 10, 17], ["input virus", "OBSERVATION", 21, 32], ["absolute", "OBSERVATION_MODIFIER", 44, 52], ["amount", "OBSERVATION_MODIFIER", 53, 59], ["progeny virus", "OBSERVATION", 63, 76], ["reduction", "OBSERVATION_MODIFIER", 127, 136], ["viral titers", "OBSERVATION", 140, 152], ["infection", "OBSERVATION", 243, 252]]], ["In addition, ARV-induced CPE is characterized by cell fusion, detachment of infected cells from culture flask, cell lysis and death.", [["cell", "ANATOMY", 49, 53], ["cells", "ANATOMY", 85, 90], ["cell", "ANATOMY", 111, 115], ["CPE", "DISEASE", 25, 28], ["death", "DISEASE", 126, 131], ["cell", "CELL", 49, 53], ["cells", "CELL", 85, 90], ["cell", "CELL", 111, 115], ["infected cells", "CELL_TYPE", 76, 90], ["ARV-induced CPE", "PROBLEM", 13, 28], ["cell fusion", "PROBLEM", 49, 60], ["detachment", "PROBLEM", 62, 72], ["infected cells", "PROBLEM", 76, 90], ["culture flask", "TEST", 96, 109], ["cell lysis", "TREATMENT", 111, 121], ["death", "PROBLEM", 126, 131], ["cell fusion", "OBSERVATION", 49, 60], ["infected cells", "OBSERVATION", 76, 90], ["cell lysis", "OBSERVATION", 111, 121]]], ["ARV-induced CPE and cell death were reduced dramatically after the addition of MG132 (Fig. 1C).The ubiquitin-proteasome system is involved in an early step of virus replication but does not block virus internalization ::: Results", [["cell", "ANATOMY", 20, 24], ["death", "DISEASE", 25, 30], ["MG132", "CHEMICAL", 79, 84], ["MG132", "CHEMICAL", 79, 84], ["cell", "CELL", 20, 24], ["MG132", "SIMPLE_CHEMICAL", 79, 84], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 99, 108], ["ARV", "TREATMENT", 0, 3], ["induced CPE", "PROBLEM", 4, 15], ["cell death", "PROBLEM", 20, 30], ["MG132", "TREATMENT", 79, 84], ["The ubiquitin-proteasome system", "TREATMENT", 95, 126], ["virus replication", "TREATMENT", 159, 176], ["CPE", "OBSERVATION_MODIFIER", 12, 15], ["cell death", "OBSERVATION", 20, 30]]]], "efc07d2aae6fa8397dbbdc2aa60362c0f020d166": [], "PMC7132423": [["The value of the network is in its breadth and the ability of users to assemble large communities with members from distant locales that would otherwise not be able to interact.", [["large", "OBSERVATION_MODIFIER", 80, 85]]], ["LinkedIn, Tumblr, and Snapchat (currently only a smartphone app) are additional platforms, and each outlet varies in its content, focus, ability to add images or links, and character limits.IntroductionThere are social aspects of communities formed around Reddit and other forums that promote sharing and discussion among users.", [["Tumblr", "TREATMENT", 10, 16], ["Snapchat", "TREATMENT", 22, 30], ["additional platforms", "TREATMENT", 69, 89], ["images", "TEST", 152, 158]]], ["This article focuses on social media that allow universal access and in which individual users curate a home page (also called a wall), as well as interact with other users.IntroductionThe reasons to use social media vary among users, and these reasons partially determine the level of user activity.", [["wall", "ANATOMY", 129, 133], ["wall", "TISSUE", 129, 133], ["social media", "TREATMENT", 24, 36], ["social media", "TREATMENT", 204, 216]]], ["The passive user utilizes social media feeds to aggregate news, both by following news outlets directly and by seeing items shared within one's social network.", [["social network", "MULTI-TISSUE_STRUCTURE", 144, 158], ["social media feeds", "TREATMENT", 26, 44]]], ["A 2016 Pew Research Study shows that 62% of American adults get news from social media, up from 49% in a 2012 study [1].", [["adults", "ORGANISM", 53, 59], ["Research Study", "TEST", 11, 25]]], ["Subscribing to scientific journal feeds, society feeds, and science journalists provides up-to-date information on the latest conference, education, and research publication news.", [["society feeds", "TREATMENT", 41, 54]]], ["The active user posts his or her ideas, articles of interest, or responses to other users for a variety of reasons.", [["active", "OBSERVATION_MODIFIER", 4, 10]]], ["The type of activity is often dictated in part by the format of the platform.Structure Dictates Function: Different Social Media Platform StylesEach social media platform (in this case, application or website for interaction) varies in its ease of link sharing, image uploading, and character limits.", [["image uploading", "TEST", 262, 277]]], ["These characteristics reach different audiences and convey different types of information.Structure Dictates Function: Different Social Media Platform StylesThe most widely known and used social media platform by far is Facebook: 79% of online Americans have an account, and 76% of those with accounts check in daily [2].", [["most widely", "OBSERVATION_MODIFIER", 161, 172]]], ["For this reason, many professional outlets maintain an active Facebook fan page.", [["active", "OBSERVATION_MODIFIER", 55, 61]]], ["Followers learn microbiology facts; view images from ASM's annual Agar Art contest; and receive links to books, reports, and blogs on microbiology topics.", [["view images", "TEST", 36, 47]]], ["The page is also a major source of news about ASM events, resources, and opportunities.", [["ASM", "CELL", 46, 49]]], ["ASM uses the large reach of its Facebook site to promote upcoming conferences, journal publications, and fellowship availability.", [["ASM", "PROBLEM", 0, 3], ["large", "OBSERVATION_MODIFIER", 13, 18]]], ["These promotions are an effective way to engage an audience: social media, especially Facebook, can promote continuing medical education options more effectively than email [6].Structure Dictates Function: Different Social Media Platform StylesMany ASM Facebook fan posts lead readers away from Facebook, where they can read a blog post, sign up for a conference, or submit a fellowship application.", [["ASM", "CELL", 249, 252], ["continuing medical education options", "TREATMENT", 108, 144]]], ["This accessibility is important to engage a wide audience; introductory microbiology students are unlikely to be ASM members, but their experience with the Gram stain during laboratory courses allows them to feel part of the community.Structure Dictates Function: Different Social Media Platform StylesInstagram is one of the most visually appealing platforms, originally based entirely on images during its launch in 2010 and expanding to video in 2013.", [["the Gram stain", "TEST", 152, 166], ["Different", "OBSERVATION_MODIFIER", 264, 273]]], ["Each image or video is accompanied by a caption, and hashtags are often used to guide people to key search words.", [["people", "ORGANISM", 86, 92], ["people", "SPECIES", 86, 92]]], ["Captions have 2,200-character limits but require the reader to \u201copen\u201d the caption beyond the first three lines.Structure Dictates Function: Different Social Media Platform StylesThe compelling images of Instagram make it a great platform for educational outreach.", [["Captions", "TEST", 0, 8]]], ["New York University graduate student Sally Warring posts videos at of microscopy images taken from water samples near her New York City neighborhood [8].", [["microscopy images", "TEST", 70, 87]]], ["With a following of over 45,000, Warring attracts many people by the images and the short stories she tells about her microbes, which allows her to teach an international audience about environmental microbes.Structure Dictates Function: Different Social Media Platform StylesInstagram typically has less user engagement than Facebook, in that there is less commentary discussion on most images.", [["people", "ORGANISM", 55, 61], ["people", "SPECIES", 55, 61], ["most images", "TEST", 383, 394], ["less", "OBSERVATION_MODIFIER", 300, 304]]], ["Users can access their accounts to view images on a computer, but posting photos is restricted to use of the Instagram app on one's smartphone.", [["view images", "TEST", 35, 46]]], ["Additionally, Instagram does not convert hyperlinks, and normally, only a single link can be referenced in an account summary, making promotion of other websites using Instagram more cumbersome than Facebook.Structure Dictates Function: Different Social Media Platform StylesTwitter is a medium that promotes short-form posts with a limit of 140 characters per post (or \u201ctweet\u201d).", [["hyperlinks", "PROBLEM", 41, 51], ["hyperlinks", "OBSERVATION", 41, 51]]], ["Shortened links count toward the character count, but Twitter changed its parameters in September 2016 to allow photo and video attachments outside the limit.", [["Shortened links count", "PROBLEM", 0, 21], ["photo and video attachments", "TREATMENT", 112, 139]]], ["A 2012 study of 8,826 scholars from 5 universities showed that 1 in 40 scholars (faculty, postdoctoral students, or graduate students) were active Twitter users [9].", [["A 2012 study", "TEST", 0, 12]]], ["A 2016 study of 587 academics recruited using Twitter showed that Twitter, Facebook, and LinkedIn predominate among academic scientists' use of social media [3] and that most scientist Twitter users consider fellow scientists to be their major audience [3].Structure Dictates Function: Different Social Media Platform StylesDespite this, personal twitter accounts are used for a variety of non-exclusive purposes.", [["A 2016 study", "TEST", 0, 12], ["Different", "OBSERVATION_MODIFIER", 286, 295]]], ["Because both journalists and scientific journals promote science stories through their own accounts, Twitter can be a great listening device that facilitates quick news aggregation.", [["a great listening device", "TREATMENT", 116, 140]]], ["Feeds can be organized by creating lists, which can filter feeds by topic if one is using Twitter to follow mainstream science news, science communication specialists, and tuberculosis researchers simultaneously.", [["tuberculosis", "DISEASE", 172, 184], ["Feeds", "TREATMENT", 0, 5], ["tuberculosis", "OBSERVATION", 172, 184]]], ["Additionally, viewing the tweets helps attendees find each other, which can happen through recognition of profile photos or through more formal \u201ctweet-ups,\u201d where twitter community members meet at a given time and place, sometimes meeting for the first time in person after interacting for years online.Structure Dictates Function: Different Social Media Platform Styles#Hashtags may also act as a quick cultural flash response.", [["person", "SPECIES", 261, 267]]], ["This was the case after Tim Hunt proclaimed that the trouble with women in the laboratory is the romantic relationships that inevitably follow; this popularized the hashtag #distractinglysexy as women responded by posting photos of themselves in laboratory gear.", [["women", "ORGANISM", 66, 71], ["women", "ORGANISM", 195, 200], ["women", "SPECIES", 66, 71], ["women", "SPECIES", 195, 200]]], ["The #distractinglysexy hashtag seems to have been born from a single tweet calling for women to post photos of themselves at work [12].", [["women", "ORGANISM", 87, 92], ["women", "SPECIES", 87, 92]]], ["Self-promotion of one's research or education protocols can also establish a niche within a field.", [["education protocols", "TREATMENT", 36, 55]]], ["Hosting these accounts contributes to the greater scientific community and also to the established expertise of those invited to host one of the accounts.Branding ::: Applications of Social MediaEstablishing one's expertise goes hand in hand with increasing one's network.", [["hand", "ANATOMY", 229, 233], ["hand", "ANATOMY", 237, 241], ["hand", "ORGANISM_SUBDIVISION", 229, 233], ["hand", "ORGANISM_SUBDIVISION", 237, 241], ["network", "MULTI-TISSUE_STRUCTURE", 264, 271]]], ["Following colleagues after meeting them at a networking event, like a conference, can extend the relationship between two researchers; similarly, interacting with colleagues virtually can encourage interactions in real life.Education ::: Applications of Social MediaThe educational aspect of social media is hard to deny.", [["Social Media", "TREATMENT", 254, 266]]], ["Lectures were divided into tweet-size statements with associated links and images, and the course was aggregated with the hash tag #microMOOCSEM.", [["images", "TEST", 75, 81], ["size", "OBSERVATION_MODIFIER", 33, 37]]], ["This gives the general public a forum to ask questions about emerging infectious diseases, such as Zika, the importance of influenza vaccination, or antibiotic resistance.Public outreach ::: Applications of Social MediaAnalysis of public chats, like that hosted by the CDC on Zika [15], can inform researchers and public health officials on the concerns of the public with emerging infectious disease, which may be different than the information provided to the public.", [["infectious diseases", "DISEASE", 70, 89], ["Zika", "DISEASE", 99, 103], ["influenza", "DISEASE", 123, 132], ["infectious disease", "DISEASE", 382, 400], ["emerging infectious diseases", "PROBLEM", 61, 89], ["Zika", "PROBLEM", 99, 103], ["influenza vaccination", "TREATMENT", 123, 144], ["antibiotic resistance", "TREATMENT", 149, 170], ["emerging infectious disease", "PROBLEM", 373, 400], ["infectious", "OBSERVATION", 382, 392]]], ["In the case of the Zika chat, the CDC was emphasizing infection symptoms and prevention while the public was more engaged with the outcomes of infection for women and infants [16].", [["infection", "DISEASE", 54, 63], ["infection", "DISEASE", 143, 152], ["women", "ORGANISM", 157, 162], ["infants", "ORGANISM", 167, 174], ["women", "SPECIES", 157, 162], ["infants", "SPECIES", 167, 174], ["infection symptoms", "PROBLEM", 54, 72], ["infection", "PROBLEM", 143, 152], ["infection", "OBSERVATION", 54, 63], ["infection", "OBSERVATION", 143, 152]]], ["This type of constructive post-publication review, previously concentrated in comments sections on websites like the NIH Pubmed Commons and bioRxiv (which also captures tweets for each article), facilitates transparency in publication decisions and interaction between editors, authors, and readers that promotes a culture of open science.Social media as a research tool ::: Applications of Social MediaUsing social media as a listening tool allows researchers to learn behavioral patterns, given the right search terms.", [["bioRxiv", "TREATMENT", 140, 147], ["a culture", "TEST", 313, 322], ["right", "ANATOMY_MODIFIER", 501, 506]]], ["Researchers have used Twitter to track influenza in the United States [18], Zika in Latin America [19], and Middle East respiratory syndrome in the Middle East [20].", [["influenza", "DISEASE", 39, 48], ["Middle East respiratory syndrome", "DISEASE", 108, 140], ["Middle East respiratory syndrome", "PROBLEM", 108, 140], ["Middle", "ANATOMY_MODIFIER", 108, 114], ["respiratory syndrome", "OBSERVATION", 120, 140], ["Middle", "ANATOMY_MODIFIER", 148, 154]]], ["These studies show that social media tracking and Internet search history can complement traditional outbreak-tracking measures.", [["These studies", "TEST", 0, 13]]], ["Searches have even extended to the social restaurant review site yelp.com, which the New York City Department of Health and Mental Hygiene used to identify previously unknown foodborne illness outbreaks based on keyword searches [21].Social media as a research tool ::: Applications of Social MediaNot all populations have equal access to social media or the Internet, and understanding the accuracy of social media broadcast cases is important to refine the identification of unreported subclinical infections.", [["foodborne illness", "DISEASE", 175, 192], ["infections", "DISEASE", 500, 510], ["unreported subclinical infections", "PROBLEM", 477, 510], ["subclinical", "OBSERVATION_MODIFIER", 488, 499], ["infections", "OBSERVATION", 500, 510]]], ["A University of Washington research group used geotagged dengue disease events on Twitter to study the relationship between reporting events on Twitter, socioeconomic status, and confirmed dengue cases in an attempt to measure the accuracy of social media reporting.", [["dengue disease", "DISEASE", 57, 71], ["dengue", "DISEASE", 189, 195], ["geotagged dengue disease events", "PROBLEM", 47, 78], ["dengue cases", "PROBLEM", 189, 201]]], ["They found that populations most at risk for dengue-related morbidity and mortality were also less likely to tweet about dengue [22].", [["dengue", "DISEASE", 45, 51], ["dengue", "DISEASE", 121, 127], ["dengue", "SPECIES", 45, 51], ["dengue", "PROBLEM", 45, 51], ["related morbidity", "PROBLEM", 52, 69]]], ["Their study highlights the important recognition that social media users are self-selected and do not necessarily represent the larger population.Social media as a research tool ::: Applications of Social MediaThe aggregation of individuals from around the world onto social media platforms has benefitted rare disease research.", [["Their study", "TEST", 0, 11], ["Social Media", "TREATMENT", 198, 210], ["The aggregation of individuals", "PROBLEM", 210, 240], ["rare disease research", "PROBLEM", 306, 327], ["larger", "OBSERVATION_MODIFIER", 128, 134], ["population", "OBSERVATION", 135, 145], ["aggregation", "OBSERVATION_MODIFIER", 214, 225], ["disease", "OBSERVATION", 311, 318]]], ["Scientists focusing on disease with low incidence can more easily find and interact with cohorts [23] and, conversely, parents of sick children can more easily interact with clinicians and form virtual support groups [24].", [["children", "ORGANISM", 135, 143], ["children", "SPECIES", 135, 143]]], ["Most diseases for which these community structures have been utilized have been rare inherited genetic diseases, but infectious disease communities may use similar means to facilitate clinician-patient interactions and to build patient cohorts and communities given the success seen in other fields.Tips for New Social Media UsersRegardless of what social media platform you want to start using, maintaining a constant stream of content is important.", [["genetic diseases", "DISEASE", 95, 111], ["infectious disease", "DISEASE", 117, 135], ["patient", "ORGANISM", 194, 201], ["patient", "ORGANISM", 228, 235], ["patient", "SPECIES", 194, 201], ["patient", "SPECIES", 228, 235], ["Most diseases", "PROBLEM", 0, 13], ["rare inherited genetic diseases", "PROBLEM", 80, 111], ["genetic", "OBSERVATION_MODIFIER", 95, 102], ["diseases", "OBSERVATION", 103, 111], ["New", "OBSERVATION_MODIFIER", 308, 311]]]]}